Splice switcher and gapmer antisense oligonucleotides targeting FMR1
Splice-switching oligonucleotides with specific spacers and modified linkages address the poor efficacy of conventional antisense oligonucleotides by reducing FMRI-217 transcript levels and treating related diseases effectively.
Patent Information
- Application Number
- PCT/US2026/028414
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-06
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional antisense oligonucleotides exhibit poor efficacy in modulating gene expression for treating diseases such as Fragile X syndrome, Fragile X-associated Primary Ovarian Insufficiency, Fragile X-associated tremor and ataxia syndrome, Parkinson’s disease, Multiple sclerosis, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Limbic-predominant age-related TDP-43 encephalopathy.
Development of splice-switching oligonucleotides, including gapmers, with specific spacers and modified internucleoside linkages, that are at least 85% complementary to FMRI sequences, capable of modulating the splicing of FMRI-related diseases.
The splice-switching oligonucleotides effectively reduce FMRI-217 transcript levels by up to 90% while maintaining or increasing FMRI-205 levels, thereby treating associated diseases.
Smart Images

Figure US2026028414_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. QRL-028WOSPLICE SWITCHER AND GAPMER ANTISENSE OLIGONUCLEOTIDESTARGETING FMRICROSS-REFENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U. S. Provisional Patent Application No. 63 / 806,436, filed May 15, 2025, and U. S. Provisional Patent Application No. 63 / 977,356, filed February 6, 2026, the disclosures of which are hereby incorporated by reference in its entirety for all purposes.SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 07, 2026, is named QRL-028WO_SL.xml and is 3,160,216 bytes in size.BACKGROUND
[0003] Antisense oligonucleotides are nucleic acid-based compounds that can be used to modulate expression of certain genes that are linked to diseases. Although antisense oligonucleotides can be generally designed to hybridize with target genes and / or RNA, conventional antisense oligonucleotides often exhibit poor efficacy. Thus, there is a need to develop modified antisense oligonucleotides that exhibit improved performance and efficacy for preventing, ameliorating, and treating diseases, examples of which include neurodevelopmental and neurodegenerative diseases.
[0004] Thus, there is a pressing need to identify compounds and / or compositions capable of preventing, ameliorating, and treating repeat expansion disorders or FMRP-related diseases such as Fragile X syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor and ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), or TDP-43 related diseases such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).SUMMARY
[0005] Disclosed herein are FMRI oligonucleotides. Also disclosed herein are splice-switching oligonucleotides. Also disclosed herein are splice-switching oligonucleotides, wherein the spliceswitching oligonucleotide comprises a spacer.Attorney Docket No. QRL-028WO
[0006] Provided herein, in one aspect, are Fragile X Messenger Ribonucleoprotein 1 (FMRI) oligonucleotides, wherein the FMRI oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 967.
[0007] In various embodiments, the FMRI oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 976.
[0008] In various embodiments, the splicing of SEQ ID NO: 976 is capable of being modulated to treat a FMRI -related disease or disorder.
[0009] In various embodiments, the FMRI oligonucleotide comprises a sequence that is at least 90% complementary to SEQ ID NO: 977. In various embodiments, the FMRI oligonucleotide comprises a sequence that is at least 90% complementary to positions 2-71 of SEQ ID NO: 977.
[0010] In various embodiments, the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. In various embodiments, the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 454-465.
[0011] In various embodiments, the FMRI oligonucleotide comprises a spacer.
[0012] In various embodiments, the FMRI oligonucleotide comprises a gapmer. In various embodiments, the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 1247-1254.
[0013] Provided herein, in one aspect, are splice-switching oligonucleotides, wherein the spliceswitching oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 967, and further wherein the splice-switching oligonucleotide comprises a spacer.
[0014] In various embodiments, the splice-switching oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 976.
[0015] In various embodiments, the splicing of SEQ ID NO: 976 is capable of being modulated to treat a FMRI-related disease or disorder.
[0016] In various embodiments, at least one ( / .<., one or more) internucleoside linkage of the splice-switching oligonucleotide is a non-natural linkage.
[0017] In various embodiments, the splice-switching oligonucleotide comprises a sequence that is between 85% to 93% complementary to an equal length portion of SEQ ID NO: 976.
[0018] In various embodiments, the splice-switching oligonucleotide comprises a sequence that is at least 85% complementary to SEQ ID NO: 977. In various embodiments, the spliceswitching oligonucleotide comprises a sequence that is at least 90% complementary to SEQ ID NO: 977. In various embodiments, the splice-switching oligonucleotide comprises a sequence that is at least 93% complementary to SEQ ID NO: 977. In various embodiments, the splice-Attorney Docket No. QRL-028WOswitching oligonucleotide comprises a sequence that is at least 90% complementary to an equal length portion of SEQ ID NO: 976, or to a 15 to 50 contiguous nucleotide portion thereof.
[0019] In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 11 linked nucleosides. In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 10, 9, or 8 linked nucleosides. In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 7 linked nucleosides.
[0020] In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides. In various embodiments, every segment of the spliceswitching oligonucleotide comprises at most 7 linked nucleosides.
[0021] In various embodiments, the splice-switching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. In various embodiments, the splice-switching oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
[0022] In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 7 linked nucleosides, and wherein the splice-switching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the spliceswitching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. In various embodiments, the splice-switching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the splice-switching oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
[0023] In various embodiments, the splice-switching oligonucleotide comprises any one of SEQ ID NOs: 484-564 or 1021-1075. In various embodiments, the sequence comprises any one of SEQ ID NOs: 1076-1132. In various embodiments, the sequence comprises any one of SEQ ID NOs: 1133-1189. In various embodiments, the sequence comprises any one of SEQ ID NOs: 1190-1246.
[0024] In various embodiments, the splice-switching oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In various embodiments, the splice-switching oligonucleotide is at least 23 oligonucleotide units in length.Attorney Docket No. QRL-028WO
[0025] In various embodiments, the spacer is a nucleoside-replacement group comprising a nonsugar substitute that is incapable of linking to a nucleotide base.
[0026] In various embodiments, the spacer is located between positions 10 and 15 of the spliceswitching oligonucleotide. In various embodiments, the spacer is located between positions 7 and 11 of the splice-switching oligonucleotide. In various embodiments, the splice-switching oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 14 and 22 of the splice-switching oligonucleotide. In various embodiments, the spacer and the second spacer are separated by at least 5 nucleotides, at least 6 nucleotides, or at least 7 nucleotides in the splice-switching oligonucleotide. In various embodiments, the spacer is located between positions 7 and 9 of the splice-switching oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the splice-switching oligonucleotide. In various embodiments, the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide.
[0027] In various embodiments, the splice-switching oligonucleotide comprises any one of SEQ ID NOs: 484-564 or 1021-1246.
[0028] In various embodiments, the spacer is located between positions 2 and 5 of the oligonucleotide. In various embodiments, the splice-switching oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide. In various embodiments, the splice-switching oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides.
[0029] In various embodiments, at least one of the two spacers is adjacent to a guanine nucleobase. In various embodiments, each of the at least one of the two spacers immediately precedes a guanine nucleobase.
[0030] In various embodiments, each of the first or second spacers is a nucleoside-replacement group comprising a non-sugar substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal, hemiacetal, aminal, or hemiaminal moiety, and is incapable of forming a covalent bond with a nucleotide base.
[0031] In various embodiments, each of the first or second spacers is independently represented by Formula (X), wherein:Formula (X)Attorney Docket No. QRL-028WORing A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and thesymbol represents the point of connection to an intemucleoside linkage.
[0032] In various embodiments, each of the first or second spacers is independently represented by Formula (Xa), wherein:Formula (Xa).
[0033] In various embodiments, ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.
[0034] In various embodiments, ring A is tetrahydrofuranyl. In various embodiments, ring A is tetrahydropyranyl.
[0035] In various embodiments, each of the first or second spacers is independently represented by Formula (I), wherein:Formula (I)X is selected from -CH2- and -O-; andn is 0, 1, 2 or 3.
[0036] In various embodiments, each of the first or second spacers is independently represented by Formula (F), wherein:Formula (F)X is selected from -CH2- and -O-; andn is 0, 1, 2 or 3.
[0037] In various embodiments, each of the first or second spacers is independently represented by Formula (la), wherein:Attorney Docket No. QRL-028WOFormula (la); andn is 0, 1, 2 or 3.
[0038] In various embodiments, each of the first or second spacers is independently represented by Formula (la’), wherein:n is 0, 1, 2 or 3.
[0039] In various embodiments, each of the first or second spacers is independently represented by Formula (II), wherein:Formula (II); andX is selected from -CH2- and -O-.
[0040] In various embodiments, each of the first or second spacers is independently represented by Formula (IF), wherein:Formula (IF); andX is selected from -CH2- and -O-.
[0041] In various embodiments, each of the first or second spacers is independently represented by Formula (IIa), wherein:Formula (IIa).
[0042] In various embodiments, each of the first or second spacers is independently represented by Formula (lia’), wherein:Attorney Docket No. QRL-028WOFormula (lia’).
[0043] In various embodiments, each of the first or second spacers is independently represented by Formula (Ili), wherein:Formula (Ili)X is selected from -CH2- and -O-.
[0044] In various embodiments, each of the first or second spacers is independently represented by Formula (Ili’), wherein:Formula (Ili’)X is selected from -CH2- and -O-.
[0045] In various embodiments, each of the first or second spacers is independently represented by Formula (Ilib), wherein:Formula (Ilib).
[0046] In various embodiments, each of the first or second spacers is independently represented by Formula (Ilib’), wherein:Formula (Ilib’).
[0047] In various embodiments, each of the first or second spacers is independently represented by Formula (III), wherein:Attorney Docket No. QRL-028WOX is selected from -CH2- and -O-.
[0048] In various embodiments, each of the first or second spacers is independently represented by Formula (III’), wherein:X is selected from -CH2- and -O-.
[0049] In various embodiments, each of the first or second spacers is independently represented by Formula (Illa), wherein:
[0050] In various embodiments, each of the first or second spacers is independently represented by Formula (Illa’), wherein:
[0051] In various embodiments, each of the first or second spacers is independently represented by Formula (IV):Formula (IV).
[0052] In various embodiments, each of the first or second spacers is independently represented by Formula (V):Attorney Docket No. QRL-028WO
[0053] In various embodiments, the splice-switching oligonucleotide comprising the spacer has a GC content of at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, or at least 50%.
[0054] In various embodiments, the splice-switching oligonucleotide is between 12 and 40 oligonucleotide units in length.
[0055] In various embodiments, at least one ( / .<., one or more) internucleoside linkage of the oligonucleotide is independently selected from the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodi ami date linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage. In various embodiments, one or more internucleoside linkage of the oligonucleotide is a modified internucleoside linkage. In various embodiments, the modified internucleoside linkage of the oligonucleotide is a phosphorothioate linkage. In various embodiments, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages. In various embodiments, the phosphorothioate linkage is in one of a Rp configuration or a rip configuration.
[0056] In various embodiments, the oligonucleotide comprises at least one modified sugar moiety. In various embodiments, the modified sugar moiety is one of a 2’-0Me modified sugar moiety, bicyclic sugar moiety, 2’ -O-(2 -methoxy ethyl) (2’-M0E), 2’-deoxy-2’-fluoro nucleoside, 2’-fluoro-P-D-arabinonucleoside, locked nucleic acid (LNA), 2’-O-(N-methylacetamide) nucleoside, constrained ethyl 2’ -4’ -bridged nucleic acid (cEt), ri-cEt, hexitol nucleic acids (HNA), and tricyclic analog (e.g., tcDNA).
[0057] In various embodiments, the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217. In various embodiments, the oligonucleotide exhibits at least a 10% decrease of FMRI-217 transcript levels or the levels of the protein encoded by FMRI-217.Attorney Docket No. QRL-028WOIn various embodiments, the oligonucleotide exhibits at least a 20% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217. In various embodiments, the oligonucleotide exhibits at least a 30% decrease of FMRI-217 transcript levels or the levels of the protein encoded by FMRI -217. In various embodiments, the oligonucleotide exhibits at least a 40% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMR1-217. In various embodiments, the oligonucleotide exhibits at least a 50% decrease of FMRI-217 transcript levels or the levels of the protein encoded by FMRI -217. In various embodiments, the oligonucleotide exhibits at least a 60% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI-217. In various embodiments, the oligonucleotide exhibits at least a 70% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMR1-217. In various embodiments, the oligonucleotide exhibits at least an 80% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217. In various embodiments, the oligonucleotide exhibits at least a 90% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
[0058] In various embodiments, decrease of the FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217 achieved using the splice-switching oligonucleotide or FMRI oligonucleotide is measured in comparison to a level of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217 achieved using a control oligonucleotide.
[0059] In various embodiments, the oligonucleotide exhibits at least a 40%, 50%, 60%, 70%, 80%, or 90% reduction of the level of FMRI -217 transcripts.
[0060] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 10%.
[0061] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 20%.
[0062] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%.
[0063] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%, and the oligonucleotide exhibits at least a 30% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
[0064] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%, and the oligonucleotide exhibits at least a 60% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
[0065] In various embodiments, the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 10%, and the oligonucleotide exhibits at least a 70% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.Attorney Docket No. QRL-028WO
[0066] Provided herein, in another aspect, are methods of treating a FMRI -related disease or disorder and / or a neuropathy in a patient in need thereof, the method comprising administering to the patient a splice-switching oligonucleotide or FMRI oligonucleotide of any one disclosed herein.
[0067] In various embodiments, the FMRI -related disease or disorder is selected from the group consisting of Fragile X Syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
[0068] Provided herein, in another aspect, are methods of restoring axonal outgrowth and / or regeneration of a neuron, the method comprising exposing the neuron to a splice-switching oligonucleotide or FMRI oligonucleotide of any one disclosed herein.
[0069] In various embodiments, the neuron is a neuron in the central nervous system.
[0070] In various embodiments, the neuron is a neuron of a patient in need of treatment of a FMRI -related disease or disorder.
[0071] Provided herein, in another aspect, are methods of restoring glia (e.g., astrocytes, microglia, or oligodendrocyte) cell health and / or function, the method comprising exposing the glia to a splice-switching oligonucleotide or FMRI oligonucleotide of any one disclosed herein.
[0072] In various embodiments, the exposing is performed in vivo or ex vivo.
[0073] In various embodiments, the exposing comprises administering the splice-switching oligonucleotide or FMRI oligonucleotide to a patient in need thereof.
[0074] In various embodiments, the splice-switching oligonucleotide or FMRI oligonucleotide is administered topically, parenterally, intravenously, subcutaneously, intrathecally, intrathalamically, intraci stemally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, intraduodenally, intraparenchymally, or intracerebroventricularly. In various embodiments, the splice-switching oligonucleotide or FMRI oligonucleotide is administered orally, intravenously, or intrathecally. In various embodiments, a therapeutically effective amount of the splice-switching oligonucleotide is administered intrathecally, intraparenchymally, intravenously, or subcutaneously.
[0075] In various embodiments, the patient is a human.
[0076] Provided herein, in another aspect, are pharmaceutical compositions comprising the splice-switching oligonucleotide or FMRI oligonucleotide of any one disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.Attorney Docket No. QRL-028WO
[0077] In various embodiments, the pharmaceutical composition is suitable for topical, intrathecal, intrathalamic, intracisternal, intracerebroventricular, intraparenchymal, parenteral, intravenous, subcutaneous, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.
[0078] Provided herein, in another aspect, are methods of treating a FMRI -related disease or disorder or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of any one disclosed herein.
[0079] In various embodiments, the FMRI -related disease or disorder is selected from the group consisting of Fragile X Syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
[0080] In various embodiments, the pharmaceutical composition is administered topically, parenterally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intraci stemally, intrathecally, intraparenchymally, intrathalamically, transdermally, intraduodenally, or intracerebroventricularly. In various embodiments, the pharmaceutical composition is administered intrathecally, intrathalamically, intravenously, subcutaneously, or intracisternally. In various embodiments, a therapeutically effective amount of the spliceswitching oligonucleotide or FMRI oligonucleotide is administered intrathecally, intrathalamically, intravenously, subcutaneously, or intracisternally.
[0081] In various embodiments, the patient is human.
[0082] Provided herein, in another aspect, are methods of treating a FMRI -related disease or disorder in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed herein, in combination with a second therapeutic agent.
[0083] In various embodiments, the second therapeutic agent is selected from propranolol, primidone, gabapentin, topiramate, levetiracetam, amantadine, buspirone, varenicline, riluzole, carbidopa / levodopa, donepezil, galantamine, rivastigmine, Citocoline, memantine, allopregnanolone, sulfarophane, methylphenidate (Ritalin, Concerta, Methylyn, Metadate, Focalin, Aptensio, Daytrana, Quillivant), amphetamines and mixed amphetamine salts (Adderall), lisdexamphetamine (Vyvanse), dextroamphetamine (Dexedrine), atomoxetine (Strattera), modafinil (Provigil), fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), trazodone (Desyrel), bupropion (Wellbutrin),Attorney Docket No. QRL-028WOvenlafaxine (Effexor), tricyclics (amitriptyline, imipramine, etc), Mirtazapine (Remeron), clonidine (Catapres, Kapvay), guanfacine (Tenex, Intuniv), haloperidol (Haldol), risperidone (Risperdal), aripiprazole (Abilify), quetiapine (Seroquel), ziprasidone (Geodon), olanzapine (Zyprexa), thioridazine (Mellaril), lurasidone (Latuda), iloperidone (Fanapt), brexpiprazole (Rexulti), topiramate (Topamax), Lithium, valproic acid (Depakote), carbamazepine (Tegretol), oxcarbazepine (Trileptal), lamotrigine (Lamictal), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), alprazolam (Xanax), buspirone (Buspar, Vanspar), Ambien, Fenobam, Mavoglurant, Basimglurant, lithium, lovastatin, trofinetide, minocycline, metformin, BPN14770, actinogen, CX516, ganaxolone, metadoxine (Alcobra), Arbaclofen, Acamprosate, gaboxadole, Donepezil, cannabidiol (CBD), Ergoloid mesylates / 5HTP, Sulindac, SPG601, sertraline, NNZ-2566, AZD7325, MG01C1, Oxytocin, CTH120, aripipazole, epigallocatechin Gallate (EGCG), STX107, Vitamin C, Vitamin E, NPL-2009, CX-516, and acamprosate.BRIEF DESCRIPTION OF THE DRAWINGS
[0084] FIG. 1 is a diagram displaying the alternative splicing of FMRI pre-mRNA transcript that results in the mRNA transcript for FMRI -217, a mis-spliced transcript, and the canonical variant that results in FMRP protein.DETAILED DESCRIPTION
[0085] The features and other details of the disclosure will now be more particularly described. Certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
[0086] Disclosed herein are oligonucleotides capable of targeting a region of a transcript transcribed from a gene. In various embodiments, such oligonucleotides target a Fragile X Messenger Ribonucleoprotein 1 (FMRI) transcript. Additionally disclosed herein are oligonucleotides, including antisense oligonucleotide sequences, and methods for treating neurodevelopmental and neurodegenerative diseases, such as Fragile X Syndrome (FXS), Fragile X-associated tremor and ataxia Syndrome (FXTAS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE) using the antisense oligonucleotidesAttorney Docket No. QRL-028WOdisclosed herein. In various embodiments, the oligonucleotides target a sequence of FMRI transcripts resulting in the reduction of the splice variant FMRI -217. In various embodiments, the oligonucleotides target a sequence of FMRI transcripts resulting in the reduction of the splice variant FMRI-217 without reducing the levels of the FMRI canonical variant (e.g., FMRI-205). In various embodiments, the oligonucleotides target a sequence of FMRI transcripts resulting in the reduction of the splice variant FMRI -217 and an increase of the levels of the FMRI canonical variant (e.g., FMRI-205). In various embodiments, the oligonucleotides target a sequence of the splice variant FMRI -217 and do not target the FMRI canonical variant. In various embodiments, the oligonucleotides target a sequence of the splice variant FMRI -217 and bind the FMRI canonical variant. Also disclosed are pharmaceutical compositions comprising FMRI oligonucleotides that target a region of FMRI transcripts for treating FXS, FXTAS, FXPOI, PD, MS, AD, ALS, FTD, or LATE. Also disclosed are manufacture of medicaments containing a disclosed FMRI oligonucleotide that targets a region of FMRI to be used in treating FXS, FXTAS, FXPOI, PD, MS, AD, ALS, FTD, or LATE.Definitions
[0087] The terms “treat,” “treatment,” “treating,” and the like are used herein to generally mean obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic in terms of partially or completely curing a disease and / or adverse effect attributed to the disease. The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) inhibiting the disease, / .<., preventing the disease from increasing in severity or scope; (b) relieving the disease, / .<., causing partial or complete amelioration of the disease; or (c) preventing relapse of the disease, / .<., preventing the disease from returning to an active state following previous successful treatment of symptoms of the disease or treatment of the disease.
[0088] “Preventing” includes delaying the onset of clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition developing in a subject that may be afflicted with or predisposed to the state, disorder, disease, or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder, disease, or condition. “Preventing” includes prophylactically treating a state, disorder, disease, or condition in or developing in a subject, including prophylactically treating clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition in or developing in a subject.
[0089] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein interchangeably refers to any and all solvents, dispersion media,Attorney Docket No. QRL-028WOcoatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
[0090] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one biologically active compound, for example, a FMRI antisense oligonucleotide (AON), as disclosed herein formulated together with one or more pharmaceutically acceptable excipients.
[0091] “ Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or non-human primates, and most preferably humans. The compounds of the invention can be administered to a mammal, such as a human, but can also be other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals e.g., rats, mice, guinea pigs, non-human primates, and the like). In some embodiments, the mammal treated in the methods of the invention is desirably a mammal in whom modulation of splice variant FMR1-217 expression and / or activity is desired.
[0092] As used herein, the term “antisense oligonucleotide” or “AON” encompasses antisense oligonucleotides that target genes or gene products of FMRI or genes or gene products of splice variant FMRI -217. “Antisense oligonucleotide” or “AON” encompass any of a parent oligonucleotide, an oligonucleotide variant, an oligonucleotide with one or more spacers, or an oligonucleotide variant with one or more spacers. Examples of antisense oligonucleotides include oligonucleotides comprising a sequence of any one of antisense oligonucleotide comprising any one of SEQ ID NOs: 1-564.
[0093] The term “parent oligonucleotide” refers to an oligonucleotide that targets a transcript (e.g., a FMRI transcript) and is capable of increasing, restoring, or stabilizing full-length activity e.g., full length expression, for example, full length mRNA and / or full length protein expression. Parent oligonucleotides do not include a spacer. Examples of parent oligonucleotides include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. As described hereafter, oligonucleotide with spacers and oligonucleotide variants are described in relation to a corresponding parent oligonucleotide. In various embodiments, a parent oligonucleotide is a 23mer or 25mer.
[0094] The term “oligonucleotide variant” refers to an oligonucleotide that represents a modified version of a corresponding parent oligonucleotide. For example, an oligonucleotide variant represents a shortened version of a parent oligonucleotide. In various embodiments, anAttorney Docket No. QRL-028WOoligonucleotide variant is any one of a 15mer, 16mer, 17mer, 18mer 19mer, 20mer, 21mer, 22mer, 24mer, 26mer, or 27mer.
[0095] The term “oligonucleotide with one or more spacers” or “oligonucleotide comprising a spacer” refers to an oligonucleotide with at least one spacer. An oligonucleotide with one or more spacers can, in various embodiments, include one spacer, two spacers, three spacers, four spacers, five spacers, six spacers, seven spacers, eight spacers, nine spacers, or ten spacers. In various embodiments, an oligonucleotide comprising one or more spacers includes at least one segment with at most 7 linked nucleosides. For example, as described in a 5’ to 3’ direction, an oligonucleotide comprising a spacer can include a segment with 7 linked nucleosides, followed by a spacer, a second segment with 9 linked nucleosides, followed by a second spacer, and a third segment with 7 linked nucleosides. Here, the first segment of 7 linked nucleosides and the third segment of 7 linked nucleosides each represents segments with at most 7 linked nucleosides. As another example, an oligonucleotide comprising a spacer can include a segment with 10 linked nucleosides, followed by a spacer, a second segment with 10 linked nucleosides, followed by a second spacer, and a third segment with 3 linked nucleosides. Here, the third segment of 3 linked nucleosides represents the segment with at most 7 linked nucleosides. In various embodiments, an oligonucleotide with one or more spacers includes multiple segments with at most 7 linked nucleosides. In various embodiments, every segment of an oligonucleotide with one or more spacers has at most 7 linked nucleosides. For example, the oligonucleotide may be a 23mer and include two spacers that divide the 23mer into three separate segments of 7 linked nucleosides each. Therefore, each segment of the oligonucleotide has at most 7 linked nucleosides.
[0096] Generally, oligonucleotides comprising one or more spacers are described in reference to a corresponding parent oligonucleotide or a corresponding oligonucleotide variant. Example oligonucleotides comprising one or spacers include any of SEQ ID NOs: 484-564 or 1021-1246.
[0097] As used herein, “2’-M0E nucleoside” (also 2’ -O-(2 -methoxy ethyl) nucleoside) means a nucleoside comprising a 2’-M0E modified sugar moiety.
[0098] As used herein, “2’-substituted nucleoside” means a nucleoside comprising a substituent at the 2’-position of the furanose ring other than H or OH. In certain embodiments, 2’ substituted nucleosides include nucleosides with bicyclic sugar modifications.
[0099] As used herein, “5-methyl cytosine” (5-MeC) means a cytosine modified with a methyl group attached to the 5 position. A 5-methyl cytosine (5-MeC) is a modified nucleobase.
[0100] As used herein, “contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moi eties, and / or intemucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediatelyAttorney Docket No. QRL-028WOadjacent to each other in a sequence. As an example to the contrary, two nucleosides separated by a spacer are not contiguous.
[0101] As used herein, a “spacer” refers to a nucleoside-replacement group (e.g., a nonnucleoside group that replaces a nucleoside present in an FMRI parent oligonucleotide). The spacer is characterized by the lack of a nucleotide base and by the replacement of the nucleoside sugar moiety with a non-sugar substitute. In some embodiments, the non-sugar substitute group includes a carbon with a different oxidation state than a corresponding carbon of a nucleoside sugar moiety. The non-sugar substitute group of a spacer lacks an aldehyde, ketone, acetal, ketal, hemiacetal or hemiketal group. The non-sugar substitute group of a spacer is thus capable of connecting to the 3’ and 5’ positions of the nucleosides adjacent to the spacer through an intemucleoside linkage as described herein, but not capable of forming a covalent bond with a nucleotide base (z.e., not capable of linking a nucleobase to another group, such as an intemucleoside linkage, conjugate group, or terminal group in an oligonucleotide).
[0102] As used herein, an “intemucleoside linkage” can be a modified intemucleoside linkage or a naturally occurring intemucleoside linkage. In some embodiments, an intemucleoside linkage links nucleoside to nucleoside. In some embodiments, an intemucleoside linkage links spacer to a nucleoside. In some embodiments, an intemucleoside linkage links a first spacer to second spacer. In some embodiments, an intemucleoside linkage links a nucleoside to a spacer.
[0103] As used herein, “modified intemucleoside linkage” refers to a substitution or any change from a naturally occurring intemucleoside linkage (e.g., a phosphodiester intemucleoside bond).
[0104] As used herein, “modified nucleobase” means any nucleobase other than adenine, cytosine, guanine, thymine, or uracil. Examples of a modified nucleobase include 5-methyl cytosine, pseudouridine, or 5-methoxyuridine. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).
[0105] As used herein, a “modified nucleoside” means a nucleoside having, independently, a modified sugar moiety and / or modified nucleobase. A universal base is a modified nucleobase that can pair with any one of the five unmodified nucleobases. Modified nucleosides include abasic nucleosides, which lack a nucleobase. However, modified nucleosides do not include spacers or other groups that are incapable of linking a nucleobase.
[0106] As used herein, “linked nucleosides” are nucleosides that are connected in a contiguous sequence (z.e., no additional nucleosides are presented between those that are linked). In various embodiments, an oligonucleotide may have different segments of linked nucleosides connected through a spacer. Here, the spacer (z.e., nucleoside replacement) is not considered a nucleoside and therefore, divides up the oligonucleotide into two segments of linked nucleosides. TheAttorney Docket No. QRL-028WOoligonucleotide may have a first segment of Y linked nucleosides e.g., Y nucleosides that are connected in a contiguous sequence), followed by a spacer, and then a second segment of Z linked nucleosides. Here, the Y and Z linked nucleosides is described in either the 5’ to 3’ direction or the 3’ to 5’ direction. In various embodiments, the first segment consists of 7 or fewer linked nucleosides (e.g., Y = 7 or fewer) whereas the second segment comprises 8 or more linked nucleosides (e.g., Z = 8 or more).
[0107] As used herein, “modified oligonucleotide” means an oligonucleotide comprising at least one (i.e., one or more) modified intemucleoside linkage, modified sugar, and / or modified nucleobase.
[0108] As used herein, “modified sugar” or “modified sugar moiety” means a modified furanosyl sugar moiety or a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide.
[0109] As used herein, “natural sugar moiety” means a sugar moiety found in DNA (2’-H) or RNA (2’-OH).
[0110] As used herein, “naturally occurring internucleoside linkage” means a 3’ to 5’ phosphodiester linkage.
[0111] As used herein, “nucleoside” refers to a nucleobase linked to a sugar. The term “nucleoside” also includes a “modified nucleoside” which has independently, a modified sugar moiety and / or modified nucleobase.
[0112] As used herein, an “oligonucleotide unit” can be either a nucleoside (e.g., a nucleoside which includes a sugar and a nucleobase) or a nucleoside-replacement group (e.g., a spacer) of the oligonucleotide. In some embodiments, an oligonucleotide has oligonucleotides units of nucleosides. In some embodiments, an oligonucleotide has oligonucleotides units of nucleosides and nucleoside-replacement groups.Antisense Therapeutics
[0113] Antisense therapeutics are a class of nucleic acid-based compounds that can be used to modulate a transcript, such as pre-mRNA or mRNA. In various embodiments, antisense therapeutics comprise one or more spacers and can be used to modulate a transcript that is transcribed from a gene, such as a FMRI pre-mRNA or mRNA.
[0114] Antisense therapeutics may be single- or double-stranded deoxyribonucleic acid (DNA)-based, ribonucleic acid (RNA)-based, or DNA / RNA chemical analogue compounds. In general, antisense therapeutics are designed to include a sequence that is complementary or nearly complementary to an mRNA or pre-mRNA sequence transcribed from a given gene in order toAttorney Docket No. QRL-028WOpromote binding between the antisense therapeutic and the pre-mRNA or mRNA. In certain embodiments, antisense therapeutics act by binding to an mRNA or pre-mRNA, thereby inhibiting protein translation, altering pre-mRNA splicing into mature mRNA (e.g., by preventing appropriate proteins such as splicing activator proteins from binding), and / or causing destruction of mRNA. In certain embodiments, the antisense therapeutic sequence is complementary to a portion of a targeted gene’s or mRNA’s sense sequence. In certain embodiments, antisense therapeutics described herein are oligonucleotide-based compounds that include an oligonucleotide sequence complementary to a pre-mRNA sequence, or a portion thereof, and one or more spacers. In certain embodiments, antisense therapeutics described herein can also be nucleotide chemical analog-based compounds.
[0115] In certain embodiments, an oligonucleotide, such as disclosed herein, may be an oligonucleotide of 5 to 100 oligonucleotide units in length, for example, 10 to 60 oligonucleotide units in length, for example, 12 to 50 oligonucleotide units in length, 14 to 40 oligonucleotide units in length, 10 to 30 oligonucleotide units in length, for example, 14 to 30 oligonucleotide units in length, for example, 14 to 25 or 15 to 22 oligonucleotide units in length, or 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 oligonucleotide units in length.
[0116] In particular embodiments, the oligonucleotides are 25 oligonucleotide units in length. In particular embodiments, the oligonucleotides are 23 oligonucleotide units in length. In particular embodiments, the oligonucleotides are 21 oligonucleotide units in length. In particular embodiments, the oligonucleotides are 19 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 18 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 19 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 20 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 21 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 22 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 23 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 24 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 25 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 26 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 27 oligonucleotide units in length.
[0117] In particular embodiments, AONs disclosed herein are splice-switching oligonucleotides. As used herein, a “splice-switching oligonucleotide” refers to an oligonucleotide that binds to a target site and modulates the splicing of the target nucleic acid. In various embodiments, splice-Attorney Docket No. QRL-028WOswitching oligonucleotides can be used to modulate a transcript that is transcribed from a gene, such as a FMRI pre-mRNA.
[0118] In some embodiments, AONs disclosed herein are gapmer oligonucleotides. The term “gapmer oligonucleotide” or “gapmer AON” refers to an AON with at least three distinct structural regions including a 5'-wing region, a central region, and a 3'-wing region, in a 5’ - 3’ orientation. The 5’ wing region and 3’ wing region comprise RNA nucleosides. The central region comprises a stretch of nucleosides that enable recruitment and activation of RNAseH. For example, the central region comprises linked DNA nucleosides, 2' -Fluoro Arabino Nucleic Acids (FANA), and / or Fluoro Cyclohexenyl nucleic acid (F-CeNA). In some embodiments, all of the nucleosides of the central region are DNA nucleosides. In further embodiments the central region may consist of a mixture of DNA nucleosides and other nucleosides (2’ -Fluoro Arabino Nucleic Acids (FANA), and Fluoro Cyclohexenyl nucleic acid (F- CeNA)) capable of mediating RNase H cleavage. In some embodiments, a gapmer oligonucleotide comprises one or more spacers. In some embodiments, a gapmer oligonucleotide comprises one spacer. In some embodiments, a gapmer oligonucleotide comprises two spacers. In some embodiments, a gapmer oligonucleotide comprises three spacers.
[0119] In certain embodiments, AONs may include chemically modified nucleosides (for example, 2’-O-methylated nucleosides or 2’-O-(2-methoxyethyl) nucleosides) as well as modified internucleoside linkages (for example, phosphorothioate linkages). In certain embodiments, AONs described herein include oligonucleotide sequences that are complementary to RNA sequences, such as FMRI pre-mRNA. In certain embodiments, AONs described herein can include chemically modified nucleosides and modified internucleoside linkages (for example, phosphorothioate linkages). In particular embodiments, AONs described herein include one or more spacers.
[0120] In various embodiments, the oligonucleotides comprise one or more spacers. In particular embodiments, the oligonucleotides comprise one spacer. In various embodiments, the oligonucleotides comprise two spacers. For example, the oligonucleotide includes 23 oligonucleotide units with 21 nucleotides and two nucleoside replacement groups (e.g., two spacers). Further embodiments of oligonucleotides with one spacer and oligonucleotides with two spacers are described herein. In various embodiments, the oligonucleotides comprise three spacers.
[0121] In some embodiments, an antisense oligonucleotide can be, but is not limited to, inhibitors of a gene transcript (for example, shRNAs, siRNAs, antisense oligonucleotides (AON) that include PNAs, LNAs, 2’-(9-methyl (2’OMe), 2’-O-[2-(methylamino)-2-oxoethyl] (2’NMA), 2’-(9-(2-methoxyethyl) (MOE), amido-bridged nucleic acids (AmNAs), guanidine-bridgedAttorney Docket No. QRL-028WOnucleic acids (GuNAs), or LNAs with a cyclopropyl substitution, or morpholino oligomers (e.g., phosphorodiamidate morpholino (PMO))), or compositions that include such compounds. In some embodiments an oligonucleotide is an antisense oligonucleotide (AON) comprising 2’OMe (e.g., an AON comprising one or more 2’OMe modified sugar), MOE e.g., an AON comprising one or more MOE modified sugar), 2'-O-[2-(methylamino)-2-oxoethyl] (2’NMA) e.g., an AON comprising one or more 2’NMA modified sugar), amido-bridged nucleic acids (AmNAs) e.g., an AON comprising one or more AmNA), guanidine-bridged nucleic acids (GuNAs) e.g., an AON comprising one or more GuNAs), LNAs with a cyclopropyl substitution e.g., an AON comprising one or more LNAs with a cyclopropyl substitution), peptide nucleic acids e.g., an AON comprising one or more 7V-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), locked nucleic acids e.g., an AON comprising one or more locked ribose, and can be a mixture of 2’ -deoxy nucleotides or 2’OMe nucleotides), c-ET e.g., an AON comprising one or more cET sugar), constrained methoxy ethyl (cMOE) e.g., an AON comprising one or more cMOE sugar), morpholino oligomer e.g., an AON comprising a backbone comprising one or more PMO), deoxy -2 ’-fluoro nucleoside e.g., an AON comprising one or more 2’-fluoro-P-D-arabinonucleoside), tricyclo-DNAs (tcDNA) e.g., an AON comprising one or more tcDNA modified sugar), 2’-O,4’-C-Ethylene-bridged nucleic acid (ENA) e.g., an AON comprising one or more ENA modified sugar), or hexitol nucleic acids (HNA) e.g., an AON comprising one or more HNA modified sugar). In some embodiments, an AON comprises one or more intemucleoside linkage independently selected from a phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, phosphorodiamidate morpholino (PMO) (morpholino) linkage, phosphoryl guanidine (PN) linkage, phosphoryl sulfonamide linkage, PNA linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, a phosphoramidothioate linkage, thiophosphorodiamidate linkage, phosphorodiamidate morpholino (PMO) (morpholino) linkage, phosphoryl guanidine (PN) linkage, phosphoryl sulfonamide linkage, and PNA linkage. In some embodiments, a FMRI AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.
[0122] Peptide nucleic acids (PNAs) are short, artificially synthesized polymers with a structure that mimics DNA or RNA. PNAs include a backbone composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. In certain embodiments, PNAs described herein can be used as antisense therapeutics that bind to RNA sequences with high specificity and stabilizeAttorney Docket No. QRL-028WOlevels of total FMRI mRNA and / or protein levels and / or decrease levels of FMRI splice variant FMRI -217.
[0123] Locked nucleic acids (LNAs) are oligonucleotide sequences that include one or more modified RNA nucleotides in which the ribose moiety is modified with a bridge connecting the 2’ oxygen and 4’ carbon. LNAs are believed to have higher Tm’s than analogous oligonucleotide sequences. In certain embodiments, LNAs described herein can be used as antisense therapeutics that bind to RNA sequences with high specificity. For example, LNAs can bind to FMRI pre-mRNA and reduce levels of FMRI splice variant FMRI-217.
[0124] Morpholino oligomers are oligonucleotide compounds that include bases attached to a backbone of methylenemorpholine rings linked through phosphorodiamidate groups. In certain embodiments, morpholino oligomers of the present invention can be designed to bind to specific pre-mRNA sequence of interest.FMRI Oligonucleotides Targeting Regions of the FMRI Transcript
[0125] As used herein, “FMRI” (also known as Fragile X Messenger Ribonucleoprotein 1, FMRP, FRAXA, FMRP Translational Regulator 1, MGC87458, POF1, POF, Fragile X Messenger Ribonucleoprotein, Synaptic Functional Regulator FMRI, Fragile X Mental Retardation 1, Premature Ovarian Failure 1, and Protein FMR-1) refers to the gene or gene products (e.g., protein or mRNA transcript (including pre-mRNA) encoded by the gene) identified by Entrez Gene ID No. 2332 and allelic variants thereof, as well as orthologs found in non-human species (e.g., non-human primates or mice).
[0126] FMRI transcript sequences are shown to contain thymine (T), but one of skill in the art will appreciate that thymine (T) can generally be replaced with uracil (U) in RNA sequences.
[0127] In some embodiments of the disclosure, the FMRI gene product is a FMRI mRNA or FMRI pre-mRNA comprising sequences from a FMRI gene sequence (for example the FMRI gene sequence of NCBI Reference Sequence NM_002024.6 (SEQ ID NO: 967), the FMRI gene sequence of NCBI Reference Sequence NC_000023.11 (Reference GRCh38.pl4 Primary Assembly), or a FMRI coding sequence), or a portion thereof. In some embodiments of the disclosure, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA or FMRI pre-mRNA sequence (for example, the FMRI gene sequence of NCBI Reference Sequence NM_002024.6 (SEQ ID NO: 967; e.g., FMRI-205), or a FMRI coding sequence), or a portion thereof. FMRI -205 encodes the full-length 632 amino acid FMRP.Attorney Docket No. QRL-028WO
[0128] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NR 033699.2 (SEQ ID NO: 969). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NR 033699.2 (SEQ ID NO:969).
[0129] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NR 033700.2 (SEQ ID NO:970). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NR_033700.2 (SEQ ID NO:970).
[0130] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NM_002024.6 (SEQ ID NO:967). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NM_002024.6 (SEQ ID NO:967).
[0131] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185075.2 (SEQ ID NO:972). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185075.2 (SEQ ID NO:972).
[0132] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185076.2 (SEQ ID NO:973). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185076.2 (SEQ ID NO:973).Attorney Docket No. QRL-028WO
[0133] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185082.2 (SEQ ID NO:974). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185082.2 (SEQ ID NO:974).
[0134] In various embodiments, the FMRI gene product is a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185081.2 (SEQ ID NO:975). In various embodiments, the FMRI gene product comprises a sequence that shares at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a FMRI mRNA sequence comprising NCBI Reference Sequence NM_001185081.2 (SEQ ID NO:975).
[0135] In various embodiments, the FMRI gene product is an FMRI RNA sequence comprising a sequence of a splice variant listed in Table A below.Table A. Additional Canonical Splice Variants of the FMRI geneAttorney Docket No. QRL-028WO
[0136] FMRI pre-mRNA has various exons and introns, displayed in FIG. 1. The 5’ untranslated region (5’ UTR) of the FMRI gene contains a CGG trinucleotide repeat that is typically about 5-44 repeats long in a normal gene (or about 15-132 nucleotides).. In some gene instances, the FMRI gene has CGG repeats ranging from 55 to 200 repeats, leading to increased risk for developing Fragile X-associated tremor and ataxia Syndrome. In some instances, the FMRI gene has CGG repeats ranging from 200 to >1000 repeats. A longer CGG repeat region results in an increasingly methylated region, which leads to silencing of the FMRI gene.Individuals with a FMRI gene region that have >200 CGG repeats have a higher chance of developing FXS. FMRI genes with CGG repeats over 55 nucleotides are associated with expression of the splice variant FMRI-217 (SEQ ID NO: 978). FMRI-217 is a mis-spliced form of the FMRI gene resulting from an intron retention (IR) event. FMRI -217 comprises exon 1 of FMRI and a pseudo-exon from the intron 1 of FMRI (FIG. 1). FMRI-217 encodes a short protein corresponding to UniProt Accession No. A0A087X1M7 (SEQ ID NO: 979).
[0137] In various embodiments, a FMRI oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of a transcript comprising a sequence at least 90% identity to SEQ ID NO: 976, or a contiguous 15 to 50 nucleotide portion of SEQ ID NO: 976. In various embodiments, a FMRI oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of a transcript comprising a sequence at least 90% identity to SEQ ID NO: 976, or a contiguous 15 to 50 nucleotide portion of SEQ ID NO: 976. In various embodiments, a FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. FMRI target sequences are shown to contain thymine (T), but one of skill in the art will appreciate that thymine (T) can generally be replaced with uracil (U) in RNA sequences.
[0138] In various embodiments, FMRI oligonucleotides are characterized by having one or more spacers, where each spacer divides up the FMRI oligonucleotide into segments of linked nucleosides. In various embodiments, FMRI oligonucleotides have two spacers. In one embodiment, FMRI oligonucleotides have two segments of linked nucleosides separated by one spacer. In one embodiment, FMRI oligonucleotides have three segments of linked nucleosides separated by two spacers. In such embodiments, FMRI oligonucleotides have one segment with at most 7 linked nucleosides. For example, a FMRI oligonucleotide may have, from the 5’ to theAttorney Docket No. QRL-028WO3’ end, 5 linked nucleosides, followed by a spacer, 10 linked nucleosides, followed by a second spacer, and 8 linked nucleosides. Thus, the first segment of 5 linked nucleosides satisfies the one segment with at most 7 linked nucleosides. In various embodiments, FMRI oligonucleotides have three spacers that divide the FMRI oligonucleotide into four segments. In various embodiments, each of the four segments of the FMRI oligonucleotide have at most 7 linked nucleosides.
[0139] As used herein, the term “FMRI oligonucleotide” encompasses a “FMRI parent oligonucleotide,” a “FMRI oligonucleotide with one or more spacers” (e.g., FMRI oligonucleotide with two spacers or a FMRI oligonucleotide with three spacers), a “FMRI oligonucleotide variant with one or more spacers. Examples of FMRI oligonucleotides include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
[0140] The term “FMRI parent oligonucleotide” refers to an oligonucleotide that targets a FMRI transcript and is capable of decreasing splice variant FMRI -217 transcripts and affecting or not affecting the canonical variant expression. FMRI parent oligonucleotides do not include a spacer.
[0141] In various embodiments, FMRI parent AONs may be an oligonucleotide sequence of 23 or 25 nucleotides in length.
[0142] Examples of FMRI parent oligonucleotides include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255. As described hereafter, FMRI oligonucleotide with spacers and FMRI oligonucleotide variants are described in relation to a corresponding FMRI parent oligonucleotide.
[0143] The term “FMRI oligonucleotide variant” refers to a FMRI oligonucleotide that represents a version of a corresponding FMRI parent oligonucleotide with a modified length. For example, a FMRI oligonucleotide variant represents a shortened version of a FMRI parent oligonucleotide. In various embodiments, a FMRI oligonucleotide variant is any one of a 15mer, 16mer, 17mer, 18mer 19mer, 20mer, 21mer, 22mer, or24mer.
[0144] In various embodiments, FMRI oligonucleotides comprise one or more spacers. In some embodiments, FMRI oligonucleotides comprising a spacer comprise a sequence of any one of SEQ ID NOs: 484-564 or 1021-1246.
[0145] The term “FMRI oligonucleotide with one or more spacers” or “FMRI oligonucleotide comprising a spacer” refers to a FMRI oligonucleotide or FMRI oligonucleotide variant with at least one spacer. An oligonucleotide with one or more spacers can, in various embodiments, include one spacer, two spacers, three spacers, four spacer, five spacers, six spacers, seven spacers, eight spacers, nine spacers, or ten spacers. In various embodiments, an oligonucleotide comprising one or more spacers includes at least one segment with at most 7 linked nucleosides.Attorney Docket No. QRL-028WOFor example, as described in a 5’ to 3’ direction, an oligonucleotide comprising a spacer can include a segment with 7 linked nucleosides, followed by a spacer, a second segment with 9 linked nucleosides, followed by a second spacer, and a third segment with 7 linked nucleosides. Here, the first segment of 7 linked nucleosides and the third segment of 7 linked nucleosides each represents segments with at most 7 linked nucleosides. As another example, an oligonucleotide comprising a spacer can include a segment with 10 linked nucleosides, followed by a spacer, a second segment with 10 linked nucleosides, followed by a second spacer, and a third segment with 3 linked nucleosides. Here, the third segment of 3 linked nucleosides represents the segment with at most 7 linked nucleosides. In various embodiments, an oligonucleotide with one or more spacers includes multiple segments with at most 7 linked nucleosides. In various embodiments, every segment of an oligonucleotide with one or more spacers has at most 7 linked nucleosides. For example, the oligonucleotide may be a 23mer and include two spacers that divide the 23mer into three separate segments of 7 linked nucleosides each. Therefore, each segment of the oligonucleotide has at most 7 linked nucleosides.
[0146] Generally, FMRI oligonucleotides comprising one or more spacers are described in reference to a corresponding FMRI parent oligonucleotide or a corresponding FMRI oligonucleotide variant. Example FMRI oligonucleotides comprising one or spacers include any of SEQ ID NOs: 484-564 or 1021-1246.
[0147] The phrase “a FMRI oligonucleotide that targets a FMRI transcript” refers to a FMRI oligonucleotide that binds to a FMRI transcript. In various embodiments, FMRI AONs disclosed herein are complementary to a FMRI transcript comprising any one of SEQ ID NOs: 967-975. In various embodiments, FMRI AONs disclosed herein are complementary to a FMRI transcript comprising a sequence that shares at least 85% (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to any one of SEQ ID NOs: 967-975. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to any one of SEQ ID NOs: 967-975. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 967. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to NCBI Reference Sequence NC 000023.11. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 969. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 970. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 972. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 973. In some embodiments, a FMRI AON comprises a sequenceAttorney Docket No. QRL-028WOthat is at least 90% complementary to SEQ ID NO: 974. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 975.
[0148] In various embodiments, the oligonucleotide binds to a sequence in an intron of FMRI.
[0149] In various embodiments, FMRI AONs disclosed herein are complementary to specific regions of FMRI transcripts comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 976. In some embodiments, a FMRI AON comprises a sequence that is at least 85% complementary to SEQ ID NO: 976. In some embodiments, a FMRI AON comprises a sequence that is between 85% to 93% complementary to SEQ ID NO: 976. In some embodiments, a FMRI AON comprises a sequence that is between 90% to 95% complementary to SEQ ID NO: 976.
[0150] In some embodiments, the FMRI AON comprises a sequence that is between 85% to 93% complementary to an equal length portion of SEQ ID NO: 976 or to a 15 to 50 contiguous nucleotide portion thereof. In some embodiments, the FMRI AON comprises a sequence that is at least 90% complementary to an equal length portion of SEQ ID NO: 976 or to a 15 to 50 contiguous nucleotide portion thereof.
[0151] In various embodiments, FMRI AONs disclosed herein are complementary to specific regions of FMRI transcripts (for example, a sequence in intron 1 of FMRI) comprising a sequence that shares at least 85% (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 977. In some embodiments, a FMRI AON comprises a sequence that is at least 85% complementary to SEQ ID NO: 977. In some embodiments, a FMRI AON comprises a sequence that is between 85% to 93% complementary to SEQ ID NO: 977. In some embodiments, a FMRI AON comprises a sequence that is at least 90% complementary to SEQ ID NO: 977. In some embodiments, a FMRI AON comprises a sequence that is between 90% to 93% complementary to SEQ ID NO: 977.
[0152] In some embodiments, the FMRI AON comprises a sequence that is between 85% to 93% complementary to an equal length portion of SEQ ID NO: 977 or to a 15 to 50 contiguous nucleotide portion thereof. In some embodiments, the FMRI AON comprises a sequence that is at least 90% complementary to an equal length portion of SEQ ID NO: 977 or to a 15 to 50 contiguous nucleotide portion thereof.
[0153] In some embodiments, a FMRI AON targets a specific portion of a FMRI transcript, the specific portion of the FMRI transcript comprising SEQ ID NO: 976.
[0154] In some embodiments, the FMRI AON has a segment that has, at most, 7 linked nucleosides. In some embodiments, the FMRI AON has a segment that has, at most, 6, 5, 4, 3, or 2 linked nucleosides. The segments of the FMRI AON may be separated from other segments of the FMRI AON through a spacer. In various embodiments, the segment of the FMRI AON isAttorney Docket No. QRL-028WOcomplementary to a specific region of the FMRI transcript comprising a sequence that shares at least 85% (e.g., 85%, 86%, 87% 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 976. In various embodiments, the segment of the FMRI AON is complementary to a specific region of the FMRI transcript (for example, a FMRI transcript comprising SEQ ID NO: 976) comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 977. In various embodiments, the segment of the FMRI AON is complementary to a specific region of the FMRI transcript comprising a sequence that shares between 85% to 93% identity to SEQ ID NO: 977.
[0155] In various embodiments, the segment of the FMRI AON is complementary to a specific region of the FMRI transcript comprising a sequence that shares at least 85% (e.g., 85%, 86%, 87% 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 977. In various embodiments, the segment of the FMRI AON is complementary to a specific region of the FMRI transcript comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 977. In various embodiments, the segment of the FMRI AON is complementary to a specific region of the FMRI transcript comprising a sequence that shares between 85% to 93% identity to SEQ ID NO: 977.
[0156] In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 90% complementary to an equal length portion of SEQ ID NO: 976. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 90% complementary to an equal length portion of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 90% complementary to an equal length portion of nucleotides within any one of positions 189-298 of SEQ ID NO: 976. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 90% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 91% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 92% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a portion of at least 7 contiguous nucleotides that is at least 93% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977.Attorney Docket No. QRL-028WO
[0157] In some embodiments, the FMRI AON comprises a sequence that is at least 90% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 91% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 92% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 93% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 94% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 95% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 96% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 97% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 98% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 99% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is 100% complementary to an equal length portion of nucleotides within positions 2-71 of SEQ ID NO: 977.
[0158] In some embodiments, the FMRI AON comprises a sequence that is at least 90% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 91% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 92% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 93% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 94% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 95% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 96%Attorney Docket No. QRL-028WOcomplementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 97% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO:977. In some embodiments, the FMRI AON comprises a sequence that is at least 98% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is at least 99% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977. In some embodiments, the FMRI AON comprises a sequence that is 100% complementary to an equal length portion of nucleotides within positions 69-109 of SEQ ID NO: 977.Table 1. FMRI target sequencesAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOFMRI Oligonucleotide Variants
[0159] In various embodiments, FMRI AONs include different variants, hereafter referred to as FMRI AON variants. A FMRI AON variant may be an oligonucleotide sequence of 10 to 100 nucleotides or oligonucleotide units in length, for example, 10 to 40 nucleotides or oligonucleotide units in length, for example, 14 to 40 nucleotides or oligonucleotide units in length, 10 to 30 nucleotides or oligonucleotide units in length, for example, 14 to 30 nucleotides or oligonucleotide units in length, for example, 16 to 28 nucleotides or oligonucleotide units in length, for example, 19 to 22 nucleotides or oligonucleotide units in length. In various embodiments, FMRI AON variants are 17 to 22, 24, or 26-30 nucleotides in length, for example, 17, 18, 19, 20, 21, 22, 24, 26, 27, 28, 29, or 30 nucleotides in length. A FMRI AON variant may be an oligonucleotide sequence complementary to a portion of a FMRI pre-mRNA sequence or a FMRI gene sequence
[0160] In various embodiments, a FMRI AON variant represents a modified version of a corresponding FMRI parent oligonucleotide that includes a nucleotide sequence selected from any one of SEQ ID NOs: 1-483, 983-1019, or 1255. In some embodiments, a FMRI AON variant includes a nucleotide sequence that represents a shortened version of a nucleotide sequence of a FMRI AON. As one example, if a FMRI parent oligonucleotide includes a 23mer or 25mer (e.g., 23 or 25 nucleotides in length) a variant (e.g., a FMRI variant) may include a shorter version (e.g., 15mer, 17mer, 19mer, 21mer, or 22mer) of the 23mer or 25mer FMRI parent oligonucleotide. In one embodiment, a nucleotide sequence of a FMRI AON variant differs from a corresponding nucleotide sequence of a FMRI parent oligonucleotide in that 1, 2, 3, 4, 5, or 6 nucleotides are removed from one or both of the 3’ and 5’ ends of the nucleotide sequence of the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 21mer where two nucleotides are removed from each of the 3’ and 5’ ends of the 25mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 21mer where four nucleotides are removed from either the 3’ or 5’ end of the 25mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 19mer where three nucleotides are removed from each of the 3’ and 5’ ends of the 25mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 19mer where up to six nucleotides are removed from either the 3’ or 5’ end of the 23mer or 25mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant mayAttorney Docket No. QRL-028WOinclude a 21mer where one nucleotide is removed from each of the 3’ and 5’ ends of the 23mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 21mer where two nucleotides are removed from either the 3’ or 5’ end of the 23mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 19mer where two nucleotides are removed from each of the 3’ and 5’ ends of the 23mer included in the FMRI parent oligonucleotide. In one embodiment, the corresponding FMRI AON variant may include a 17mer where up to eight nucleotides are removed from either the 3’ or 5’ end of the 23mer or 25mer included in the FMRI parent oligonucleotide.
[0161] Example sequences of FMRI parent AONs are shown below in Table 2A and Table 2B.Table 2A. FMRI Parent Oligonucleotide SequencesAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.Table 2B. FMRI Parent Oligonucleotide SequencesAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.
[0162] In some embodiments, the FMRI AONs disclosed herein are gapmers. In some embodiments, SEQ ID NOs: 1247-1254 are gapmer FMRI AONs. Example FMRI AONs gapmers documented below in Table 2C.Table 2C. FMRI Oligonucleotide Gapmer SequencesAttorney Docket No. QRL-028WO*dA= DNA base A; dT= DNA base T, dG= DNA base G; 5mC = 5 methy DNA base C. All intemucleoside linkages are phosphorothioate linkages.Antisense Oligonucleotides with One or more Spacers
[0163] In various embodiments, antisense oligonucleotides comprise one or more spacers. In particular embodiments, an antisense oligonucleotide includes one spacer. In particular embodiments, an antisense oligonucleotide includes two spacers. In particular embodiments, an antisense oligonucleotide includes three spacers. Generally, a spacer refers to a nucleoside-replacement group lacking a nucleotide base and wherein the nucleoside sugar moiety is replaced by a non-sugar substitute group. The non-sugar substitute group is not capable of linking to a nucleobase, but is capable of linking with the 3’ and 5’ positions of nucleosides adjacent to the spacer through an intemucleoside linking group.
[0164] In certain embodiments, an oligonucleotide with one or more spacers, such as disclosed herein, may be an oligonucleotide with 5 to 100 oligonucleotide units in length, for example, 10 to 60 oligonucleotide units in length, for example, 12 to 50 oligonucleotide units in length, 14 to 40 oligonucleotide units in length, 10 to 30 oligonucleotide units in length, for example, 14 to 30 oligonucleotide units in length, for example, 14 to 25 or 15 to 23 oligonucleotide units in length, or 18, 19, 20, 21, 22, 23, 24, or 25 oligonucleotide units in length. As used herein, an “oligonucleotide unit” refers to either a nucleoside (e.g., a nucleoside which includes a sugar and a nucleobase) or a nucleoside-replacement group (e.g., a spacer) of the oligonucleotide.
[0165] In particular embodiments, oligonucleotides with one or more spacers are 25 oligonucleotide units in length. In particular embodiments, the oligonucleotides with one or more spacers are 23 oligonucleotide units in length. In particular embodiments, the oligonucleotides with one or more spacers are 21 oligonucleotide units in length. In particular embodiments, the oligonucleotides with one or more spacers are 19 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In various embodiments, the oligonucleotides have one spacer. In various embodiments, the oligonucleotides with one spacer are at least 18 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 19 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 20 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 21Attorney Docket No. QRL-028WOoligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 22 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 23 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 24 oligonucleotide units in length. In various embodiments, the oligonucleotides with one spacer are at least 25 oligonucleotide units in length.
[0166] In various embodiments, a FMRI AON comprises a sequence that shares at least 80% identity with an equal length portion of SEQ ID NO: 976. In various embodiments, a FMRI AON comprises a sequence that shares at least 85% identity with an equal length portion of SEQ ID NO: 976. In various embodiments, a FMRI AON comprises a sequence that shares at least 90% identity with an equal length portion of SEQ ID NO: 976. In various embodiments, a FMRI AON comprises a sequence that shares at least 95% identity with an equal length portion of SEQ ID NO: 976. In various embodiments, a FMRI AON comprises a sequence that shares 100% identity with an equal length portion of SEQ ID NO: 976.
[0167] In some embodiments, the spacer is of Formula (X):wherein ring A is as defined herein.
[0168] In some embodiments, the spacer is of Formula (Xa):wherein ring A is as defined herein and the -CH2-O- group is on a ring A atom adjacent to the -O- group.
[0169] As generally defined herein, ring A of formulae (X) and (Xa), is an optionally substituted 4-8 member monocyclic cycloalkyl group (e.g., ring A is cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl) or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N (e.g., ring A is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl). In some embodiments, ring A is tetrahydrofuranyl. In some embodiments, ring A is tetrahydropyranyl. In some embodiments, ring A is pyrrolidinyl. In someAttorney Docket No. QRL-028WOembodiments, ring A is cyclopentyl. In some embodiments, the monocyclic cycloalkyl or monocyclic heterocyclyl is not further substituted. In some embodiments, the cycloalkyl or heterocyclyl is further substituted with 0, 1, 2 or 3 substituents selected from halo (e.g., -F, -Cl), -OMe, -OEt, -O(CH2)OMe, -O(CH2)2OMe, -OCH2C(O)NHMe, and CN.
[0170] In some embodiments, tetrahydrofuranyl is substituted with 1 or 2 substituents selected from halo (e.g., -F, -Cl), -OMe, -OEt, -O(CH2)OMe, -O(CH2)2OMe, -OCH2C(O)NHMe, and CN. In some embodiments, tetrahydrofuranyl is substituted with 2 substituents selected from halo (e.g., -F, -Cl), -OMe, -OEt, -O(CH2)OMe, -O(CH2)2OMe, -OCH2C(O)NHMe, and CN. In some embodiments, tetrahydrofuranyl is substituted with 1 substituent selected from halo (e.g., -F, -Cl), -OMe, -OEt, -O(CH2)OMe, -O(CH2)2OMe, -OCH2C(O)NHMe, and CN. In some embodiments, tetrahydrofuranyl is substituted with -O(CH2)2OMe.
[0171] In some embodiments, the spacer is represented by Formula (I), wherein:Formula (I)X is selected from -CH2- and -O-; andn is 0, 1, 2 or 3.
[0172] In some embodiments, the spacer is represented by Formula (I’), wherein:X is selected from -CH2-and -O-; andn is 0, 1, 2 or 3.
[0173] In some embodiments, the spacer is represented by Formula (la), wherein:Formula (la)Attorney Docket No. QRL-028WOand n is 0, 1, 2 or 3.
[0174] In some embodiments, the spacer is represented by Formula (la’), wherein:Formula (la’)and n is 0, 1, 2 or 3.
[0175] As generally defined herein, X is selected from -CH2- and -O-. In some embodiments, X is -CH2-. In other embodiments, X is -O-.
[0176] As generally defined herein, n is 0, 1, 2 or 3. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, n is 1. In other embodiments, n is 2. In certain embodiments, n is 3.
[0177] In some embodiments, the spacer is represented by Formula (II), wherein:Formula (II)X is selected from -CH2- and -O-.
[0178] In some embodiments, the spacer is represented by Formula (IF), wherein:Formula (IF)X is selected from -CH2- and -O-.
[0179] In some embodiments, the spacer is represented by Formula (IIa), wherein:Formula (IIa).
[0180] In some embodiments, the spacer is represented by Formula (lia’), wherein:Attorney Docket No. QRL-028WOa (lia’ ).bodiments, the spacer is represented by Formula (Ilib), wherein:Formula (Ilib).
[0182] In some embodiments, the spacer is represented by Formula (Ilib’), wherein:Formula (Ilib’).odiments, the spacer is represented by Formula (III), wherein:a (III)X is selected from -CH2- and -O-.
[0184] In some embodiments, the spacer is represented by Formula (III’), wherein:Formula (III’)X is selected from -CH2- and -O-.
[0185] In some embodiments, the spacer is represented by Formula (Illa), wherein:Attorney Docket No. QRL-028WOFormula (Illa).
[0186] In some embodiments, the spacer is represented by Formula (Illa’), wherein:Formula (IIIa').
[0188] In some embodiments, the spacer is represented by Formula (V):
[0189] In some embodiments, the open positions of Formulae (I), (F), (la), (la’), (II), (IF), (lia), (lia’), (III), (III’), (Illa), (Illa’), (IV), and (V) ( / .<., the positions not specifically depicted as bearing exclusively hydrogen atoms, including the -CH2- group of X) are further substituted with 0-3 substituents selected from halo (e.g., -F, -Cl), - OMe, -OEt -O(CH2)OMe, -O(CH2)2OMe, -OCH2C(O)NHMe, and CN. In some embodiments, Formulae (I), (I’), (la), (la’), (II), (IF), (lia), (lia’), (III), (III’), (Illa) and (Illa’) are not further substituted.FMRI
[0190] As described further below, a FMRI oligonucleotide with one or more spacers is described in reference to a corresponding FMRI parent oligonucleotide. In various embodiments, a FMRI oligonucleotide with a spacer differs from a FMRI parent oligonucleotide in that the spacer replaces a nucleoside in the FMRI parent oligonucleotide. As used hereafter, the “position” of the FMRI oligonucleotide refers to a particular location as counted from the 5’ end of the FMRI oligonucleotide. In various embodiments, the spacer replaces a nucleoside at anyAttorney Docket No. QRL-028WOone of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 of the FMRI parent oligonucleotide. In particular embodiments, a spacer replaces a nucleoside at one of positions 7, 8, 11, 14, 15, 16, 17, 18, 19, 20, or 21 of the FMRI parent oligonucleotide.
[0191] In various embodiments, a FMRI oligonucleotide includes one spacer that replaces a nucleoside in the FMRI parent oligonucleotide (e.g., one spacer replaces one nucleoside of the FMRI parent oligonucleotide). In particular embodiments, the spacer replaces a nucleoside between positions 7 and 15 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 8 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside between positions 9 and 12 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 10 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 11 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 12 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside between positions 12 and 17 of the FMRI parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 16 of the FMRI parent oligonucleotide.
[0192] In various embodiments, a FMRI oligonucleotide including one spacer has 2 segments, where at least one of the 2 segments has at most 11 linked nucleosides. For example, the FMRI oligonucleotide may be 23 oligonucleotide units in length, and the spacer can be located at position 12. Therefore, the FMRI oligonucleotide has 2 segments divided by the spacer, where both of the 2 segments are 11 nucleotides in length. In various embodiments, a FMRI oligonucleotide including one spacer has 2 segments, where at least one of the 2 segments has at most 10 linked nucleosides. For example, the FMRI oligonucleotide may be 21 oligonucleotide units in length, and the spacer can be located at position 11. Therefore, the FMRI oligonucleotide has 2 segments divided by the spacer, where both of the 2 segments are 10 nucleotides in length. As another example, the FMRI oligonucleotide may be 25 oligonucleotide units in length, and the spacer can be located at position 15. Therefore, the FMRI oligonucleotide has 2 segments divided by the spacer, where one of the 2 segments is 14 nucleotides in length and the second of the 2 segments is 10 nucleotides in length.
[0193] In various embodiments, a FMRI oligonucleotide includes two spacers that each replace a nucleoside in the FMRI parent oligonucleotide (e.g., two spacers replace two separate nucleosides of the FMRI parent oligonucleotide). In various embodiments, a first spacer and a second spacer are separated by at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, or at least 10 nucleotides in the oligonucleotide. InAttorney Docket No. QRL-028WOparticular embodiments, a first spacer and a second spacer are separated by at least 5 nucleotides, at least 6 nucleotides, or at least 7 nucleotides. In particular embodiments, the first spacer and the second spacer are not adjacent to one another in the oligonucleotide.
[0194] In particular embodiments, the first spacer replaces a nucleoside between positions 7 and 11 of the FMRI parent oligonucleotide. In various embodiments, the first spacer replaces a nucleoside between positions 8 and 11, positions 9 and 11, positions 10 and 11, positions 7 and 10, positions 7 and 9, positions 7 and 8, positions 8 and 10, positions 8 and 9, or positions 9 and 10 of the FMRI parent oligonucleotide. In particular embodiments, the second spacer replaces a nucleoside between positions 13 and 22 of the FMRI parent oligonucleotide. In various embodiments, the second spacer replaces a nucleoside between positions 15 and 22, positions 16 and 22, positions 17 and 22, position 18 and 22, position 19 and 22, positions 20 and 22, positions 21 and 22, positions 15 and 21, position 16 and 21, positions 17 and 21, positions 18 and 21, positions 19 and 21, positions 20 and 21, positions 15 and 20, positions 16 and 20, positions 17 and 20, positions 18 and 20, positions 19 and 20, positions 15 and 19, positions 16 and 19, positions 17 and 19, positions 18 and 19, positions 15 and 18, position 16 and 18, position 17 and 18, positions 15 and 17, positions 16 and 17, or positions 15 and 16 of the FMRI parent oligonucleotide. In various embodiments, the first spacer is located at position 7 of the oligonucleotide and the second spacer is located at position 14 of the oligonucleotide.
[0195] In preferred embodiments, the first spacer replaces a nucleoside at position 7 of the FMRI parent oligonucleotide and the second spacer replaces a nucleoside at position 14 of the FMRI parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 8 of the FMRI parent oligonucleotide and the second spacer replaces a nucleoside at position 16 of the FMRI parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 11 of the FMRI parent oligonucleotide and the second spacer replaces a nucleoside at position 22 of the FMRI parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 9 of the FMRI parent oligonucleotide and the second spacer replaces a nucleoside at position 19 of the FMRI parent oligonucleotide.
[0196] In various embodiments, a FMRI oligonucleotide includes three spacers that each replace a nucleoside in the FMRI parent oligonucleotide (e.g., three spacers replace three separate nucleosides of the FMRI parent oligonucleotide). In particular embodiments, the first spacer replaces a nucleoside between positions 6 and 12 of the FMRI parent oligonucleotide. In particular embodiments, the second spacer replaces a nucleoside between positions 13 and 22 of the FMRI parent oligonucleotide. In particular embodiments, the third spacer replaces a nucleoside between positions 21 and 24 of the FMRI parent oligonucleotide. In someAttorney Docket No. QRL-028WOembodiments, the first spacer replaces a nucleoside between positions 2 and 5 of the FMRI parent oligonucleotide. In particular embodiments, the second spacer replaces a nucleoside between positions 8 and 12 of the FMRI parent oligonucleotide. In particular embodiments, the third spacer replaces a nucleoside between positions 18 and 24 of the FMRI parent oligonucleotide.
[0197] In various embodiments, the three spacers in a FMRI oligonucleotide are positioned such that each of the four segments of the FMRI oligonucleotide are at most 7 linked nucleosides in length. For example, a FMRI oligonucleotide may have a first segment with 7 linked nucleosides connected to a first spacer, then a second segment with 7 linked nucleosides connected on one end to the first spacer and connected on another end to a second spacer, then a third segment with 6 linked nucleosides connected on one end to the second spacer and connected on another end to a third spacer, then a fourth segment with 6 linked nucleosides connected to the third spacer.
[0198] In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more adenosine or uracil nucleosides (as opposed to guanine or cytosine nucleosides). For example, the one or more spacers can replace one, two, three, four, five, six, seven, eight, or nine adenosine or thymine nucleosides in the oligonucleotide. In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more guanine or cytosine nucleosides (as opposed to adenosine or thymine nucleosides). For example, the one or more spacers can replace one, two, three, four, five, six, seven, eight, or nine guanine or cytosine nucleosides in the oligonucleotide. In various embodiments, the spacers are positioned in the oligonucleotide to replace an equal number of adenosine / thymine nucleosides and guanine / cytosine nucleosides. For example, a first spacer in the oligonucleotide may replace an adenosine / thymine nucleoside and a second spacer in the oligonucleotide may replace a guanine / cytosine nucleoside.
[0199] In various embodiments, the one or more spacers are positioned in the oligonucleotide to control the sequence content in the oligonucleotide. For example, the one or more spacers are positioned such that at least one of the spacers is located adjacent to a guanine nucleoside. In various embodiments, the one or more spacers are positioned such that at least one of the spacers is located next to a 5-methyl cytosine. In various embodiments, the one or more spacers are positioned such that at least one the spacers is located next to a 2’ -MOE guanine. In various embodiments, an oligonucleotide with spacers can include one spacer adjacent to a guanine nucleoside, two spacers adjacent to guanine groups, three spacers adjacent to guanine nucleosides, four spacers adjacent to guanine nucleosides, or five spacers adjacent to guanine nucleosides. In one embodiment, if counting from the 5’ end of the oligonucleotide, a spacerAttorney Docket No. QRL-028WOimmediately precedes a guanine nucleoside in the sequence. Thus, in various embodiments, an oligonucleotide with spacers can include one spacer that immediately precedes a guanine nucleoside, two spacers that each immediately precede a guanine nucleoside, three spacers that each immediately precede a guanine nucleoside, four spacers that each immediately precede a guanine nucleoside, or five spacers that each immediately precede a guanine nucleoside. In one embodiment, if counting from the 5’ end of the oligonucleotide, a guanine nucleoside is immediately succeeded by a spacer. Thus, in various embodiments, an oligonucleotide with spacers can include one spacer that immediately succeeds a guanine nucleoside, two spacers that each immediately succeed a guanine nucleoside, three spacers that each immediately succeed a guanine nucleoside, four spacers that each immediately succeed a guanine nucleoside, or five spacers that each immediately succeed a guanine nucleoside. In various embodiments, the spacers in the oligonucleotide can be positioned to maximize the number of spacers adjacent to guanine nucleosides.
[0200] In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more adenosine or uracil nucleosides such that the one or more spacers are located adjacent guanine nucleosides. For example, two spacers can replace adenosine or thymine nucleosides in the oligonucleotide, each of the two spacers being located adjacent to a guanine nucleoside.
[0201] In various embodiments, the FMRI oligonucleotide with one or more spacers has a particular GC content. As used herein, GC content (or guanine-cytosine content) is the percentage of nitrogenous bases in the oligonucleotide that are either guanine (G) or cytosine (C). In various embodiments, the FMRI oligonucleotide with one or more spacers has at least 10% GC content, at least 20% GC content, at least 25% GC content, at least 30% GC content, at least 35% GC content, at least 40% GC content, at least 45% GC content, at least 50% GC content, at least 55% GC content, at least 60% GC content, at least 65% GC content, at least 75% GC content, at least 80% GC content, at least 85% GC content, at least 90% GC content, or at least 95% GC content. In particular embodiments, the FMRI oligonucleotide with one or more spacers has at least 30% GC content. In particular embodiments, the FMRI oligonucleotide with one or more spacers has at least 40% GC content. In various embodiments, the one or more spacers are positioned in the FMRI oligonucleotide to maximize GC content. For example, instead of selecting a guanine or cytosine for replacement by a spacer in the FMRI oligonucleotide, a thymine or adenine can be selected for replacement by a spacer.
[0202] In various embodiments, a FMRI oligonucleotide with spacers is designed such that 1) each segment of the FMRI oligonucleotide has at most 7 linked nucleosides and 2) at least two, three, or four spacers are positioned adjacent to a guanine nucleoside. In some embodiments, aAttorney Docket No. QRL-028WOFMRI oligonucleotide with spacers is designed such that 1) each segment of the FMRI oligonucleotide has at most 7 linked nucleosides and 2) each of two spacers precede a guanine nucleoside.
[0203] In various embodiments, the inclusion of one or more spacers in the FMRI oligonucleotide does not decrease the effectiveness of the FMRI oligonucleotide with the spacers in decreasing FMRI -217 mRNA or stabilizing total FMRI mRNA in comparison to the effect of a corresponding FMRI parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the FMRI oligonucleotide increases the effectiveness of the FMRI oligonucleotide with the spacers in decreasing FMRI -217 mRNA or stabilizing total FMRI mRNA in comparison to the effect of a corresponding FMRI parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the FMRI oligonucleotide does not decrease the effectiveness of the FMRI oligonucleotide with the spacers in reducing quantity of FMRI -217 transcripts in comparison to the effect of a corresponding FMRI parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the FMRI oligonucleotide increases the effectiveness of the FMRI oligonucleotide with the spacers in reducing quantity of FMRI-217 transcripts in comparison to the effect of a corresponding FMRI parent oligonucleotide.
[0204] Tables 3-5 document example FMRI oligonucleotides with one or more spacers and their relation to corresponding FMRI parent oligonucleotides. Each FMRI oligonucleotide is assigned a sequence name. As used hereafter, the nomenclature of the sequence name is expressed as “X_spA” (for a FMRI AON with one spacer), “X_spA_spB” (for a FMRI AON with two spacers), or “X_spA_spB_spC” (for a FMRI AON with three spacers). Here, “X” refers to the length of the FMRI AON, “A” refers to the position in the FMRI AON where the first spacer is located, “B” refers to the position in the FMRI AON where the second spacer is located, and if present, “C” refers to the position in the FMRI AON where the third spacer is located.
[0205] In various embodiments, FMRI oligonucleotides include one spacer. In various embodiments, the inclusion of a spacer divides up the FMRI oligonucleotide into two separate segments, where at least one of the segments is at most 11 linked nucleosides in length. In various embodiments, the inclusion of a spacer divides up the FMRI oligonucleotide into two separate segments, where at least one of the segments is at most 10 linked nucleosides in length.
[0206] In various embodiments, the spacer is located between positions 10 and 15 of the oligonucleotide. In various embodiments, the spacer is located between positions 10 and 12 of the oligonucleotide. In particular embodiments, the spacer is located at position 10 of the oligonucleotide. In particular embodiments, the spacer is located at position 11 of theAttorney Docket No. QRL-028WOoligonucleotide. In particular embodiments, the spacer is located at position 12 of the oligonucleotide. In particular embodiments, the spacer is located at position 13 of the oligonucleotide. In particular embodiments, the spacer is located at position 14 of the oligonucleotide. In particular embodiments, the spacer is located at position 15 of the oligonucleotide.
[0207] Example FMRI AONs with one spacer are documented below in Table 3. Generally, the architecture of the FMRI AONs with one spacer shown in Table 3 can be applied to any of the FMRI parent AON sequences disclosed in Tables 2A or 2B.Table 3: Identification of FMRI AONs with one spacer. Here, each FMRI AON has 2 segments.* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, aAttorney Docket No. QRL-028WOmethylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.
[0208] In various embodiments, FMRI oligonucleotides include two spacers. In various embodiments, the inclusion of a spacer divides up the FMRI oligonucleotide into three separate segments, where at least one of the segments is at most 7 linked nucleosides in length. ExampleFMRI AONs with two spacers are documented below in Table 4. Generally, the architecture of the FMRI AONs with two spacers shown in Table 4 can be applied to any of the FMRI parent AON sequences (25mers in length) disclosed in Tables 2 A or 2B.Table 4: Identification of FMRI AONs with two spacers. Here, each FMRI AON has 3 segments, where at least one of the segments has at most 7 linked nucleosides.Attorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.Attorney Docket No. QRL-028WO
[0209] In various embodiments, FMRI oligonucleotides include three spacers. The inclusion of three spacers divides up the FMRI oligonucleotide into four separate segments. In various embodiments, the three spacers are located at different positions of the FMRI oligonucleotide such that each of the segments of the FMRI oligonucleotide are at most 7 linked nucleosides in length.
[0210] In various embodiments, FMRI AONs with three spacers are 27 oligonucleotide units in length. For example, a FMRI AON with three spacers can divide up a FMRI AON into four separate segments. In various embodiments, each of the four separate segments are 6 oligonucleotide units in length. For example, the FMRI AON may be as follows (from 5’ to 3’ end): a first segment of 6 linked nucleosides, a first spacer, a second segment of 6 linked nucleosides, a second spacer, a third segment of 6 linked nucleosides, a third spacer, and a fourth segment of 6 linked nucleosides. Generally, the architecture of the FMRI AONs with three spacers shown in Table 5 can be applied to any of the FMRI parent AON sequences (23mers or 25mers in length) disclosed in Tables 2A or 2B.
[0211] Example FMRI AONs with three spacers are documented below in Table 5.Table 5: Identification of FMRI AONs or AON variants with three spacers. Here, each FMRI AON has 4 segments, where each segment has at most 7 linked nucleosides.Attorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.
[0212] In various embodiments, FMRI AONs with one or more spacers are reduced in length in comparison to the FMRI AONs described above in Tables 3-5. For example, such FMRI AONs may be FMRI oligonucleotide variants with one or more spacers. In various embodiments, the FMRI oligonucleotides with one or more spacers are 25mers, 23mers, 21mers, 20mers, or 19mers. In various embodiments, FMRI oligonucleotide variants include two spacers such that the FMRI oligonucleotide variant includes three segments that are divided up by the two spacers. In various embodiments, at least one of the three segments has at most 7 linked nucleosides. In various embodiments, each of the three segments has at most 7 linked nucleosides. Exemplary FMRI parent and variant oligonucleotide with one or more spacers are shown below in Table 6. The architecture of the FMRI AONs with two spacers shown in Table 6 can be applied to the FMRI parent AON sequences disclosed in Tables 2A or 2B. For example, for a FMRI parent AON in Tables 2A or 2B with 23 oligonucleotides, the third row of Table 6 discloses an exemplary architecture in which spacers are substituted at positions 8 and 16.Table 6: FMRI AONs with two spacers. Here, each FMRI AON variant has 3 segments.Attorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO* At least one internucleoside linkage of the nucleotide sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.
[0213] In various embodiments, FMRI AONs include two spacers. In various embodiments, the inclusion of a spacer divides up the FMRI AONs into three separate segments, where at least one of the segments is at most 7 linked nucleosides in length. Example FMRI AONs with two spacers are documented below in Table 7. In some embodiments, the spacers of SEQ ID NO: 484-564 or 1021-1075 comprise the formula of Formula (IIa). In some embodiments, the spacers of SEQ ID NO: 484-564 or 1021-1075 comprise the formula of Formula (Illa’ ).Table 7. FMRI Oligonucleotide sequence with 2 spacers.Attorney Docket No. QRL-028WOAttorney Docket No. QRL-028WO
[0214] *At least one intemucleoside linkage of the nucleoside sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage. In one embodiment, S represents a spacer of Formula (lia’) as disclosed herein.
[0215] In some embodiments, the two spacers of SEQ ID NO: 1076-1132 comprise the formula of Formula (V), represented by (S*) in the sequence. In some embodiments, the two spacers of SEQ ID NO: 1133-1189 comprise the formula of Formula (IV), represented by (S#) in theAttorney Docket No. QRL-028WOsequence. Example FMRI AONs with two spacers comprise the formula of Formula (V) orFormula (IV) are documented below in Table 8A.Table 8A. FMRI Oligonucleotide sequences with 2 spacers.Attorney Docket No. QRL-028WO
[0216] AAt least one intemucleoside linkage of the nucleoside sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage. In one embodiment, (S*) represents a spacer of Formula (V) as disclosed herein. (S#) represents a spacer of Formula (IV) as disclosed herein.
[0217] In some embodiments, the two spacers of SEQ ID NO: 1190-1246 comprise the formula of Formula (Ilib) or Formula (Ilib ’), represented by (S!) in the sequence. Example FMRI AONs with two spacers comprise the formula of Formula (Ilib) or Formula (Ilib’) are documented below in Table 8B.Table 8B. FMRI Oligonucleotide sequences with 2 spacers.Attorney Docket No. QRL-028WOAt least one internucleoside linkage of the nucleoside sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage. In one embodiment, (S!) represents a spacer of Formula (Ilib) or Formula (Ilib ’ ) as disclosed herein.Attorney Docket No. QRL-028WOPerformance of FMRI Oligonucleotides
[0218] Generally, FMRI oligonucleotides (e.g, FMRI oligonucleotides with sequences of any of SEQ ID NOs: 484-564 or 1021-1246) target FMRI transcripts (for example, a FMRI pre-mRNA comprising intron 1) comprising a sequence that shares at least 90% (e.g, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 976 in order to decrease levels of the splice variant FMRI -217. In some embodiments, the FMRI oligonucleotides do not reduce the levels of the FMRI canonical variant (e.g., FMRI-205; SEQ ID NO: 967). In some embodiments, the FMRI oligonucleotides increase the levels of the FMRI canonical variant (e.g., FMRI -205; SEQ ID NO: 967). Additional canonical variants are listed in Table A. In various embodiments, FMRI AONs can exhibit at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 10% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 20% decrease of the splice variant FMRI-217. In some embodiments, the FMRI AONs exhibit at least a 30% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 40% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 50% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 60% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 70% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 80% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit at least a 90% decrease of the splice variant FMRI -217. In some embodiments, the FMRI AONs exhibit a decrease of the splice variant FMRI -217 between 10% to 90%. In some embodiments, the FMRI AONs exhibit a decrease of the splice variant FMRI-217 between 20% to 90%. In some embodiments, the FMRI AONs exhibit a decrease of the splice variant FMRI-217 between 30% to 90%. In some embodiments, the FMRI AONs exhibit a decrease of the splice variant FMRI -217 between 40% to 90%. In some embodiments, the percent decrease of the splice variant FMRI -217 is decreased in comparison to a level of the splice variant FMR1-217 achieved using a non-targeting control antisense oligonucleotide. For example, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217.
[0219] In another example, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 without reducing the levels of the FMRI canonical variant. In another example, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI-217 without reducing the levels of FMRI -205. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI-Attorney Docket No. QRL-028WO205 remain above 40%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI -205 remain above 50%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI-205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide can be used to decrease the splice variant FMRI -217 while the levels of FMRI -205 remain above 95%.
[0220] In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 10%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 20%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 30%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 40%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 50%, while the levels of FMRI-205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 60%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 70%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 80%, while the levels of FMRI -205 remain above 90%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 90%, while the levels of FMRI -205 remain above 90%.
[0221] In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 10%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 20%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 30%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 40%, while the levels ofAttorney Docket No. QRL-028WOFMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 50%, while the levels of FMRI-205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 60%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 70%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 80%, while the levels of FMRI -205 remain above 80%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 90%, while the levels of FMRI -205 remain above 80%.
[0222] In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 10%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 20%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 30%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 40%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 50%, while the levels of FMRI-205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 60%, while the levels of FMRI-205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 70%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 80%, while the levels of FMRI -205 remain above 70%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 90%, while the levels of FMRI -205 remain above 70%.
[0223] In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 10%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 20%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI-217 by at least 30%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 40%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotideAttorney Docket No. QRL-028WOdecreases the splice variant FMRI-217 by at least 50%, while the levels of FMRI-205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 60%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 70%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 80%, while the levels of FMRI -205 remain above 60%. In some embodiments, a FMRI antisense oligonucleotide decreases the splice variant FMRI -217 by at least 90%, while the levels of FMRI -205 remain above 60%.
[0224] In some embodiments, FMRI AONs can exhibit at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% decrease of the splice variant FMRI -217. In some embodiments, the percent decrease of the splice variant FMRI -217 refers to the % of the splice variant FMR1-217 following depletion using a FMRI antisense oligonucleotide in comparison to a negative control (e.g., cells that did not undergo depletion or treatment or cells that were treated with a vehicle solution).Modifications
[0225] A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2’, 3’ or 5’ hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the intemucleoside linkages of the oligonucleotide.
[0226] Modifications to antisense compounds encompass substitutions or changes to intemucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased activity.
[0227] Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.Attorney Docket No. QRL-028WOModified Intemucleoside Linkages
[0228] The naturally occurring internucleoside linkage of RNA and DNA is a 3’ to 5’ phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, intemucleoside linkages are often selected over antisense compounds having naturally occurring intemucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.
[0229] Oligonucleotides having modified intemucleoside linkages include intemucleoside linkages that retain a phosphorus atom as well as intemucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing intemucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.
[0230] In certain embodiments, antisense compounds targeted to a FMRI nucleic acid comprise one or more modified intemucleoside linkages. In certain embodiments, the modified intemucleoside linkages are interspersed throughout the antisense compound. In certain embodiments, the modified intemucleoside linkages are phosphorothioate linkages. In certain embodiments, each intemucleoside linkage of an antisense compound is a phosphorothioate intemucleoside linkage. In certain embodiments, the modified intemucleoside linkages are mesyl phosphoroamidate linkages. In certain embodiments, the modified intemucleoside linkages are phosphoryl guanidine (PN) linkages. In certain embodiments, the antisense compounds targeted to a FMRI nucleic acid comprise at least one phosphodiester linkage and at least one phosphorothioate linkage.Modified Sugar Moieties
[0231] Antisense compounds can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise chemically modified ribofuranose ring moieties. Examples of chemically modified ribofuranose rings include without limitation, addition of substituent groups (including 5’ and 2’ substituent groups, bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the ribosyl ring oxygen atom with S, N(R) or C(RI)(R2) (R, Ri and R2 are each independently H, C1-C12 alkyl or a protecting group) and combinations thereof. Examples of chemically modified sugars include 2’-F-5’-methyl substituted nucleoside (see PCT International Application WO 2008 / 101157 Published on Aug. 21, 2008 disclosed 5’,2’-bis substituted nucleosides) or replacement of the ribosyl ringAttorney Docket No. QRL-028WOoxygen atom with S with further substitution at the 2’ -position (see published U. S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5 ’-substitution of a BNA (see PCT International Application WO 2007 / 134181 Published on Nov. 22, 2007) wherein LNA is substituted with for example a 5’-methyl or a 5’-vinyl group, or a 5’ cyclopropyl substituted nucleoside or a modified locked nucleic acid (LNA), including amido-bridged nucleic acids (AmNAs), guanidine-bridged nucleic acids (GuNAs), and LNAs with a cyclopropyl substitution (see PCT International Application WO 2022 / 234855).
[0232] Examples of nucleosides having modified sugar moieties include without limitation nucleosides comprising 5’-vinyl, 5’-methyl (R or S), 4’-S, 2’-F, 2’-OCH3, 2’-OCH2CH3, 2’-0 CH2CH2F, 2'-O-[2-(methylamino)-2-oxoethyl] (-OCH2C(O)NHMe; 2’NMA), and 2’-O(CH2)2OCH3 substituent groups. The substituent at the 2’ position can also be selected from allyl, amino, azido, thio, O-allyl, O — Ci-Cio alkyl, OCF3, OCH2F, O(CH2)2S CH3, O(CH2)2— O— N(Rm)(Rn), O— CH2— C(=O)— N(Rm)(Rn), and O— CH2— C(=O)— N(Ri)— ( CH2)2— N(Rm)(Rn)-, where each Ri, Rmand Rnis, independently, H or substituted or unsubstituted Ci-C10 alkyl.
[0233] Additional examples of modified sugar moieties include a 2’-OMe modified sugar moiety, bicyclic sugar moiety, -O-(2 -methoxy ethyl) (2’-M0E), 2’-deoxy-2’-fluoro nucleoside, 2’-fluoro-P-D-arabinonucleoside, 2’-O-(N-methylacetamide) nucleoside, locked nucleic acid (LNA), constrained ethyl 2’ -4’ -bridged nucleic acid (cEt), A'-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (e.g., tcDNA). In some embodiments, the nucleosides of the FMRI AONs may be modified nucleosides with 2’ -MOE sugar moieties. In some embodiments, the nucleosides of the FMRI AONs may be modified nucleosides with 2’ -MOE sugar moieties, and each “C” may be replaced with a 5-MeC. In some embodiments, each of the internucleoside linkages between the nucleosides of the FMRI oligonucleotides are phosphorothioate intemucleoside linkages.
[0234] As used herein, “bicyclic nucleosides” refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include without limitation nucleosides comprising a bridge between the 4’ and the 2’ ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides comprising a 4’ to 2’ bridge. Examples of such 4’ to 2’ bridged bicyclic nucleosides, include but are not limited to one of the formulae: 4’-(CH2)— O-2’ (LNA); 4’-(CH2)— S-2’; 4’-(CH2)2— O-2’ (ENA); 4’-CH(CH3)— O-2’ and 4’-CH(CH2OCH3)— O-2’ (and analogs thereof see U. S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4’-C(CH3)(CH3) — O-2’ (and analogs thereof see published International Application WO / 2009 / 006478, published Jan. 8, 2009); 4’-CH2— N(OCH3)-2’ (and analogs thereof see published International Application WO / 2008 / 150729, published Dec. 11, 2008); 4’-Attorney Docket No. QRL-028WOCH2 — O — N(CH3)-2’ (see published U. S. Patent Application US2004-0171570, published Sep.2, 2004); 4’- CH2 — N(R) — 0-2’, wherein R is H, C1-C12 alkyl, or a protecting group (see U. S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4’-CH2 — C(H)(CH3)-2’ (see Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4’-CH2 — C — (=CH2)-2’ (and analogs thereof see published International Application WO 2008 / 154401, published on Dec. 8, 2008).
[0235] Further reports related to bicyclic nucleosides can also be found in published literature (see for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 2007, 129(26) 8362-8379; Elayadi et al., Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; and Orum et al., Curr. Opinion Mol. Then, 2001, 3, 239-243; U. S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345;U. S. Patent Publication No. US2008-0039618; US2009-0012281; U. S. Patent Ser. No.60 / 989,574; 61 / 026,995; 61 / 026,998; 61 / 056,564; 61 / 086,231; 61 / 097,787; and 61 / 099,844; Published PCT International applications WO 1994 / 014226; WO 2004 / 106356; WO 2005 / 021570; WO 2007 / 134181; WO 2008 / 150729; WO 2008 / 154401; and WO 2009 / 006478. Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example a-L-ribofuranose and P-D-ribofuranose (see PCT international application PCT / DK98 / 00393, published on Mar. 25, 1999 as WO 99 / 14226).
[0236] In certain embodiments, bicyclic sugar moi eties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4’ and the 2’ position of the pentofuranosyl sugar moiety wherein such bridges independently comprise 1 or from 2 to 4 linked groups independently selected from — [C(Ra)(Rb)]n—, — C(Ra)=C(Rb) —, — C(Ra)=N —, — C(=O)—, — C(=NRa)—, — C(=S) —, — O—, — Si(Ra)2—, — S(=O)X—, and — N(Ra)—; wherein:x is 0, 1, or 2;n is 1, 2, 3, or 4;each Raand Rb is, independently, H, a protecting group, hydroxyl, C1-C12 alkyl, substituted Ci-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJi, NJ1J2, SJi, N3, COOJi, acyl (C(=O) — H), substituted acyl, CN, sulfonyl (S(=O)2-Ji), or sulfoxyl (S(=O)-Ji); andeach Ji and J2 is, independently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl,Attorney Docket No. QRL-028WOsubstituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted Cs-C2oaryl, acyl (C(=O) — H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl or a protecting group.
[0237] In certain embodiments, the bridge of a bicyclic sugar moiety is — [C(Ra)(Rb)]n —, — [ — [C(Ra)(Rb)]n— O—, — C(RaRb)— N(R)— O— or — C(RaRb)— O— N(R)—. In certain embodiments, the bridge is 4’-CH2-2’, 4’-(CH2)2-2’, 4’-(CH2)3-2’, 4’-CH2— O-2’, 4’-(CH2)2— O-2’, 4’-CH2 — O — N(R)-2’ and 4’-CH2 — N(R) — O-2’- wherein each R is, independently, H, a protecting group or C1-C12 alkyl, each Ra and Rb is, independently, H, a protecting group, hydroxyl, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJi, NJ1J2, SJi, N3, COOJi, acyl (C(=O) — H), substituted acyl, CN, sulfonyl (S(=0)2-Ji), or sulfoxyl (S(=O)-Ji); each Ji and J2 is, independently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, Cs-C2oaryl, substituted Cs-C2oaryl, acyl (C(=O) — H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl or a protecting group; and R is H, C1-C12 alkyl, or a protecting group (see U. S. Pat. No. 7,427,672, issued on Sep. 23, 2008).
[0238] In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4’-2’ methyleneoxy bridge, may be in the a-L configuration or in the P-D configuration. Previously, a-L-methyleneoxy (4’-CH2 — O-2’) BNA’s have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).
[0239] In certain embodiments, bicyclic nucleosides include, but are not limited to, a-L-methyleneoxy (4’-CH2 — O-2’) BNA, P-D-methyleneoxy (4’-CH2 — O-2’) BNA, ethyleneoxy (4’-(CH2)2— 0-2) BNA, aminooxy (4’-CH2— O— N(R)-2’) BNA, oxyamino (4’-CH2— N(R)— 0-2’) BNA, methyl(methyleneoxy) (4’-CH(CH3) — 0-2’) BNA, methylene-thio (4’-CH2 — S-2’) BNA, methylene-amino (4’-CH2 — N(R)-2’) BNA, methyl carbocyclic (4’-CH2 — CH(CH3)-2’) BNA, and propylene carbocyclic (4’-(CH2)3-2’) BNA; wherein R is H, C1-C12 alkyl, or a protecting group (see U. S. Pat. No. 7,427,672, issued on Sep. 23, 2008).Pharmaceutical Compositions
[0240] The present disclosure provides, in some embodiments, methods for treating, ameliorating, or preventing a neurodevelopmental and / or neurodegenerative disease and / or a neuropathy further include methods of administering, to a patient, a pharmaceutically acceptableAttorney Docket No. QRL-028WOcomposition, for example, a pharmaceutically acceptable formulation that includes one or more FMRI oligonucleotides. FMRI oligonucleotides can decrease the activity of splice variant FMRI-217, for example, decrease levels of the splice variant FMRI-217.
[0241] The present disclosure also provides pharmaceutical compositions comprising a FMRI oligonucleotide formulated together with one or more pharmaceutically or cosmetically acceptable excipients. These formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intrathalamic, intravenous, subcutaneous, intraci sternal, intracerebroventricular, intraparenchymal, parenteral (e.g., subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) administration, transmucosal (e.g., buccal, vaginal, and rectal), or for topical use, e.g., as part of a composition suitable for applying topically to skin and / or mucous membrane, for example, a composition in the form of a gel, a paste, a wax, a cream, a spray, a liquid, a foam, a lotion, an ointment, a topical solution, a transdermal patch, a powder, a vapor, or a tincture. Although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular FMRI oligonucleotide being used.
[0242] The present disclosure also provides a pharmaceutical composition comprising a FMRI oligonucleotide or a pharmaceutically acceptable salt thereof (for example, a FMRI AON that includes a sequence of any of SEQ ID NOs: 484-564 or 1021-1246).
[0243] The present disclosure also provides methods that include the use of pharmaceutical compositions comprising a FMRI AON is formulated together with one or more pharmaceutically acceptable excipients. Exemplary compositions provided herein include compositions comprising a FMRI AON and one or more pharmaceutically acceptable excipients. Formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intrathalamic, intracisternal, intracerebroventricular, intraparenchymal, parenteral (e.g., subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) administration, transmucosal (e.g., buccal, vaginal, and rectal), or for topical use. The most suitable form of administration in any given case will depend on the clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition that one is trying to prevent in a subject; the state, disorder, disease, or condition one is trying to prevent in a subject; and / or on the nature of the particular compound and / or the composition being used.Additional Chemically Modified Oligonucleotides
[0244] FMRI AONs described herein, can include chemically modified nucleosides, including modified ribonucleosides and modified deoxyribonucleosides. Chemically modified nucleosides include, but are not limited to, uracine, uridine, 2’-O-(2-methoxyethyl) modifications, forAttorney Docket No. QRL-028WOexample, 2’-O-(2-methoxyethyl)guanosine, 2’-O-(2-methoxyethyl)adenosine, 2’-O-(2-methoxyethyl)cytosine, and 2’-O-(2-methoxyethyl)thymidine. In certain embodiments, mixed modalities, e.g., a combination of a FMRI peptide nucleic acid (PNA) and a FMRI locked nucleic acid (LNA). Chemically modified nucleosides also include, but are not limited to, locked nucleic acids (LNAs), 2’-O-(N-methylacetamide), 2’-O-methyl, 2’-fluoro, and 2’-fluoro-P-D-arabinonucleotide (FANA), and Fluoro Cyclohexenyl nucleic acid (F-CeNA) modifications. Chemically modified nucleosides that can be included in FMRI AONs described herein are described in Johannes and Lucchino, (2018) “Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs” Nucleic Acid Ther. 28(3): 178-93; Rettig and Behlke, (2012) “Progress toward in vivo use of siRNAs-II” Mol Ther 20:483-512; and Khvorova and Watts, (2017) “The chemical evolution of oligonucleotide therapies of clinical utility” Nat Biotechnol., 35(3):238-48, the contents of each of which are incorporated by reference herein.
[0245] FMRI AONs described herein can include chemical modifications that promote stabilization of an oligonucleotide’s terminal 5 ’-phosphate and phosphatase-resistant analogs of 5 '-phosphate. Chemical modifications that promote oligonucleotide terminal 5 ’-phosphate stabilization or which are phosphatase-resistant analogs of 5 '-phosphate include, but are not limited to, 5 '-methyl phosphonate, 5'-methylenephosphonate, 5'-methylenephosphonate analogs, 5 '- / / -vinyl phosphonate (5'- -VP), 5'-phosphorothioate, and 5'-C-methyl analogs. Chemical modifications that promote AON terminal 5 ’-phosphate stabilization and phosphatase-resistant analogues of 5'-phosphate are described in Khvorova and Watts, (2017) “The chemical evolution of oligonucleotide therapies of clinical utility” Nat Biotechnol., 35(3):238-48, the contents of which are incorporated by reference herein.
[0246] In some embodiments described herein, FMRI AONs described herein can include chemically modified nucleosides, for example, 2’ O-methyl ribonucleosides, for example, 2’ O-methyl cytidine, 2’ O-methyl guanosine, 2’ O-methyl uridine, and / or 2’ O-methyl adenosine. FMRI AONs described herein can include one or more chemically modified bases, including a 5-methylpyrimidine, for example, 5-methylcytosine, and / or a 5 -methylpurine, for example, 5-methylguanine. Chemically modified nucleosides can further include pseudo-uridine or5 ’methoxyuridine. FMRI AONs described herein can include any of the following chemically modified nucleosides: 5-methyl-2’-O-methylcytidine, 5-methyl-2’-O-methylthymidine, 5-methylcytidine, 5-methyluridine, and / or 5-methyl 2’-deoxycytidine.
[0247] FMRI AONs described herein can include a phosphate backbone where one or more of the oligonucleoside linkages is a phosphate linkage. FMRI AONs described herein may include a modified oligonucleotide backbone, where one or more of the internucleoside linkages of the sequence is selected from the group consisting of a phosphorothioate linkage, aAttorney Docket No. QRL-028WOphosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (e.g., comprising a phosphorodiamidate morpholino (PMO), 3’ amino ribose, or 5’ amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage. In some embodiments of FMRI AONs described herein, at least one ( / .<., one or more) intemucleoside linkage of the oligonucleotide is a phosphorothioate linkage. For example, in some embodiments of FMRI AONs described herein, one, two, three, or more intemucleoside linkages of the oligonucleotide is a phosphorothioate linkage. In preferred embodiments of FMRI AONs described herein, all intemucleoside linkages of the oligonucleotide are phosphorothioate linkages.FMRI
[0248] In some embodiments, all of the nucleotide linkages of a FMRI AON of any of SEQ ID NOs: 1-483, 983-1019, or 1255 are phosphorothioate linkages. In some embodiments, one or more of the nucleotide linkages of a FMRI AON of any of SEQ ID NOs: 1-483, 983-1019, or 1255 are phosphorothioate linkages.
[0249] In various embodiments, nucleotide linkages of FMRI AON described herein such as any of SEQ ID NOs: 1-483, 983-1019, or 1255 include a mix of phosphodiester and phosphorothioate linkages.
[0250] In some embodiments, intemucleoside linkages linking a nucleotide at position 3 of a FMRI AON described herein are phosphodiester bonds. For example, the nucleotide at position 3 may be linked to each adjacent nucleotide (e.g., preceding nucleotide and succeeding nucleotide) through a phosphodiester bond. An example 25mer FMRI AON with phosphodiester bonds linking the nucleotide at position 3 can be denoted as:XXoDoXXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 3. Any nucleotide in the AON can be a nucleotide analog.
[0251] In some embodiments, one of the intemucleoside linkages linking a nucleotide at position 3 of a FMRI AON described herein is a phosphodiester bond. For example, the nucleotide at position 3 may be linked to either the preceding nucleotide or the succeeding nucleotide through a phosphodiester bond. An example 25mer FMRI AON with aAttorney Docket No. QRL-028WOphosphodiester bond linking the nucleotide at position 3 to a preceding nucleotide can be denoted as:XXoDXXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 3. Any nucleotide in the AON can be a nucleotide analog.
[0252] An example 25mer FMRI AON with a phosphodi ester bond linking the nucleotide at position 3 to a succeeding nucleotide can be denoted as:XXD oXXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 3. Any nucleotide in the AON can be a nucleotide analog.
[0253] In various embodiments, in addition to one of the internucleoside linkages linking a nucleotide at position 3 of a FMRI AON described herein being a phosphodiester bond, the FMRI AON further includes two spacers. The two spacers can be positioned in the FMRI AON such that the FMRI AON includes a segment with at most 7 linked nucleosides. An example 25mer FMRI AON with two spacers and with a phosphodiester bond linking the nucleotide at position 3 to a preceding nucleotide can be denoted as:XXODS1XXXXXXXXXS2XXXXXXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond and “D” represents the nucleotide at position 3. Any nucleotide in the AON can be a nucleotide analog.
[0254] An example 25mer FMRI AON with two spacers and with a phosphodiester bond linking the nucleotide at position 3 to a succeeding nucleotide can be denoted as:XXD oXXXXXXXSi XXXXXXXXXS2XXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond and “D” represents the nucleotide at position 3. Any nucleotide in the AON can be a nucleotide analog.
[0255] In some embodiments, internucleoside linkages linking a nucleotide at position 4 of a FMRI AON described herein are phosphodiester bonds. For example, the nucleotide at position 4 may be linked to each adjacent nucleotide (e.g., preceding nucleotide and succeeding nucleotide) through a phosphodiester bond. An example 25mer FMRI AON with phosphodiester bonds linking the nucleotide at position 4 can be denoted as:XXXoDoXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 4. Any nucleotide in the AON can be a nucleotide analog.Attorney Docket No. QRL-028WO
[0256] In some embodiments, one of the intemucleoside linkages linking a nucleotide at position 4 of a FMRI AON described herein is a phosphodiester bond. For example, the nucleotide at position 4 may be linked to either the preceding nucleotide or the succeeding nucleotide through a phosphodiester bond. An example 25mer FMRI AON with a phosphodiester bond linking the nucleotide at position 4 to a preceding nucleotide can be denoted as:XXXoDXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 4. Any nucleotide in the AON can be a nucleotide analog.
[0257] An example 25mer FMRI AON with a phosphodi ester bond linking the nucleotide at position 4 to a succeeding nucleotide can be denoted as:XXXDoXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond and “D” represents the nucleotide at position 4. Any nucleotide in the AON can be a nucleotide analog.
[0258] In some embodiments, internucleoside linkages linking both nucleotides at position 3 and position 4 of a FMRI AON described herein are phosphodiester bonds. For example, the nucleotide at position 3 may be linked to each adjacent nucleotide (e.g., preceding nucleotide and succeeding nucleotide) through a phosphodiester bond, and the nucleotide at position 4 may be linked to each adjacent nucleotide (e.g., preceding nucleotide and succeeding nucleotide) through a phosphodiester bond. An example 25mer FMRI AON with phosphodiester bonds linking the nucleotides at positions 3 and 4 can be denoted as:XXoDoEoXXXXXXXXXXXXXXXXXXXXXwhere “o” represents a phosphodiester bond, “D” represents the nucleotide at position 3, and “E” represents the nucleotide at position 4. In various embodiments, all other nucleotides of the FMRI AON are linked through phosphorothioate bonds. Any nucleotide in the AON can be a nucleotide analog.
[0259] In various embodiments, FMRI AON described herein include one or more spacers and phosphodiester bonds are located relative to the one or more spacers. In some embodiments, the Y number of nucleotides immediately preceding a spacer are linked through phosphodiester bonds. In various embodiments, Y is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve nucleotides. In particular embodiments, Y is two nucleotides. For example, if the spacer is located at position 15, the nucleotides at positions 13 and 14 of the FMRI AON are each linked to their respective adjacent nucleotides through phosphodiester bonds. As described herein, the spacer can be located at various positions in the FMRI AON and therefore, the 2Attorney Docket No. QRL-028WOnucleotides immediately preceding the spacer can vary within the FMRI AON depending on where the spacer is situated.
[0260] In various embodiments, the FMRI AON may include more than one spacer. In some embodiments, only one of the spacers has Y number of nucleotides immediately preceding the spacer that are linked through phosphodiester bonds. In such embodiments, the other spacers are linked to respective preceding nucleotides through phosphorothioate bonds. In various embodiments, two of the spacers have Y number of nucleotides immediately preceding the spacers that are linked through phosphodiester bonds. In various embodiments, each of the spacers in the FMRI AON have Y number of nucleotides immediately preceding the spacers that are linked through phosphodiester bonds. In various embodiments, all other nucleotides of the FMRI AON are linked through phosphorothioate bonds.
[0261] In some embodiments, Y number of nucleotides immediately preceding a spacer and Z number of nucleotides immediately succeeding a spacer are linked through phosphodiester bonds. In various embodiments, Y is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve nucleotides. In various embodiments, Z is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve nucleotides. Y and Z can be independent of each other. In particular embodiments, Y is one nucleotide and Z is one nucleotide. For example, if the spacer is located at position 15, the nucleotides at positions 14 and 16 of the FMRI AON are each linked to their respective adjacent nucleotides through phosphodiester bonds. To provide an example, such a FMRI AON (e.g., 25mer) can be denoted as:XXXXXXXXXXXXXoDoSoEoXXXXXXXXXwhere “S” represents a spacer, “o” represents a phosphodiester bond, “D” represents a nucleotide immediately preceding the spacer, and “E” represents the nucleotide immediately succeeding the spacer. Any nucleotide in the AON can be a nucleotide analog.
[0262] As described herein, the spacer can be located at various positions in the FMRI AON and therefore, the nucleotides immediately preceding or immediately succeeding the spacer can vary within the FMRI AON depending on where the spacer is situated.
[0263] In various embodiments, the FMRI AON may include more than one spacer. In some embodiments, only one of the spacers has Y number of nucleotides immediately preceding the spacer and Z number of nucleotides immediately succeeding the spacer that are linked through phosphodiester bonds. In such embodiments, the other spacers of the FMRI AON are linked to respective preceding and succeeding nucleotides through phosphorothioate bonds. To provide an example, such a FMRI AON (e.g., 25mer) can be denoted as:XXXXODOS1OEOXXXXXXXXXXXS2XXXXXXAttorney Docket No. QRL-028WOwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents a nucleotide immediately preceding the spacer, and “E” represents the nucleotide immediately succeeding the spacer. Any nucleotide in the AON can be a nucleotide analog.
[0264] As another example, such a FMRI AON (e.g., 25mer) can be denoted as:XXXXXS! XXXXXXXXXXXODOS20E0XXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents a nucleotide immediately preceding the spacer, and “E” represents the nucleotide immediately succeeding the spacer. Any nucleotide in the AON can be a nucleotide analog.
[0265] In some embodiments, one of the spacers is linked to the immediately preceding nucleotide through a phosphodiester bond. For example, a FMRI AON includes a first spacer that is linked to the immediately preceding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXoSxXXXXXXXXXXXS2XXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0266] As another example, a FMRI AON includes a second spacer that is linked to the immediately preceding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXSxXXXXXXXXXXXoS2XXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0267] In various embodiments, the FMRI AON may be an AON variant (e.g., a 21mer or a 19mer) where one of the spacers is linked to the immediately preceding nucleotide through a phosphodiester bond. For example, the FMRI AON may be a 21mer with a first spacer that is linked to the immediately preceding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXXoSxXXXXXS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0268] As another example, the FMRI AON may be a 21mer with a second spacer that is linked to the immediately preceding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXXSxXXXXXoS2XXXXXXXAttorney Docket No. QRL-028WOwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0269] In some embodiments, the FMRI AON may be an AON variant (e.g., a 21mer or a 19mer) where one of the spacers is linked to the immediately preceding nucleotide through a phosphodiester bond and the immediately preceding nucleotide is further linked to the preceding nucleotide through a phosphodiester bond. An example 21mer FMRI AON can be denoted as:XXXXEODOS1XXXXXXS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the nucleotide immediately preceding Si and " E" represents the nucleotide immediately preceding " D." Any nucleotide in the AON can be a nucleotide analog.
[0270] As another example, a 21mer FMRI AON can be denoted as:XXXXXXS1XXXXEODOS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the nucleotide immediately preceding S2 and " E" represents the nucleotide immediately preceding “D.” Any nucleotide in the AON can be a nucleotide analog.
[0271] In some embodiments, the FMRI AON may be an AON variant (e.g., a 21mer or a 19mer) where a nucleotide that immediately precedes a first spacer is linked to another nucleotide through a phosphodiester bond. The nucleotide that immediately precedes the first spacer may be linked to the first spacer through a non-phosphodiester bond, such as a phosphorothioate bond. Additionally, a second spacer is linked to an immediately preceding nucleotide through a phosphodiester bond. An example of a 21mer FMRI AON can be denoted as:XXXXEODS1XXXXXXOS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the nucleotide immediately preceding Si and “E” represents the nucleotide immediately preceding “D.” Here, the nucleotide “D” is linked to the first spacer Si through a non-phosphodiester bond (e.g., phosphorothioate bond). Additionally, the nucleotide “D” is linked to nucleotide “E” through a phosphodiester bond. The second spacer S2 is linked to an immediately preceding nucleotide through a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0272] Another example of such a 21mer FMRI AON can be denoted as:XXXXXXOS1XXXXEODS2XXXXXXXAttorney Docket No. QRL-028WOwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the nucleotide immediately preceding S2 and “E” represents the nucleotide immediately preceding “D ” Here, the nucleotide “D” is linked to the second spacer S2 through a non-phosphodiester bond (e.g., phosphorothioate bond). Additionally, the nucleotide “D” is linked to nucleotide “E” through a phosphodiester bond. The first spacer Si is linked to an immediately preceding nucleotide through a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0273] In some embodiments, one of the spacers is linked to the immediately succeeding nucleotide through a phosphodiester bond. For example, a FMRI AON includes a first spacer that is linked to the immediately succeeding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXSi oXXXXXXXXXXXS2XXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0274] As another example, a FMRI AON includes a second spacer that is linked to the immediately succeeding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXS-! XXXXXXXXXXXS2oXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0275] In various embodiments, the FMRI AON may be an AON variant (e.g., a 21mer or a 19mer) where one of the spacers is linked to the immediately succeeding nucleotide through a phosphodiester bond. For example, the FMRI AON may be a 21mer with a first spacer that is linked to the immediately succeeding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXXSi oXXXXXS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0276] As another example, the FMRI AON may be a 21mer with a second spacer that is linked to the immediately succeeding nucleotide through a phosphodiester bond, which can be denoted as:XXXXXXXS-! XXXXXS2oXXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond. Any nucleotide in the AON can be a nucleotide analog.
[0277] In various embodiments, two of the spacers have Y number of nucleotides immediately preceding the spacers and Z number of nucleotides immediately succeeding the spacers that areAttorney Docket No. QRL-028WOlinked through phosphodiester bonds. In various embodiments, each of the spacers in the FMRI AON have Y number of nucleotides immediately preceding the spacers and Z number of nucleotides immediately succeeding the spacers that are linked through phosphodiester bonds. An example of such a FMRI AON (e.g., 25mer) can be denoted as:XXXXODOS1OEOXXXXXXXXXXOFOS2OHOXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, “o” represents a phosphodiester bond, “D” represents a nucleotide immediately preceding the first spacer, “E” represents the nucleotide immediately succeeding the first spacer, “F” represents a nucleotide immediately preceding the second spacer, and “H” represents the nucleotide immediately succeeding the second spacer. In various embodiments, all other nucleotides of the FMRI AON are linked through phosphorothioate bonds. Any nucleotide in the AON can be a nucleotide analog.
[0278] In various FMRI AON includes two or more spacers and a range of nucleotides located between the two spacers are linked through phosphodiester bonds. In various embodiments, the range of nucleotides include two, three, four, five, six, or seven nucleotides linked through phosphodiester bonds. In particular embodiments, the range of nucleotides include two nucleotides linked through phosphodiester bonds. In particular embodiments, the range of nucleotides include four nucleotides linked through phosphodiester bonds. In various embodiments, all other nucleotides of the FMRI AON are linked through phosphorothioate bonds. Any nucleotide in the AON can be a nucleotide analog.
[0279] In various embodiments, the range of nucleotides linked through phosphodiester bonds are positioned Y number of nucleotides succeeding the first spacer and Z number of preceding the second spacer. In various embodiments, Y is one, two, three, four, five, six, or seven nucleotides. In various embodiments, Z is one, two, three, four, five, six, or seven nucleotides. Y and Z can be independent of each other. Any nucleotide in the AON can be a nucleotide analog.
[0280] In particular embodiments, Y is five nucleotides and Z is four nucleotides. To provide an example, such a FMRI AON (e.g., 25mer) can be denoted as:XXXXXXXXS1XXXXoDoEoFoHoXXXS2XXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, and “o” represents a phosphodiester bond. The nucleotides “D,” “E,” “F,” and “H” represent the range of nucleotides that are linked through phosphodiester bonds. In this example, the range of nucleotides is located five nucleotides after the first spacer (e.g., D is positioned five nucleotides after the first spacer) and the range of nucleotides is located four nucleotides preceding the second spacer (e.g., H is positioned four nucleotides before the second spacer). Any nucleotide in the AON can be a nucleotide analog.Attorney Docket No. QRL-028WO
[0281] In particular embodiments, Y is four nucleotides and Z is three nucleotides. To provide an example, such a FMRI AON (e.g., 23mer) can be denoted as:XXXXXXXS1XXXODOEOXXS2XXXXXXXwhere “Si” represents a first spacer, “S2” represents a second spacer, and “o” represents a phosphodiester bond. The nucleotides “D” and “E” represent the range of nucleotides that are linked through phosphodiester bonds. In this example, the range of nucleotides is located four nucleotides after the first spacer (e.g., D is positioned four nucleotides after the first spacer) and the range of nucleotides is located three nucleotides preceding the second spacer (e.g., E is positioned three nucleotides before the second spacer). In various embodiments, the positions of the two spacers differ than shown above and therefore, the range of nucleotides linked through phosphodiester bonds are differently positioned. In various embodiments, all other nucleotides of the FMRI AON are linked through phosphorothioate bonds. Any nucleotide in the AON can be a nucleotide analog.
[0282] In some embodiments, a disclosed FMRI AON may have at least one modified nucleobase, e.g., 5-methylcytosine, and / or at least one methylphosphonate nucleotide, which is placed, for example, either at only one of the 5' or 3' ends or at both 5' and 3' ends or along the oligonucleotide sequence.
[0283] FMRI AONs may include at least one modified sugar. For example, the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2 -OH group may be replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH2, NR2, N3, CN, F, Cl, Br, and I (wherein R is an alkyl or aryl and R' is an alkylene). Examples of a modified sugar moiety include a 2’-0Me modified sugar moiety, bicyclic sugar moiety, 2’-< -(2-methoxyethyl) (2’-M0E or MOE), 2’-O-(N-methylacetamide), 2 ’-deoxy -2 ’-fluoro nucleoside, 2’-fluoro-P-D-arabinonucleoside, locked nucleic acid (LNA), 2’-O-(N-methylacetamide) nucleoside, constrained ethyl 2’ -4’ -bridged nucleic acid (cEt), A-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (e.g., tcDNA).
[0284] In some embodiments, FMRI AONs comprise 2’0Me (e.g., a FMRI AON comprising one or more 2’0Me modified sugar), 2’-M0E or MOE (e.g., a FMRI AON comprising one or more 2’-M0E modified sugar), PNA (e.g., a FMRI AON comprising one or more N-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), LNA (e.g., a FMRI AON comprising one or more locked ribose, and can be a mixture of 2’-deoxy nucleotides or 2’0Me nucleotides), c-ET (e.g., a FMRI AON comprising one or more cET sugar), cMOE (e.g., a FMRI AON comprising one or more cMOE sugar), morpholino oligomer (e.g., a FMRI AON comprising a backbone comprising one or more PMO), deoxy-2’ -fluoro nucleoside (e.g., a FMRI AON comprising oneAttorney Docket No. QRL-028WOor more 2’-fluoro-P-D-arabinonucleoside), tcDNA (e.g., a FMRI AON comprising one or more tcDNA modified sugar), ENA (e.g., a FMRI AON comprising one or more ENA modified sugar), or HNA e.g., a FMRI AON comprising one or more HNA modified sugar). In some embodiments, a FMRI AON comprises one or more phosphor othioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, phosphoramidothioate linkage, thiophosphorodiamidate linkage, phosphoryl guanidine (PN) linkage, morpholino linkage, phosphoryl sulfonamide linkage, PNA linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, phosphoryl guanidine (PN) linkage, morpholino linkage, phosphoryl sulfonamide linkage, and PNA linkage. In some embodiments, a FMRI AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.
[0285] In some embodiments, FMRI AONs with a sequence of any one of SEQ ID NOs: 484- 564 or 1021-1246 is a chirally controlled oligonucleotide, such as a chirally controlled oligonucleotide described in any of US Patent No. 9,982,257, US Patent No. 10,590,413, US 10,724,035, US 10,450,568, and PCT Publication No. WO2019200185, each of which is hereby incorporated by reference in its entirety.
[0286] For example, a FMRI AON with a sequence of any one of SEQ ID NOs: 484-564 or 1021-1246 is a chirally controlled oligonucleotide comprising a plurality of oligonucleotides of at least one type, wherein each type is defined by: 1) base sequence; 2) pattern of backbone linkages; 3) pattern of backbone chiral centers; and 4) pattern of backbone X-moi eties ( — X-L- R1); wherein: the oligonucleotides of the at least one type comprise one or more phosphorothioate triester internucleotidic linkages and one or more phosphate diester linkage; the oligonucleotides of the at least one type comprise at least two consecutive modified internucleotidic linkages; and oligonucleotides of the at least one oligonucleotide type comprise one or more modified internucleotidic linkages independently having the structure of:wherein: P* is an asymmetric phosphorus atom and is either Rp or Sp;W is O, S or Se; each of X, Y and Z is independently — O —, — S —, — NQL-R1) —, or L; L is a covalent bond or an optionally substituted, linear or branched C1-C50 alkylene, wherein one or more methylene units of L are optionally and independently replaced by an optionally substituted Ci-C6alkylene, Ci-C6alkenylene, — C=C—, — C(R')2—, -Cy-, — O—, — S—, — S— S—, — N(R')—, — C(O)—, — C(S)—, — C(NR')—, — C(O)N(R')—, — N(R')C(O)N(R')—, —Attorney Docket No. QRL-028WON(R')C(O)—, — N(R')C(O)O—, — OC(O)N(R')—, — S(O)—, — S(O)2—, — S(O)2N(R')—, — N(R')S(O)2— — SC(O)—, — C(O)S—, — OC(O)—, or — C(O)O—; R1is halogen, R, or an optionally substituted C1-C10 aliphatic wherein one or more methylene units are optionally and independently replaced by an optionally substituted Ci-Ce alkylene, Ci-Ce alkenylene, — C=C —, — C(R')2—, -Cy-, — O—, — S—, — S— S—, — N(R')—, — C(O)—, — C(S)—, — C(NR')—, — C(O)N(R')—, — N(R')C(O)N(R')—, — N(R')C(O)—, — N(R')C(O)O—, — OC(O)N(R')—, — S(O)—, — S(O)2—, — S(O)2N(R')—, — N(R')S(O)2—, — SC(O)—, — C(O)S—, — OC(O)—, or — C(O)O —; each R' is independently — R, — C(O)R, — CO2R, or — SO2R, or: two R' on the same nitrogen are taken together with their intervening atoms to form an optionally substituted heterocyclic or heteroaryl ring, or two R' on the same carbon are taken together with their intervening atoms to form an optionally substituted aryl, carbocyclic, heterocyclic, or heteroaryl ring; -Cy- is an optionally substituted bivalent ring selected from phenylene, carbocyclylene, arylene, heteroarylene, or heterocyclylene; each R is independently hydrogen, or an optionally substituted group selected from Ci-Ce aliphatic, phenyl, carbocyclyl, aryl, heteroaryl, orheterocyclyl; and eachindependently represents a connection to a nucleoside. In some embodiments, a FMRI AON with a sequence of any one of SEQ ID NOs: 484-564 or 1021-1246 is a chirally controlled oligonucleotide comprising certain chemical modifications (e.g., 2’F (2’ Fluoro, which contains a fluorine molecule at the 2’ ribose position (instead of 2’-hydroxyl group in an RNA monomer)), 2’-0Me, phosphorothioate linkages, lipid conjugation, etc.), as described in U. S. Patent No. 10,450,568.FMRI-Related Diseases or Disorders
[0287] Fragile X Syndrome (FXS) is a genetic disorder that occurs as a result of expanded CGG repeats in the FMRI gene. FXS is a common inherited form of developmental and intellectual disability. FMRI makes a protein FMRP that has a critical role and function in the central nervous system development. CGG repeat expansions of >50 or >200 repeats in the FMRI gene cause there to be reduced FMRP protein, which causes the symptoms of FXS. Fragile X-associated Tremor and Ataxia Syndrome (FXTAS) is a late-onset condition that may develop in individuals with expanded CGG repeats in the FMRI gene, for example >55 or <200 CGG repeats. Individuals with FXTAS do not develop the intellectual or developmental disabilities that are common in FXS, but may develop late onset neurodegeneration. In addition, female permutation carriers may develop Fragile X-associated primary ovarian insufficiency (FXPOI).
[0288] A decrease in FMRP is also associated with Alzheimer’s Disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS).Attorney Docket No. QRL-028WO
[0289] Symptoms of FXS include intellectual disabilities, developmental disabilities, behavioral challenges, anxiety, muscle pain, spasms, slurred speech, difficulty swallowing, loss of muscle controljoint pain, difficulty swallowing, eating, speaking, and limb movement. These symptoms are also sometimes accompanied by depression, loss of memory, difficulty with planning, language deficits, and altered behavior. Symptoms of FXTAS include muscle pain, tremors, spasms, slurred speech, dementia, death, and a shuffling gait. FXPOI in women causes hypergonadotropic hypogonadism and women cease menstruating before age 40, a condition also known as premature ovarian failure (POF), which can include symptoms such as low bone density, early onset osteoporosis and bone fractures, impaired endothelial function, early onset coronary heart disease, and increased cardiovascular mortality.
[0290] FXS and FXTAS can be assessed and diagnosed by a clinician of skill, for example, a neurologist, using various tools and tests, as well as by addressing the familial history of these diseases. For example, the presence or risk of developing a FXS or FXTAS can be diagnosed using blood and urine tests (for example, tests that assay the FMRI gene), magnetic resonance imaging (MRI), electromyography (EMG), nerve conduction study (NCS), spinal tap, lumbar puncture, and / or muscle biopsy. Motor symptoms can be diagnosed with the aid of a physical exam and / or a neurological exam to assess motor and sensory skills, nerve function, hearing and speech, vision, coordination and balance, mental status, and changes in mood or behavior.
[0291] Parkinson’s disease (PD) can be assessed and diagnosed using various tools and tests including physical and neurological examinations, a single-photon emission computerized tomography (SPECT) scan called a dopamine transporter (DAT) scan, genetic testing, and alpha-synuclein test. Symptoms of PD include slowed movements, muscle tremors, rigidity or stiffness, other motor symptoms, autonomic nervous system symptoms (e.g., orthostatic hypotension (low blood pressure when standing up), constipation, gastrointestinal problems, and urinary incontinence), depression, loss of sense of smell, and sleep problems.
[0292] Multiple sclerosis (MS) can be assessed and diagnosed using various tools and tests including magnetic resonance imaging (MRI), lumbar puncture, optical coherence tomography, and neuropsychological testing. Symptoms of MS include a loss of vision, a loss of feeling in the arms or legs, weakness in the arms or legs, dizziness and imbalance, and bowel and bladder problems.
[0293] Alzheimer's disease (AD) can be assessed and diagnosed using various tools and tests including a physical exam and neurological exam, brain MRI, cognitive tests, CT scan, PET scan, and psychiatric and mental health evaluations. Symptoms of AD include a loss of memory, decreased reasoning, difficulty speaking or communicating, mood or personality changes, and mood swings.Attorney Docket No. QRL-028WO
[0294] TDP-43 related diseases
[0295] TDP-43 and FMRP are known to co-regulate translation of mRNAs. TDP-43 and FMRP also have roles in dendritic mRNA transport processes. The decrease in FMRP due to the presence of CGG repeat expansions of >50 or >200 repeats in the FMRI gene may affect these cellular processes.
[0296] Amyotrophic Lateral Sclerosis
[0297] ALS is a progressive motor neuron disease that disrupts signals to all voluntary muscles. ALS results in atrophy of both upper and lower motor neurons. Symptoms of ALS include weakening and wasting of the bulbar muscles, general and bilateral loss of strength, spasticity, muscle spasms, muscle cramps, fasciculations, slurred speech, and difficulty breathing or loss of ability to breathe. Some individuals with ALS also suffer from cognitive decline. At the molecular level, ALS is characterized by protein and RNA aggregates in the cytoplasm of motor neurons, including aggregates of the RNA-binding protein TDP43.
[0298] ALS is slightly more common in men above 40 years of age than women, although it can also occur in women and children. Risk of ALS is also heightened in individuals who smoke, are exposed to chemicals such as lead, or who have served in the military. Most instances of ALS are sporadic, while only about 10% of cases are familial. Causes of ALS include sporadic or inherited genetic mutations, high levels of glutamate, protein mishandling.
[0299] Frontotemporal Dementia
[0300] Frontotemporal dementia (FTD) is a form of dementia that affects the frontal and temporal lobes of the brain. FTD includes frontotemporal lobar degeneration (FTLD). It has an earlier average age of onset than Alzheimer’s disease - 40 years of age. Symptoms of FTLD include extreme changes in behavior and personality, speech and language problems, and movement-related symptoms such as tremor, rigidity, muscle spasm, weakness, and difficulty swallowing. Subtypes of FTD include behavior variant frontotemporal dementia (bvFTD), characterized by changes in personality and behavior, and primary progressive aphasia (PPA), which affects language skills, speaking, writing and comprehension. FTD is associated with tau protein accumulation (Pick bodies) and altered TDP-43 function. About 30% of cases of FTD are familial, and no other risk factors other than family history of the disease are known.
[0301] Limbic-predominant age-related TDP-43 encephalopathy (LATE)
[0302] Limbic-predominant age-related TDP-43 encephalopathy (LATE) is characterized by accumulation of misfolded TDP-43 protein in the brain, specifically in the limbic system. LATE is a neurological disorder that typically manifests in older patients (e.g., greater than 80 years old). LATE can be a diagnosis for dementia and LATE often mimics the symptoms of Alzheimer’s Disease including memory loss, confusion, and mood changes.Attorney Docket No. QRL-028WOMethods of Treatment
[0303] The disclosure contemplates, in part, treating neurodevelopmental and neurodegenerative diseases including any of Fragile X Syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a patient in need thereof comprising administering a FMRI AON. In some embodiments, provided herein are methods for treatment of a neurodevelopmental and neurodegenerative disease in a patient in need thereof, comprising administering a disclosed FMRI AON. In some embodiments of the disclosure, an effective amount of a disclosed FMRI oligonucleotide may be administered to a patient in need thereof to treat a neurodevelopmental and neurodegenerative disease, and / or to decrease levels of the splice variant FMRI -217 without reducing the levels of the FMRI canonical variant, and thereby restore FMRI activity and / or function.
[0304] In some embodiments, treating a FMRI -related disease comprises at least ameliorating or reducing one symptom associated with the disease (for example, reducing tremors). Methods of treating a FMRI -related disease (for example, FXS, FXPOI, FXTAS, AD, PD, MS, ALS, FTD, or LATE) in a patient suffering therefrom are provided, that include administering a disclosed FMRI AON. In some embodiments, methods of slowing the progression of a FMR1-related disease, are provided.
[0305] Provided herein are methods of treating, reducing the risk of developing, or delaying the onset of a FXS, FXPOI, FXTAS, AD, PD, MS, ALS, FTD, or LATE in a subject in need thereof comprising administering a disclosed FMRI AON. The methods include for example, treating a subject at risk of developing FXS, FXPOI, FXTAS, AD, PD, MS; ALS, FTD, or LATE e.g., administering to the subject an effective amount of a disclosed FMRI AON. FMRI -related diseases that can be treated in this manner include FXS, FXPOI, FXTAS, AD, PD, MS, ALS, FTD, or LATE.
[0306] Methods of preventing or treating FMRI -related diseases (for example, FXS, FXPOI, FXTAS, AD, PD, MS, ALS, FTD, or LATE) form part of this disclosure. Such methods may comprise administering to a patient in need thereof or a patient at risk, a pharmaceutical preparation comprising a FMRI AON disclosed herein. For example, a method of preventing or treating a neurodevelopmental and neurodegenerative disease is provided comprising administering to a patient in need thereof a FMRI AON disclosed herein.
[0307] Patients treated using an above method may experience a decrease of splice variant FMRI-217 RNA expression of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%,Attorney Docket No. QRL-028WO95%, or 100% thereby decrease expression of the splice variant FMRI -217 and / or restore the expression of FMRP in a target cell (for example, a neuron, endothelial cell, or glial support cell) after administering a FMRI oligonucleotide e.g., after 1 day, 2 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 1 month, 2 months, 3, months, 4 months, 5, months, or 6 months or more. In some embodiments, administering such a FMRI oligonucleotide may be on, e.g., at least a daily basis. The FMRI oligonucleotide may be administered orally. In some embodiments, the FMRI oligonucleotide is administered intrathecally, intrathalamically, intracerebroventricularly, intraparenchymally, intraci stemally, or parenterally (e.g., subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous). For example, in an embodiment described herein, a FMRI oligonucleotide is administered intrathecally, intrathalamically intravenously, subcutaneously, or intraci stemally about every 3 months. The delay or amelioration of clinical manifestation of a neurodevelopmental and neurodegenerative disease in a patient as a consequence of administering a FMRI oligonucleotide disclosed here may be at least e.g., 6 months, 1 year, 18 months or even 2 years or more as compared to a patient who is not administered a FMRI oligonucleotide, such as one disclosed herein.
[0308] FMRI oligonucleotides can be used alone or in combination with each other whereby at least two FMRI oligonucleotides are used together in a single composition or as part of a treatment regimen. FMRI oligonucleotides may also be used in combination with other drugs or AON for treating neurodevelopmental and neurodegenerative diseases or conditions.
[0309] In various embodiments, disclosed herein is a method for treating Fragile X Syndrome (FXS), Fragile X-associated primary ovarian insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), or Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 484-564 or 1021-1246, or a pharmaceutically acceptable salt thereof; wherein at least one (i.e., one or more) internucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, aAttorney Docket No. QRL-028WOthionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage, and / or wherein at least one ( / .<., one or more) nucleoside is substituted with a component selected from the group consisting of a 2’-O-(2-methoxyethyl) nucleoside, a 2’-O-methyl nucleoside, a 2’-O-(N-methylacetamide) nucleoside, a 2 ’-deoxy-2’ -fluoro nucleoside, a 2’-fluoro-P-D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.Treatment and Evaluation
[0310] A patient, as described herein, refers to any animal at risk for, suffering from or diagnosed with a FMRI -related disease or disorder, including, but not limited to, mammals, primates, and humans. In certain embodiments, the patient may be a non-human mammal such as, for example, a cat, a dog, or a horse. A patient may be an individual diagnosed with a high risk of developing a FMRI -related disease or disorder, someone who has been diagnosed with a FMRI -related disease or disorder, someone who previously suffered from a FMRI -related disease or disorder, or an individual evaluated for symptoms or indications of a FMRI -related disease or disorder, for example, any of the signs or symptoms associated with a FMRI -related disease or disorder, such as: Fragile X Syndrome (FXS), Fragile X-associated primary ovarian insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), or Limbic-predominant age-related TDP-43 encephalopathy (LATE).
[0311] “A patient in need,” as used herein, refers to a patient suffering from any of the symptoms or manifestations of a FMRI -related disease or disorder, a patient who may suffer from any of the symptoms or manifestations of a FMRI -related disease or disorder, or any patient who might benefit from a method of the disclosure for treating a FMRI -related disease or disorder. A patient in need may include a patient who is diagnosed with a risk of developing a FMRI -related disease or disorder, a patient who has suffered from a FMRI -related disease or disorder in the past, or a patient who has previously been treated for a FMRI -related disease or disorder.
[0312] “Effective amount,” as used herein, refers to the amount of an agent that is sufficient to at least partially treat a condition when administered to a patient. The therapeutically effective amount will vary depending on the severity of the condition, the route of administration of the component, and the age, weight, etc. of the patient being treated. Accordingly, an effectiveAttorney Docket No. QRL-028WOamount of a disclosed FMRI oligonucleotide is the amount of the FMRI oligonucleotide necessary to treat an FMRI -related disease or disorder in a patient such that administration of the agent prevents an FMRI -related disease or disorder from occurring in a subject, prevents FMR1-related disease or disorder progression (e.g., prevents the onset or increased severity of symptoms of the neurological such as muscle weakening or spasms), or relieves or completely ameliorates all associated symptoms of a FMRI -related disease or disorder, i.e. causes regression of the disease.
[0313] Efficacy of treatment may be evaluated by means of evaluation of gross symptoms associated with a FMRI -related disease or disorder, analysis of tissue histology, biochemical assay, imaging methods such as, for example, magnetic resonance imaging, or other known methods. For FXS, FXTAS, FXPOI, AD, PD, MS, ALS, FTD, or LATE for instance, efficacy of treatment may be evaluated by analyzing gross symptoms of the disease such as changes in EEG (electroencephalography), AEP (auditory evoked potentials) and gaze avoidances associated with an FMRI-related disease or disorder following administration to a patient suffering from an FMRI -related disease or disorder, a disclosed FMRI oligonucleotide.
[0314] Efficacy of treatment may also be evaluated at the tissue or cellular level, for example, by means of obtaining a tissue biopsy (e.g., a brain, spinal, muscle, biopsy, or olfactory neurosphere cell biopsy) and evaluating gross tissue or cell morphology or staining properties. Biochemical assays that examine protein or RNA expression may also be used to evaluate efficacy of treatment. For instance, one may evaluate levels of a protein or gene product indicative of a FMRI -related disease or disorder, in dissociated cells or non-dissociated tissue via immunocytochemical, immunohistochemical, Western blotting, or Northern blotting methods, or methods useful for evaluating RNA levels such as quantitative or semi-quantitative polymerase chain (e.g., digital PCR (DigitalPCR, dPCR, or ddPCR), qPCR etc.) reaction. One may also evaluate the presence or level of expression of useful biomarkers (e.g., neurofilament light (NEFL), or neurofilament heavy (NEFH) found in spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, exosome-like cerebrospinal fluid extracellular vesicles (“CSF exosomes”), such as those described in Street etal., (2012) “Identification and proteomic profiling of exosomes in human cerebrospinal fluid” J Transl. Med., 10:5), urine, fecal matter, lymphatic fluid, blood, plasma, or serum to evaluate disease state and efficacy of treatment. One may also evaluate the presence or level of expression of useful biomarkers found in the plasma, neuronal extracellular vesicles / exosomes. One may also evaluate the presence or level of expression of FMRI -217, FMRI -205, and FMRP in exosomes, neuronal derived exosomes, PBMCs, plasma, serum, and cerebrospinal fluid (CSF).FMRIAttorney Docket No. QRL-028WO
[0315] In evaluating efficacy of treatment, suitable controls may be chosen to ensure a valid assessment. For instance, one can compare symptoms evaluated in a patient with a FMRI -related disease or disorder following administration of a disclosed FMRI oligonucleotide to those symptoms in the same patient prior to treatment or at an earlier point in the course of treatment or in another patient not diagnosed with the FMRI -related disease or disorder. Alternatively, one may compare the results of biochemical or histological analysis of tissue following administration of a disclosed FMRI oligonucleotide with those of tissue from the same patient to those from an individual not diagnosed with the FMRI -related disease or disorder or from the same patient prior to administration of the FMRI oligonucleotide. Alternatively, one may compare the results of biochemical or histological analysis of tissue following administration of a disclosed FMRI oligonucleotide with those of tissue from the same patient to those or from an individual diagnosed with the FMRI -related disease or disorder and not administered the FMRI oligonucleotide and / or administered a placebo. Additionally, one may compare blood, plasma, serum, cell, urine, lymphatic fluid, spinal cord fluid, cerebrospinal fluid, or fecal samples following administration of the FMRI oligonucleotide with comparable samples from an individual not diagnosed with the FMRI -related disease or disorder or from the same patient prior to administration of the FMRI oligonucleotide. In some embodiments one may compare extracellular vesicles (for example CSF exosomes), following administration of the FMRI oligonucleotide with extracellular vesicles from an individual not diagnosed with the FMR1-related disease or disorder or from the same patient prior to administration of the FMRI oligonucleotide.
[0316] Validation of FMRI oligonucleotides may be determined by direct or indirect assessment of FMRP expression levels or activity. For instance, biochemical assays that measures FMRP protein or RNA expression may be used to evaluate overall effect on FMRI transcripts (for example, splice variant FMRI-217 and the canonical transcript) comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 978. For instance, one may measure levels of protein encoded by splice variant FMRI -217 in cells or tissue by Western blot to evaluate splice variant FMR1-217 RNA levels. One may also measure splice variant FMRI -217 mRNA levels by means of Northern blot, RNAscope, or quantitative polymerase chain reaction to determine overall effect on FMRI transcripts (for example, a FMRI comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 978). One may also evaluate levels of protein encoded by splice variant FMRI -217 or levels of another protein indicative of splice variant FMRI -217 expression in dissociated cells, non-Attorney Docket No. QRL-028WOdissociated tissue, extracellular vesicles (for example, CSF exosomes), blood, serum, or fecal matter via immunocytochemical or immunohistochemical methods.
[0317] Modulation of expression levels of splice variant FMRI-217 transcripts (for example, a FMRI pre-mRNA sequence comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to NCBI Reference Sequence NC_000023.11) may also be evaluated indirectly by measuring the presence or level of expression of useful biomarkers (e.g., neurofilament light (NEFL), or neurofilament heavy (NEFH), found in plasma, spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, CSF exosomes), blood, urine, lymphatic fluid, fecal matter, or tissue to evaluate the modulation of expression of splice variant FMRI -217 transcripts comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 978). Additional measurements may include Aberrant Behavior Checklist-Community Edition, Stanford Binet Version 5 z-deviation scoring method, KiTAP, Prepulse Inhibition, Eye Tracking, Anchored CGI for FXS, FXS rating scale, Caregiver and Clinician Most Important Concerns Scales, Pediatric Anxiety Rating Scale, Motion Analysis, Social Responsiveness Scale (SRS-2) and Social Communications Scale (SCQ), Expressive Language Sampling, Weighted Communication Scale, Communication Complexity Scale, NH4B Toolbox Cognitive Battery, iBehavior FXS Behavior App, Auditory Event-Related Potentials, LENA Speech Detection Device, AISEP-3, PEDI-CAT, Peds QL 4.0 Parent Report, Repetitive Behavior Scale-Version 2, Domain specific Worst Problems Scale (VAS), Clinical Evaluation of Language Fundamentals (CELF-5), Hebb-Williams mazes, Observed behaviors Corresponding to caregiver-Perceived Anxiety, ADAMS (Anxiety, Depression and Mood Scale).
[0318] The disclosure also provides methods of decreasing expression of splice variant FMR1-217 transcripts in cells of a patient suffering from a FMRI -related disease or disorder. The level of FMRI transcript may be restored in any cell in which FMRI expression or activity occurs, including cells of the nervous system (including the central nervous system (e.g., spinal cord or brain), the peripheral nervous system, motor neurons, glial cells, astrocytes, oligodendrocytes, microglia, the brain, the brain stem, the frontal lobes, the temporal lobes, the spinal cord), the musculoskeletal system, spinal fluid, and cerebrospinal fluid. Cells of the musculoskeletal system include skeletal muscle cells (e.g, myocytes). Motor neurons include upper motor neurons and lower motor neurons.Pharmaceutical Compositions and Routes of Administration
[0319] The present disclosure also provides methods for treating a FMRI -related disease or disorder via administration of a pharmaceutical composition comprising a disclosed FMRIAttorney Docket No. QRL-028WOoligonucleotide. In another aspect, the disclosure provides a pharmaceutical composition for use in treating a FMRI -related disease or disorder. The pharmaceutical composition may be comprised of a disclosed FMRI oligonucleotide, and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutical composition” means, for example, a mixture containing a specified amount of a therapeutic compound, e.g., a therapeutically effective amount, of a therapeutic compound in a pharmaceutically acceptable carrier to be administered to a mammal, e.g., a human, in order to treat a FMRI -related disease or disorder. In some embodiments, described herein are pharmaceutical compositions comprising a disclosed FMRI oligonucleotide in the manufacture of a medicament for treating a FMRI -related disease or disorder.“Medicament,” as used herein, has essentially the same meaning as the term “pharmaceutical composition.”
[0320] As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. In one embodiment the pharmaceutical composition is administered orally and includes an enteric coating suitable for regulating the site of absorption of the encapsulated substances within the digestive system or gut. For example, an enteric coating can include an ethylacrylate-methacrylic acid copolymer.
[0321] In one embodiment, a disclosed FMRI oligonucleotide, and any pharmaceutical composition thereof may be administered by one or several routes, including topically, intrathecally, intrathalamically, intracerebroventricularly, intraparenchymally, intraci sternally, parenterally (e.g., subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, or intraduodenally. The term parenteral as used herein includes subcutaneous injections, intrapancreatic administration, intravenous, intraci sternal, intracerebroventricular, intrathecal, intrathalamic, intramuscular, intraparenchymal, intraperitoneal, intrastemal injection or infusion techniques. For example, a disclosed FMRI oligonucleotide may be administered subcutaneously to a subject. In another example, a disclosed FMRI oligonucleotide may be administered orally to a subject. In another example, a disclosed FMRI oligonucleotide may be administered directly to the nervous system, or specific regions or cells of the nervous systemAttorney Docket No. QRL-028WO(e.g., the brain, brain stem, lower motor neurons, spinal cord, upper motor neurons) via parenteral administration, for example, a disclosed FMRI oligonucleotide may be administered intrathecally, intrathalamically, intracerebroventricularly, intraparenchymally, or intraci sternally.
[0322] In various embodiments, a FMRI AON can be exposed to calcium-containing or magnesium-containing buffers prior to administration. Such calcium-containing or magnesium-containing buffers can mitigate toxicity adverse effects associated with intrathecal administration. Further details of exposing an example antisense oligonucleotide to calcium-containing buffers is described in Moazami, et al., Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System, bioRxiv 2021.02.14.431096, which is hereby incorporated by reference in its entirety.
[0323] In some embodiments, a FMRI AON, can be encapsulated in a nanoparticle coating. It is believed that nanoparticle encapsulation prevents AON degradation and enhances cellular uptake. For example, in some embodiments a FMRI oligonucleotide is encapsulated in a coating of a cationic polymer, for example, a synthetic polymer (e.g., poly-L-lysine, polyamidoamine, a poly(P-amino ester), and polyethyleneimine) or a naturally occurring polymer (e.g., chitosan and a protamine). In some embodiments, a FMRI oligonucleotide is encapsulated in a lipid or lipid-like material, for example, a cationic lipid, a cationic lipid-like material, or an ionizable lipid that is positively charged only at an acidic pH. For example, in some embodiments, a FMRI oligonucleotide is encapsulated in a lipid nanoparticle that includes hydrophobic moi eties, e.g., cholesterol and / or a polyethylene glycol (PEG) lipid.
[0324] Pharmaceutical compositions containing a disclosed FMRI oligonucleotide, such as those disclosed herein, can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration. Useful formulations can be prepared by methods well known in the pharmaceutical art. For example, see Remington’s Pharmaceutical Sciences, 18thed. (Mack Publishing Company, 1990).
[0325] Pharmaceutical formulations, in some embodiments, are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.Parenteral Administration
[0326] The pharmaceutical compositions of the disclosure can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intracisternal, intracerebroventricular, intramuscular, subcutaneous, intrathecal, intraparenchymal, intrathalamic, intralesional, or parenteral (e.g., subcutaneous, intramuscular, intradermal,Attorney Docket No. QRL-028WOintraduodenal, or intravenous) or intraperitoneal routes. The preparation of an aqueous composition, such as an aqueous pharmaceutical composition containing a disclosed FMRI oligonucleotide, will be known to those of skill in the art in light of the present disclosure.Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
[0327] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including normal saline, artificial cerebrospinal fluid, sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
[0328] Solutions of active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U. S. P., and isotonic sodium chloride solution. In one embodiment, a disclosed FMRI antisense oligonucleotide may be suspended in a carrier fluid comprising 1% (w / v) sodium carboxymethylcellulose and 0.1% (v / v) TWEEN™ 80. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0329] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. Sterile injectable solutions of the disclosure may be prepared by incorporating a disclosed FMRI antisense oligonucleotide antisense oligonucleotide in the required amount of the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods ofAttorney Docket No. QRL-028WOpreparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter.
[0330] The preparation of more, or highly concentrated solutions for intramuscular injection is also contemplated. In this regard, the use of DMSO as solvent is preferred as this will result in extremely rapid penetration, delivering high concentrations of the disclosed oligonucleotide to a small area.
[0331] Suitable preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like. Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and for example, between about pH 7 and pH 7.5. Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the solution is in the range 0.9 plus or minus 0.2%. Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium pyrrolidinyl, thiourea and the like. Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, pol oxamer 282 and tyloxapol. Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxymethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.Oral Administration
[0332] In some embodiments, contemplated herein are compositions suitable for oral delivery of a disclosed FMRI oligonucleotide, e.g., tablets that include an enteric coating, e.g., a gastro-resistant coating, such that the compositions may deliver a FMRI oligonucleotide to, e.g., the gastrointestinal tract of a patient.
[0333] For example, a tablet for oral administration is provided that comprises granules (e.g., is at least partially formed from granules) that include a disclosed FMRI oligonucleotide, e.g., a FMRI oligonucleotide represented by any SEQ ID NOs: 484-564 or 1021-1246 that targets a FMRI transcript comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 967, and pharmaceutically acceptable excipients. Such a tablet may be coated with an enteric coating. Contemplated tablets may include pharmaceutically acceptable excipients such as fillers, binders, disintegrants, and / or lubricants, as well as coloring agents, release agents, coating agents, sweetening, flavoring suchAttorney Docket No. QRL-028WOas wintergreen, orange, xylitol, sorbitol, fructose, and maltodextrin, and perfuming agents, preservatives and / or antioxidants.
[0334] In some embodiments, contemplated pharmaceutical formulations include an intra-granular phase that includes a disclosed FMRI oligonucleotide, e.g., a FMRI oligonucleotide represented by any of SEQ ID NOs: 484-564 or 1021-1246 that targets a FMRI transcript comprising a sequence that shares at least 90% e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 976, and a pharmaceutically acceptable salt. In some embodiments, contemplated pharmaceutical formulations include an intra-granular phase that includes a disclosed FMRI oligonucleotide, e.g., a FMRI oligonucleotide represented by any of SEQ ID NOs: 484-564 or 1021-1246 that targets a FMRI transcript comprising a sequence that shares at least 90% (e.g, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 976, and a pharmaceutically acceptable filler.
[0335] For example, a disclosed FMRI oligonucleotide and a filler may be blended together, optionally, with other excipients, and formed into granules. In some embodiments, the intragranular phase may be formed using wet granulation, e.g., a liquid (e.g, water) is added to the blended FMRI oligonucleotide and filler, and then the combination is dried, milled and / or sieved to produce granules. One of skill in the art would understand that other processes may be used to achieve an intragranular phase.
[0336] In some embodiments, contemplated formulations include an extra-granular phase, which may include one or more pharmaceutically acceptable excipients, and which may be blended with the intragranular phase to form a disclosed formulation.
[0337] A disclosed formulation may include an intragranular phase that includes a filler.Exemplary fillers include, but are not limited to, cellulose, gelatin, calcium phosphate, lactose, sucrose, glucose, mannitol, sorbitol, microcrystalline cellulose, pectin, polyacrylates, dextrose, cellulose acetate, hydroxypropylmethyl cellulose, partially pre-gelatinized starch, calcium carbonate, and others including combinations thereof.
[0338] In some embodiments, a disclosed formulation may include an intragranular phase and / or an extragranular phase that includes a binder, which may generally function to hold the ingredients of the pharmaceutical formulation together. Exemplary binders of the disclosure may include, but are not limited to, the following: starches, sugars, cellulose or modified cellulose such as hydroxypropyl cellulose, lactose, pre-gelatinized maize starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, low substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sugar alcohols and others including combinations thereof.Attorney Docket No. QRL-028WO
[0339] Contemplated formulations, e.g., that include an intragranular phase and / or an extragranular phase, may include a disintegrant such as but not limited to, starch, cellulose, crosslinked polyvinyl pyrrolidone, sodium starch glycolate, sodium carboxymethyl cellulose, alginates, corn starch, croscarmellose sodium, crosslinked carboxymethyl cellulose, low substituted hydroxypropyl cellulose, acacia, and others including combinations thereof. For example, an intragranular phase and / or an extragranular phase may include a disintegrant.
[0340] In some embodiments, a contemplated formulation includes an intra-granular phase comprising a disclosed FMRI oligonucleotide and excipients chosen from: mannitol, microcrystalline cellulose, hydroxypropylmethyl cellulose, and sodium starch glycolate or combinations thereof, and an extra-granular phase comprising one or more of: microcrystalline cellulose, sodium starch glycolate, and magnesium stearate or mixtures thereof.
[0341] In some embodiments, a contemplated formulation may include a lubricant, e.g., an extra-granular phase may contain a lubricant. Lubricants include but are not limited to talc, silica, fats, stearin, magnesium stearate, calcium phosphate, silicone dioxide, calcium silicate, calcium phosphate, colloidal silicon dioxide, metallic stearates, hydrogenated vegetable oil, corn starch, sodium benzoate, polyethylene glycols, sodium acetate, calcium stearate, sodium lauryl sulfate, sodium chloride, magnesium lauryl sulfate, talc, and stearic acid.
[0342] In some embodiments, the pharmaceutical formulation comprises an enteric coating. Generally, enteric coatings create a barrier for the oral medication that controls the location at which the drug is absorbed along the digestive track. Enteric coatings may include a polymer that disintegrates at different rates according to pH. Enteric coatings may include for example, cellulose acetate phthalate, methyl acrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxylpropylmethyl cellulose phthalate, methyl methacrylate-methacrylic acid copolymers, ethylacrylate-methacrylic acid copolymers, methacrylic acid copolymer type C, polyvinyl acetate-phthalate, and cellulose acetate phthalate.
[0343] Exemplary enteric coatings include Opadry® AMB, Acryl-EZE®, Eudragit® grades. In some embodiments, an enteric coating may comprise about 5% to about 10%, about 5% to about 20%, 8% to about 15%, about 8% to about 20%, about 10% to about 20%, or about 12% to about 20%, or about 18% of a contemplated tablet by weight. For example, enteric coatings may include an ethylacrylate-methacrylic acid copolymer.
[0344] For example, in a contemplated embodiment, a tablet is provided that comprises or consists essentially of about 0.5% to about 70%, e.g., about 0.5% to about 10%, or about 1% to about 20%, by weight of a disclosed FMRI oligonucleotide or a pharmaceutically acceptable salt thereof. Such a tablet may include for example, about 0.5% to about 60% by weight of mannitol, e.g., about 30% to about 50% by weight mannitol, e.g., about 40% by weight mannitol; and / orAttorney Docket No. QRL-028WOabout 20% to about 40% by weight of microcrystalline cellulose, or about 10% to about 30% by weight of microcrystalline cellulose. For example, a disclosed tablet may comprise an intragranular phase that includes about 30% to about 60%, e.g., about 45% to about 65% by weight, or alternatively, about 5 to about 10% by weight of a disclosed FMRI oligonucleotide, about 30% to about 50%, or alternatively, about 5% to about 15% by weight mannitol, about 5% to about 15% microcrystalline cellulose, about 0% to about 4%, or about 1% to about 7% hydroxypropylmethylcellulose, and about 0% to about 4%, e.g., about 2% to about 4% sodium starch glycolate by weight.
[0345] In another contemplated embodiment, a pharmaceutical tablet formulation for oral administration of a disclosed FMRI oligonucleotide comprises an intra-granular phase, wherein the intra-granular phase includes a disclosed FMRI AON or a pharmaceutically acceptable salt thereof (such as a sodium salt), and a pharmaceutically acceptable filler, and which may also include an extra-granular phase, that may include a pharmaceutically acceptable excipient such as a disintegrant. The extra-granular phase may include components chosen from microcrystalline cellulose, magnesium stearate, and mixtures thereof. The pharmaceutical composition may also include an enteric coating of about 12% to 20% by weight of the tablet. For example, a pharmaceutically acceptable tablet for oral use may comprise about 0.5% to 10% by weight of a disclosed FMRI AON or a pharmaceutically acceptable salt thereof, about 30% to 50% by weight mannitol, about 10% to 30% by weight microcrystalline cellulose, and an enteric coating comprising an ethylacrylate-methacrylic acid copolymer.
[0346] In another example, a pharmaceutically acceptable tablet for oral use may comprise an intra-granular phase, comprising about 5 to about 10% by weight of a disclosed FMRI AON, e.g., a disclosed FMRI AON or a pharmaceutically acceptable salt thereof, about 40% by weight mannitol, about 8% by weight microcrystalline cellulose, about 5% by weight hydroxypropylmethyl cellulose, and about 2% by weight sodium starch glycolate; an extra-granular phase comprising about 17% by weight microcrystalline cellulose, about 2% by weight sodium starch glycolate, about 0.4% by weight magnesium stearate; and an enteric coating over the tablet comprising an ethyl acrylate-methacrylic acid copolymer.
[0347] In some embodiments the pharmaceutical composition may contain an enteric coating comprising about 13% or about 15%, 16%, 17% or 18% by weight, e.g., AcrylEZE® (see, e.g., PCT Publication No. WO 2010 / 054826, which is hereby incorporated by reference in its entirety).
[0348] The rate at which the coating dissolves and the active ingredient is released is its dissolution rate. In an embodiment, a contemplated tablet may have a dissolution profile, e.g., when tested in a USP / EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate bufferAttorney Docket No. QRL-028WOwith a pH of 7.2, of about 50% to about 100% of the FMRI oligonucleotide releasing after about 120 minutes to about 240 minutes, for example after 180 minutes. In another embodiment, a contemplated tablet may have a dissolution profile, e.g., when tested in a USP / EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in diluted HC1 with a pH of 1.0, where substantially none of the FMRI oligonucleotide is released after 120 minutes. A contemplated tablet, in another embodiment, may have a dissolution profile, e.g., when tested in USP / EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate buffer with a pH of 6.6, of about 10% to about 30%, or not more than about 50% of the FMRI oligonucleotide releasing after 30 minutes.
[0349] In some embodiments, methods provided herein may further include administering at least one other agent that is directed to treatment of diseases and disorders disclosed herein. In one embodiment, contemplated other agents may be co-administered (e.g., sequentially or simultaneously).Combination Therapies
[0350] In various embodiments, a FMRI AON as disclosed herein can be administered in combination with one or more additional therapies. The combination therapy of the disclosed oligonucleotide and the one or more additional therapies can, in some embodiments, be synergistic in treating any of Fragile X Syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
[0351] Non-limiting examples of therapies for Fragile X Syndrome (FXS) include: medication for seizures and mood instability (e.g., lithium carbonate, gabapentin, carbamazepine, valproic acid, divalproex, lamotrigine, topiramate, phenobarbital, primidone, and phenytoin), ADHD medication (e.g., methylphenidate, dextroamphetamine, L-acetylcarnitine, venlafaxine, nefazodone, amantadine, folic acid, clonidine, and guanfacine), aggression or obsessive-compulsive disorder medication (e.g., fluoxetine, sertraline, citalopram, paroxetine, fluvoxamine, risperidone, quetiapine, and alanzapine), and medication for sleep issues (e.g., trazodone and melatonin).
[0352] Non-limiting examples of therapies for Fragile X-associated tremor / ataxia syndrome (FXTAS) include medication for tremors (e.g., beta blockers, primidone, topiramate, deep brain stimulation, and botulinum toxin), medication for psychiatric symptoms including anxiety, irritability, agitation, hostility, obsessive-compulsiveness, apathy, and depression (e.g., selective serotonin reuptake inhibitors (SSRIs)), medication for cerebellar ataxia or parkinsonism in FXTAS (e.g., carbidopa / levodopa, dopamine agonists, and eldepryl), medication for neuropathicAttorney Docket No. QRL-028WOpain and fibromyalgia pain (e.g., antidepressants, antiepileptics, and topical analgesics), and medication used to treat Alzheimer’s disease. Non-limiting examples of therapies for FXTAS include propranolol, primidone, gabapentin, topiramate, levetiracetam, amantadine, buspirone, varenicline, riluzole, carbidopa / levodopa, donepezil, galantamine, rivastigmine, Citocoline, memantine, allopregnanolone, and sulfarophane.
[0353] Example additional therapies include any of methylphenidate (Ritalin, Concerta, Methylyn, Metadate, Focalin, Aptensio, Daytrana, Quillivant), amphetamines and mixed amphetamine salts (Adderall), lisdexamphetamine (Vyvanse), dextroamphetamine (Dexedrine), atomoxetine (Strattera), modafinil (Provigil), fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), trazodone (Desyrel), bupropion (Wellbutrin), venlafaxine (Effexor), tricyclics (amitriptyline, imipramine, etc), Mirtazapine (Remeron), clonidine (Catapres, Kapvay), guanfacine (Tenex,Intuniv), haloperidol (Haldol), risperidone (Risperdal), aripiprazole (Abilify), quetiapine (Seroquel), ziprasidone (Geodon), olanzapine (Zyprexa), thioridazine (Mellaril), lurasidone (Latuda), iloperidone (Fanapt), brexpiprazole (Rexulti), topiramate (Topamax), Lithium, valproic acid (Depakote), carbamazepine (Tegretol), oxcarbazepine (Trileptal), lamotrigine (Lamictal), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), alprazolam (Xanax), buspirone (Buspar, Vanspar), Ambien, Fenobam, Mavoglurant, Basimglurant, lithium, lovastatin, trofinetide, minocycline, metformin, BPN14770, actinogen, CX516, ganaxolone, metadoxine (Alcobra), Arbaclofen, Acamprosate, gaboxadole, Donepezil, cannabidiol (CBD), Ergoloid mesylates / 5HTP, Sulindac, SPG601, sertraline, NNZ-2566, AZD7325, MG01C1, Oxytocin, CTH120, aripipazole, epigallocatechin Gallate (EGCG), STX107, Vitamin C, Vitamin E, NPL-2009, CX-516, and acamprosate. In various embodiments, an additional therapy can be a second antisense oligonucleotide. As an example, the second antisense oligonucleotide may target a FMRI transcript (e.g., FMRI pre-mRNA or FMRI -217 transcripts ) to modulate the expression levels of splice variant FMRI -217.
[0354] In various embodiments, the disclosed oligonucleotide and the one or more additional therapies can be conjugated to one another and provided in a conjugated form. Further description regarding conjugates involving the disclosed oligonucleotide is described below. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided concurrently. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided simultaneously. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided sequentially.Attorney Docket No. QRL-028WOConjugates
[0355] In certain embodiments, provided herein are oligomeric compounds, which comprise an FMRI oligonucleotide and optionally one or more conjugate groups and / or terminal groups. Conjugate groups include one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and / or at any internal position. In certain embodiments, conjugate groups are attached to the 2’ -position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3’ and / or 5 ’-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3 ’-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3 ’-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5’-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5 ’-end of oligonucleotides.
[0356] Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.Conjugate Groups
[0357] In certain embodiments, a FMRI AON is covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge, and clearance. In particular embodiments, conjugate groups modify the circulation time (e.g., increase) of the oligonucleotides in the bloodstream such that increased concentrations of the oligonucleotides are delivered to the brain. In particular embodiments, conjugate groups modify the residence time (e.g., increase residence time) of the oligonucleotides in a target organ (e.g., brain) such that increased residence time of the oligonucleotides improves their performance (e.g., efficacy). In particular embodiments, conjugate groups increase the delivery of the oligonucleotide to the brain through the blood brain barrier and / or brain parenchyma (e.g., through receptor mediated transcytosis). In particular embodiments, conjugate groups enable the oligonucleotide to target a specific organ (e.g., the brain). In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem.Attorney Docket No. QRL-028WOLett., 1994, 4, 1053-1060), a thioether, e.g., hexyl- S-tritylthiol (Manoharan et al., Ann. NY. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac -glycerol or triethyl -ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937), a tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220; and Nishina et al.. Molecular Therapy, 2008, 16, 734-740), or a GalNAc duster (e.g, WO2014 / 179620).Conjugate Moieties
[0358] Conjugate moieties include, without limitation, intercal ators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, dyes, bile acids, and phenylbutyric acid. In particular embodiments, conjugate moieties are selected from a peptide, a lipid, N-acetylgalactosamine (GalNAc), cholesterol, vitamin E, lipoic acid, panthothenic acid, polyethylene glycol, an antibody (e.g., an antibody for crossing the blood brain barrier such as anti -transferrin receptor antibody, anti-CD98 antibody, or an antibody targeting IGF1R, insulin receptor, LDL receptor, IGF2R, or TMEM30A / ATPase complex), or a cell-penetrating peptide (e.g., transactivator of transcription (TAT), aptamer, or penetratine).
[0359] In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, ($)-(+)-pranoprofen, carprofen, dansyl sarcosine, 2,3,5-triiodobenzoic acid, fmgolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.Conjugate Linkers
[0360] Conjugate moieties are attached to a FMRI AON through conjugate linkers. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain embodiments, theAttorney Docket No. QRL-028WOconjugate linker comprises a chain structure, such as a hydrocarbon chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.
[0361] In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from thioether, thioester, and disulfide. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.
[0362] In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moi eties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.
[0363] Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted Ci-Cio alkyl, substituted or unsubstituted C2-C10 alkenyl or substituted or unsubstituted C2-C10 alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.
[0364] In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, conjugate linkers comprise 2-5 linker-nucleosides. In certain embodiments, conjugate linkers comprise 3 linker-nucleosides.
[0365] In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosidesAttorney Docket No. QRL-028WOcomprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methyl cytosine, 4-N -benzoyl-5 -methyl cytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.
[0366] Herein, linker-nucleosides are not considered to be part of the oligonucleotide.Accordingly, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and / or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid.
[0367] In certain embodiments, it is desirable for a conjugate group to be cleaved from the AON. For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate linkers may comprise one or more cleavable moieties. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.
[0368] In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group.
[0369] In certain embodiments, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such embodiments, the one or more linker-nucleosides are linked to oneAttorney Docket No. QRL-028WOanother and / or to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2’-deoxy nucleoside that is attached to either the 3’ or 5’-terminal nucleoside of an oligonucleotide by a phosphate intemucleoside linkage and covalently attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2’ -deoxy adenosine.Terminal Groups
[0370] In certain embodiments, oligomeric compounds comprise one or more terminal groups. In certain such embodiments, oligomeric compounds comprise a stabilized 5’-phosphate.Stabilized 5 ’-phosphates include, but are not limited to 5 ’-phosphonates, including, but not limited to 5’-vinylphosphonates. In certain embodiments, terminal groups comprise one or more inverted nucleosides. In certain embodiments, terminal groups comprise one or more 2’ -linked nucleosides. In various embodiments, terminal groups comprise one or more spacers.Diagnostic Methods
[0371] The disclosure also provides a method of diagnosing a patient with a FMRI-related disease or disorder that relies upon detecting levels of splice variant FMRI -217 expression signal in one or more biological samples of a patient. As used herein, the term “splice variant FMR1-217 expression signal” can refer to any indication of splice variant FMRI -217 expression or mRNA product activity. Splice variant FMRI -217 products include RNA (e.g., mRNA), peptides, and proteins. Indices of splice variant FMRI -217 expression that can be assessed include, but are not limited to, FMRI gene or chromatin state, FMRI gene interaction with cellular components that regulate gene expression, splice variant FMRI -217 RNA or mRNA product expression levels (e.g., expression levels of splice variant FMRI -217 transcripts) comprising a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to any one of SEQ ID NOs: 967-975, or interaction of splice variant FMRI -217 RNA or protein with transcriptional, translational, or post-translational processing machinery.
[0372] Detection of splice variant FMRI -217 and / or FMRI expression signal may be accomplished through in vivo, in vitro, or ex vivo methods. In a preferred embodiment, methods of the disclosure may be carried out in vitro. Methods of detecting may involve detection in blood, serum, fecal matter, tissue, cerebrospinal fluid, spinal fluid, extracellular vesicles (for example, CSF exosomes), or cells of a patient. Detection may be achieved by measuring expression signal of splice variant FMRI -217 transcripts comprising a sequence that shares atAttorney Docket No. QRL-028WOleast 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to NCBI Reference Sequence NC_000023.11 or SEQ ID NO: 978 in whole tissue, tissue explants, cell cultures, dissociated cells, cell extract, extracellular vesicles (for example, CSF exosomes), or body fluids, including blood, spinal fluid, cerebrospinal fluid, urine, lymphatic fluid, or serum. Methods of detection include assays that measure levels of splice variant FMRI -217 RNA or protein product expression such as Western blotting, FACS, ELISA, other quantitative binding assays, cell or tissue growth assays, Northern blots, quantitative or semi-quantitative polymerase chain reaction, medical imaging methods (e.g., MRI), or immunostaining methods (e.g., immunohistochemistry or immunocytochemistry).Modifications in General
[0373] While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.
[0374] Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2’-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2 ’-OH in place of one 2’-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) in place of a uracil of RNA). Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and / or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleotide sequence “ATCGATCG” encompasses any oligomeric compounds having such nucleotide sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and oligomeric compounds having other modified nucleobases, such as “ATmCGAUCG,” whereinmC indicates a cytosine base comprising a methyl group at the 5-position.Attorney Docket No. QRL-028WO
[0375] Certain compounds described herein (e.g., modified oligonucleotides) have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as a or p such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Compounds provided herein that are drawn or described as having certain stereoisomeric configurations include only the indicated compounds. Compounds provided herein that contain stereocenters that are drawn or described with undefined stereochemistry included all such possible isomers, including their stereorandom and optically pure forms, unless specified otherwise. Likewise, all tautomeric forms of the compounds herein are also included unless otherwise indicated. Unless otherwise indicated, compounds described herein are intended to include corresponding salt forms.
[0376] The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the1H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to:2H or3H in place of1H,13C or14C in place of12C,15N in place of14N,17O or18O in place of16O, and33S,34S,35S, or36S in place of32S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool.EXAMPLES
[0377] The disclosure is further illustrated by the following examples. The examples are provided for illustrative purposes only, and are not to be construed as limiting the scope or content of the disclosure in any way.Example 1: Design and Selection of FMRI Oligonucleotides
[0378] FMRI AONs oligonucleotides that target a FMRI transcript comprising SEQ ID: 967 were designed and tested to identify FMRI AONs capable of reducing the quantity of splice variant FMRI -217 transcripts. Exemplary FMRI AONs were 23 nucleosides in length and include at least one spacer. Here, FMRI AONs with two spacers were developed. A spacer is represented by Formula (I), wherein:Formula (I)Attorney Docket No. QRL-028WOX is -0-; andn is 1.
[0379] These exemplary FMRI oligonucleotides are detailed below (23mers with a first spacer at position 8 and a second spacer at position 16). The FMRI AONs are shown in Table 9.Table 9: FMRI AONs with two spacersAttorney Docket No. QRL-028WO* Unless otherwise noted, each of the nucleosides of antisense oligonucleotides shown in Table 8 are modified nucleosides with 2’-O-(2-methoxyethyl) (2’ -MOE) sugar moi eties, each “C” is replaced with a 5-methylcytosine (5-MeC), and all intemucleoside linkages are phosphorothioate linkages. A spacer as indicated by S is not a nucleoside. S represents a spacer of Formula (lia’ ) as disclosed herein.Example 2: Methods for Evaluating FMRI Antisense Oligonucleotides
[0380] FMRI antisense oligonucleotides were evaluated in human cortical neurons.
[0381] Methods (Cortical neurons): iPSC derived cortical neurons, differentiated for 28 days according to a modified protocol based on Shi et al Nat Protoc, 2012 were plated on poly-omithine and laminin coated 96 well plates. The cortical neurons were cultured in neurobasal A containing B27, 2-mercaptoethanol, non-essential amino acids, glutamax and pen / strep with growth factors NGF (20ng / ml), NT-3 (lOng / ml), BDNF (lOng / ml), GDNF (lOng / ml) and arachidonic acid (lOng / ml). Rho-associated, coiled-coil containing protein kinase inhibitors (ROCKi) was added during the first three days of culturing the cells.
[0382] ASOs targeting the gene region of interest were each diluted to a working concentration and then added to the culture media (gymnotic treatment) at 100 nM or 500 nM at day 7 after seeding. As a negative control, a PBS treatment group was included. As a positive control, we used a splice switching oligonucleotide that targets FMRI designed by Shah et al (ASO ‘713’ in Shah et al, PNAS, 2023; CGCCCAGAACAGTGGAGCTC (SEQ ID NO: 980)). CorticalAttorney Docket No. QRL-028WOneurons were retreated with ASO at every subsequent medium change (DIO, D13, D17 after seeding). At D20 after seeding, cortical neurons were harvested for RNA isolation and reverse-transcribed into cDNA with a 2-step TaqMan Advanced Cells to Ct RNA Kit. cDNA was quantified with commercially available TaqMan GADPH-primer limited, FMRI -205, and custom designed FMRI-217 probes from Thermo Scientific. FMRI-205 mRNA was detected using probe Hs00924540_ml (Thermo Fisher Scientific). FMRI-217 mRNA was detected using custom designed probe with forward primer sequence (from 5’ to 3’ end):AGGAGCTGGTGGTGGAAGTG (SEQ ID NO: 1256) and reverse primer sequence AGCTCTCCGAAGTCCCAATG (SEQ ID NO: 1257). The probe sequence for FMRI-217 detection is CTCCAATGGCGCTTTC (SEQ ID NO: 1258). Relative mRNA levels were quantitated via RT-qPCR on 2uL of whole cDNA product using TaqMan Fast Advanced Master mix. FMRI-205 (SEQ ID NO: 967) encodes the full-length 632 amino acid FMRP. Each well was multiplexed, containing a housekeeping gene (GAPDH) VIC probe and a test gene (FMR1-205 or FMRI -217) FAM probe. Each individual ASO treatment consisted of three biological replicates per plate and the entire experiment was repeated (2 technical replicates for a total of 6 biological replicates). All data was calculated as % change compared to the PBS treatment group (averages and standard deviation). FMRI -205 (Ct) or FMRI -217 (Ct) was normalized to GAPDH (Ct) (DeltaCt). The deltaCt was further normalized to the average of the untreated condition (PBS), (deltadeltaCT). Relative quantity (RQ) of transcript was calculated using the equation RQ = 2VdeltadeltaCt)*100 and describes the % increase / decrease of AON treatment condition compared to the untreated condition.
[0383] Table 10 depicts the performance of FMRI AONs, including FMRI AONs with two spacers. FMRI AONs that included two spacers decreased levels of FMRI. For example, a dose of 500 nM of any one of SEQ ID NOs: 523, 526, 528, 534, or 536, resulted in about 10-20% of splice variant FMRI -217 remaining, while about 69% to 94% of FMRI -205 remained.Additionally, a dose of 500 nM of any one of SEQ ID NOs: 532, 533, or 527, resulted in about 25-30% of splice variant FMRI-217 remaining, while about 73%-98% of FMRI-205 remained. Additionally, a dose of 500 nM of any one of SEQ ID NOs: 538, 539, or 543 resulted in a reduction of about 34-40% of splice variant FMRI -217 remaining, while about 56% to 79% of FMRI-205 remained. Additionally, a dose of 500 nM of any one of SEQ ID NOs: 520, 521, 531, 541, or 542, resulted in about 41-50% of splice variant FMRI -217 remaining. Additionally, a dose of 500 nM of any one of SEQ ID NOs: 545, 537, or 540 resulted in about 52-60% of splice variant FMRI -217 remaining, while about 87%-100% of FMRI -205 remained. Additionally, a dose of 500 nM of any one of SEQ ID NOs: 522, 529, or 530 resulted in about 72-77% of splice variant FMRI -217 remaining, while over 69% of FMRI -205 remained. Additionally, a dose ofAttorney Docket No. QRL-028WO500 nM of any one of SEQ ID NOs: 546 or 535 resulted in about 85-90% of splice variant FMRI -217 remaining, while over 90% of FMRI -205 remained. Additionally, a dose of 500 nM of SEQ ID NO: 544 resulted in about 97% of splice variant FMRI-217 remaining.
[0384] For example, a dose of 100 nM of any one of SEQ ID NO: 523 resulted in about 15% of splice variant FMRI -217 remaining, while about 80% of FMRI-205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 528 or 536, resulted in about 25-30% of splice variant FMRI -217 remaining, while about 66%-82% of FMRI -205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 526, 527, 534, or 539 resulted in about 30-40% of splice variant FMRI-217 remaining, while over 70% of FMRI-205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 531, 532, 537, 538, or 542 resulted in about 41-50% of splice variant FMRI -217 remaining, while over 72% of FMRI-205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 520, 533, 541, or 543 resulted in about 52-55% of splice variant FMRI -217 remaining, while over 72% of FMRI -205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 521, 522, 530, or 540 resulted in about 67-75% of splice variant FMRI -217 remaining, while over 84% of FMRI -205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 535 or 546 resulted in about 78% of splice variant FMRI -217 remaining, while over 81% of FMRI -205 remained. Additionally, a dose of 100 nM of any one of SEQ ID NOs: 544 resulted in about 96-100% of splice variant FMRI -217 remaining, while about 100% of FMRI -205 remained.
[0385] Table 11 depicts the performance of FMRI AONs, including FMRI AONs with two spacers.
[0386] Table 12 depicts the performance of gapmer FMRI AONs.e 10: Performance of FMRI AONs, including FMRI AONs with two spacers.% Remaining FMRI-205 RNA % Remaining FMRI-217 RNASEQ ID Sequence i 500 nM 500 nM 100 nM 0 nM 500 nM 500 nM nM iNO Avg STDAvg TD AvgD448 CAGAACAGTGGAGCTCTCCGAAG 101.6 16.0 94.3 12.6 20.4 13.3 20.5449 GAACAGTGGAGCTCTCCGAAGTC I I 1.6 13.2 95.4 17.2 24.4 15.3 15.8 i450 AGAACAGTGGAGCTCTCCGAAGT 164.6 42.8 112.8 33.0 23.5 7.1 11.1 i529 CAGAACASTGGAGCTSTCCGAAG 87.4 14.4 74.6 24.2 73.8 18.1 19.0530 GAACAGTSGAGCTCTSCGAAGTC 1 12.8 18.7 108.8 45.8 76.9 13.2 384H531 AGAACAGSGGAGCTCSCCGAAGT1336 19.8 96.3 39.1 41.2 6.7 15. H233 TCTTTCTTCACAGCCCTCGCCCAGA 65.7 1 1.8 108.2 81.6 1.9 1.2 3.5 i451 TCTTTCTTCACAGCCCTCGCCCA 73.5 12.1 76.0 20.9 3.0 2.1 4.9452 TTTCTTCACAGCCCTCGCCCAGA 76.9 33.2 60.8 21.3 3.9 2.7 9.2453 CTTTCTTCACAGCCCTCGCCCAG 66.6 16.3 63.0 10.2 1.5 1.1 4.7 i532 TCTTTCTSCACAGCCSTCGCCCA 72.6 18.7 71.9 17.5 30.0 5.3 13.4 i533 TTTCTTCSCAGCCCTSGCCCAGA 73.6 16.4 88.2 16.2 24.6 8 16.6534 CTTTCTTSACAGCCCSCGCCCAG 68.9 14.6 120.1 73.3 18.5? 3 16.2 ^239 i TACTACTCTTTCTTCACAGCCCTC 95.424.7 92.5 18.8 9.8 4.8 5.6 i454 TACTACTCTTTCTTCACAGCCCT 101.8 39.6 89.3 27.7 62.0 37.7 36.8 i455 CTACTCTTTCTTCACAGCCCTCG 144.4 160.7 102.8 57.9 13.3 8.3 6.5456 ACTACTCTTTCTTCACAGCCCTC 101.1 27.9 97.5 25.7 18.8 6.5 28.1535 TACTACTSTTTCTTCSCAGCCCT 95.0 53.1 81.2 34.2 89.9 66.6 66.9 i536 CTACTCTSTCTTCACSGCCCTCG 93231.5 82.2 203 16.1 6 6 17.2 ^537 ACTACTCSTTCTTCASAGCCCTC 749 15.3 73.9 9.353.8 5? 8 24.5 ^256 TGCCGACTACCGCTTCTTACTAC 70.6 4.9 85.4 6.9 i 647 36 30.9457 TGCCGACTACCGCTTCTTACTAC 71.7 7.6 83.0 10.0 i 43.2; 12.8 19.6458 CCGACTACCGCTTCTTACTACTC 649 14.9 84.3 14 1 34.0 11.6 17. H459 GCCGACTACCGCTTCTTACTACT 55.3 14.3 67.914.757.6 31.5 13.2538 TGCCGACSACCGCTTSTTACTAC 55.6 11.2 72.2 ^ 1.1 38.2 13.7 16.4 i539 CCGACTASCGCTTCTSACTACTC 61.2 11.5 70.4 11.0 39.1 23.3 14.1 i540GCCGACTSCCGCTTCSTACTACT67.526.093.080.460.046.871.8% Remaining FMRI-205 RNA % Remaining FMRI-217 RNASEQ I Sequence i 500 nM 500 nM 100 nM 0 nM 500 nM 500 nM 100 nM 100 nM iNO vg STDAvg TD Avg STD AvgSTD552 CCATGTTSGGGTCTTSCTGAAAC 101.4 16.6 78.5 34.8 72.4 24.6 134.5; 162.9360 CACTGCTGGGCCATGTTAGGGTC 102.3 16.8 148.0 1 13.0 86.9 26.1 375 8 703.9 ^472 CACTGCTGGGCCATGTTAGGGTC 130.0 24.0 111.8 18.2 86.1 30.8 84.5 18.8 i473 CTGCTGGGCCATGTTAGGGTCTT 123.6 32.9 109.2 12.1 89.9 24.8 95.0 17.9474 ACTGCTGGGCCATGTTAGGGTCT 133.4 28.7 1 18.3 15.4 101.5 29.5 93 6 20.7553 CACTGCTSGGCCATGSTAGGGTC 143.6 28.0 1 13.3 9.4 84.0 27.0 777 I84H554 CTGCTGGSCCATGTTSGGGTCTT 129.6 22.2 114.0 13.2 100.3 27.7 95.9 13.3 i555 ACTGCTGSGCCATGTSAGGGTCT 122.1 16.3 106.5 13.9 81.9 14.6 79.4 15.2370 TTCTTCAATGCACTGCTGGGCCAT 1 11.7 63.7 189.2 180.1 93.7 24.8 98.7 14.8475 TTCTTCAATGCACTGCTGGGCCA 132.3 38.4 104.4 24.9 93.2 31.3 90.9 23.5 i476 CTTCAATGCACTGCTGGGCCATG 128.3 18.7 98.7 11.8 98.6 19.6 90.2 12.1 i477 TCTTCAATGCACTGCTGGGCCAT 1246 22.6 105.5 21 7111.0 22.8 895 12.8556 TTCTTCASTGCACTGSTGGGCCA 68.6 21.2 82.0 18.9 72 1 178 794 12.9 ^557 i CTTCAATSCACTGCTSGGCCATG 99.8 42.1 92.6 30.6 73.4 14.0 68.9 13.0 i558 TCTTCAASGCACTGCSGGGCCAT 97.5 29.3 94.0 26.9 77.2 1 1.0 79.3 15.8 i376 ATCAACTTCTTCAATGCACTGCTG 70.8 49.3 70.5 40.0 56.4 8.2 63.4 13.5478 ATCAACTTCTTCAATGCACTGCT 83.4 41.7 80.1 33.1 68.3 25.8 59.4 16.8479 CAACTTCTTCAATGCACTGCTGG 73.3 48.2 78.6 30.4 63.1 8.5 59.7 13.8 i480 TCAACTTCTTCAATGCACTGCTG 59.3 43 8 53.0 240 63.9 4.5 60.0 9.7 i559 ATCAACTSCTTCAATSCACTGCT 98.1 325 95.8 30 187.1 31.2 117.0 32.5560 CAACTTCSTCAATGCSCTGCTGG 100.4 15 8 1 15.5 102 99.6 39.9 110.7 18.2561 TCAACTTSTTCAATGSACTGCTG177.6 23.7 i 127.0 32.4 i 170.6 69.9 140.5 41.1401 AAGGGGGACGCGAATATTCACGATG 254.2 85.6; 199.2 32.2; 312.5 77.2 215.6 53. H481 AAGGGGGACGCGAATATTC ACGA 224.5 31.2 180.7 23.4 248.6 85.1 170.8 25.2482 GGGGGACGCGAATATTC ACGATG 288.2 105.5 246.5 22.2 274.1 1 1.8 266.6 88.0483 AGGGGGACGCGAATATTC A( GAT231.8 45.2 199.2 45.9 274.8 22.5 208.2 70.3 i562AAGGGGGSCGCGAATSTTCACGA 234.145.2175.522.7234.524.5165.645.8* Unless otherwise noted, each of the nucleosides of antisense oligonucleotides shown in Table 10 are modified nucleosides with 2’-O-(2- methoxy ethyl) (2’ -MOE) sugar moi eties, each “C” is replaced with a 5-methylcytosine (5-MeC), and all intemucleoside linkages are phosphorothioate linkages. A spacer as indicated by S is not a nucleoside. S represents a spacer of Formula (lia’ ) as disclosed herein.e 11: Performance of FMRI AONs, including FMRI AONs with two spacers.* Unless otherwise noted, each of the nucleosides of antisense oligonucleotides shown in Table 11 are modified nucleosides with 2’-O-(2- methoxy ethyl) (2’ -MOE) sugar moi eties, each “C” is replaced with a 5-methylcytosine (5-MeC), and all intemucleoside linkages are phosphorothioate linkages. A spacer as indicated by S is not a nucleoside. S represents a spacer of Formula (lia’ ) as disclosed herein. (S*) represents a spacer of Formula (V) as disclosed herein. (S#) represents a spacer of Formula (IV) as disclosed herein. (S!) represents a spacer of Formula (Ilib) or Formula (Ilib’) as disclosed herein.Table 12: Performance of gapmer FMR1 AONs= DNA base A; dT= DNA base T, dG= DNA base G; 5mC = 5 methyl DNA base C. A, C, T, and G refer to RNA bases
Claims
Attorney Docket No. QRL-028WOCLAIMSWHAT IS CLAIMED IS:
1. A Fragile-X Messenger Ribonucleoprotein 1 (FMRI) oligonucleotide, wherein the FMRI oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 967.
2. The FMRI oligonucleotide of claim 1, wherein the FMRI oligonucleotide comprises a spacer representing a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base.
3. The FMRI oligonucleotide of claim 1, wherein the FMRI oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO:976.
4. The FMRI oligonucleotide of claim 3, wherein the splicing of SEQ ID NO: 976 is capable of being modulated to treat a FMRI -related disease or disorder.
5. The FMRI oligonucleotide of any one of claims 1 and 3-4, wherein the FMRI oligonucleotide comprises a sequence that is at least 90% complementary to SEQ ID NO:977.
6. The FMRI oligonucleotide of any one of claims 1 and 3-4, wherein the FMRI oligonucleotide comprises a sequence that is at least 90% complementary to positions 2-71 or positions 69-109 of SEQ ID NO: 977.
7. The FMRI oligonucleotide of any one of claims 1 and 3-4, wherein the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
8. The FMRI oligonucleotide of any one of claims 1 and 3-7, wherein the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 454-465.
9. The FMRI oligonucleotide of claim 1, wherein the FMRI oligonucleotide comprises a spacer.
10. The FMRI oligonucleotide of any one of claims 1 and 3-9, wherein the FMRI oligonucleotide comprises a gapmer.Attorney Docket No. QRL-028WO11. The FMRI oligonucleotide of claim 10, wherein the FMRI oligonucleotide comprises a sequence of any one of SEQ ID NOs: 1247-1254.
12. A splice-switching oligonucleotide, wherein the splice-switching oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 967, and further wherein the splice-switching oligonucleotide comprises a spacer.
13. The splice-switching oligonucleotide of claim 12, wherein the splice-switching oligonucleotide comprises a sequence that is at least 85% complementary to an equal length portion of SEQ ID NO: 976.
14. The splice-switching oligonucleotide of claim 13, wherein the splicing of SEQ ID NO: 976 is capable of being modulated to treat a FMRI-related disease or disorder.
15. The splice-switching oligonucleotide of any one of claims 12-14, wherein at least one ( / .<., one or more) intemucleoside linkage of the splice-switching oligonucleotide is a nonnatural linkage.
16. The splice-switching oligonucleotide of any one of claims 12-15, wherein the spliceswitching oligonucleotide comprises a sequence that is between 85% to 93% complementary to an equal length portion of SEQ ID NO: 976.
17. The splice-switching oligonucleotide of any one of claims 12-16, wherein the spliceswitching oligonucleotide comprises a sequence that is at least 85% complementary to SEQ ID NO: 977.
18. The splice-switching oligonucleotide of any one of claims 12-16, wherein the spliceswitching oligonucleotide comprises a sequence that is at least 90% complementary to SEQ ID NO: 977.
19. The splice-switching oligonucleotide of claim 16, wherein the splice-switching oligonucleotide comprises a sequence that is at least 93% complementary to SEQ ID NO: 977.
20. The splice-switching oligonucleotide of any one of claims 12-16, wherein the spliceswitching oligonucleotide comprises a sequence that is at least 90% complementary to anAttorney Docket No. QRL-028WOequal length portion of SEQ ID NO: 976, or to a 15 to 50 contiguous nucleotide portion thereof.
21. The splice-switching oligonucleotide of any one of claims 12-20, wherein the spliceswitching oligonucleotide comprises a segment with at most 11 linked nucleosides.
22. The splice-switching oligonucleotide of any one of claims 12-20, wherein the spliceswitching oligonucleotide comprises a segment with at most 10, 9, or 8 linked nucleosides.
23. The splice-switching oligonucleotide of any one of claims 12-20, wherein the spliceswitching oligonucleotide comprises a segment with at most 7 linked nucleosides.
24. The splice-switching oligonucleotide of any one of claims 12-20, wherein the spliceswitching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides.
25. The splice-switching oligonucleotide of any one of claims 12-23, wherein every segment of the splice-switching oligonucleotide comprises at most 7 linked nucleosides.
26. The splice-switching oligonucleotide of any one of claims 21-25, wherein the spliceswitching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
27. The splice-switching oligonucleotide of any one of claims 21-26, wherein the spliceswitching oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
28. The splice-switching oligonucleotide of any one of claims 12-27, wherein the spliceswitching oligonucleotide comprises a segment with at most 7 linked nucleosides, and wherein the splice-switching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
29. The splice-switching oligonucleotide of claim 28, wherein the splice-switching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the splice-switching oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.Attorney Docket No. QRL-028WO30. The splice-switching oligonucleotide of claim 28 or 29, wherein the splice-switching oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the splice-switching oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-483, 983-1019, or 1255.
31. The splice-switching oligonucleotide of any one of claims 12-16, wherein the sequence comprises any one of SEQ ID NOs: 484-564 or 1021-1075.
32. The splice-switching oligonucleotide of any one of claims 12-16, wherein the sequence comprises any one of SEQ ID NOs: 1076-1132.
33. The splice-switching oligonucleotide of any one of claims 12-16, wherein the sequence comprises any one of SEQ ID NOs: 1133-1189.
34. The splice-switching oligonucleotide of any one of claims 12-16, wherein the sequence comprises any one of SEQ ID NOs: 1190-1246.
35. The splice-switching oligonucleotide of any one of claims 12-34, wherein the spliceswitching oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length.
36. The splice-switching oligonucleotide of claim 35, wherein the splice-switching oligonucleotide is at least 23 oligonucleotide units in length.
37. The splice-switching oligonucleotide of any one of claims 12-36, wherein the spacer is a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base.
38. The splice-switching oligonucleotide of claim 37, wherein the spacer is located between positions 10 and 15 of the splice-switching oligonucleotide.
39. The splice-switching oligonucleotide of claim 37, wherein the spacer is located between positions 7 and 11 of the splice-switching oligonucleotide.
40. The splice-switching oligonucleotide of any one of claim 37-39, wherein the spliceswitching oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 14 and 22 of the splice-switching oligonucleotide.Attorney Docket No. QRL-028WO41. The splice-switching oligonucleotide of claim 40, wherein the spacer and the second spacer are separated by at least 5 nucleotides, at least 6 nucleotides, or at least 7 nucleotides in the splice-switching oligonucleotide.
42. The splice-switching oligonucleotide of claim 40 or 41, wherein the spacer is located between positions 7 and 9 of the splice-switching oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the splice-switching oligonucleotide.
43. The splice-switching oligonucleotide of any one of claims 40-42, wherein the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide.
44. The splice-switching oligonucleotide of any one of claims 40-43, wherein the spliceswitching oligonucleotide comprises any one of SEQ ID NOs: 484-564.
45. The splice-switching oligonucleotide of claim 37, wherein the spacer is located between positions 2 and 5 of the oligonucleotide.
46. The splice-switching oligonucleotide of claim 45, wherein the splice-switching oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide.
47. The splice-switching oligonucleotide of claim 37, wherein the splice-switching oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides.
48. The splice-switching oligonucleotide of claim 40, wherein at least one of the two spacers is adjacent to a guanine nucleobase.
49. The splice-switching oligonucleotide of claim 48, wherein each of the at least one of the two spacers immediately precedes a guanine nucleobase.
50. The splice-switching oligonucleotide of any one of claims 40-49, wherein each of the first or second spacers is a nucleoside-replacement group comprising a non-sugar substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal,Attorney Docket No. QRL-028WOhemiacetal, aminal, or hemiaminal moiety, and is incapable of forming a covalent bond with a nucleotide base.
51. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (X), wherein:Formula (X)Ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and thesymbol represents the point of connection to an intemucleoside linkage.
52. The splice-switching oligonucleotide of claim 51, wherein each of the first or second spacers is independently represented by Formula (Xa), wherein:Formula (Xa).
53. The splice-switching oligonucleotide of claim 51 or 52, wherein ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.
54. The splice-switching oligonucleotide of claim 53, wherein ring A is tetrahydrofuranyl.
55. The splice-switching oligonucleotide of claim 53, wherein ring A is tetrahydropyranyl.Attorney Docket No. QRL-028WO56. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (I), wherein:Formula (I)X is selected from -CH2- and -O-; andn is 0, 1, 2 or 3.
57. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (I’), wherein:X is selected from -CH2- and -O-; andn is 0, 1, 2 or 3.
58. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (la), wherein:Formula (la); andn is 0, 1, 2 or 3.
59. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (la’), wherein:Attorney Docket No. QRL-028WOFormula (la’); andn is 0, 1, 2 or 3.
60. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (II), wherein:Formula (II); andX is selected from -CH2- and -O-.
61. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (IF), wherein:Formula (IF); andX is selected from -CH2- and -O-.
62. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (IIa), wherein:Formula (IIa).
63. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (lia’), wherein:Attorney Docket No. QRL-028WOFormula (lia’).
64. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Hi), wherein:Formula (Hi)Xis selected from -CH2- and -O-.
65. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Hi’), wherein:Formula (Hi’)X is selected from -CH2- and -O-.
66. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Ilib), wherein:Formula (Ilib).
67. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Ilib’), wherein:Attorney Docket No. QRL-028WOFormula (Ilib ’ ).
68. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (III), wherein:Xis selected from -CH2- and -O-.
69. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (III’), wherein:Formula (III’); andX is selected from -CH2- and -O-.
70. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Illa), wherein:Formula (Illa).
71. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (Illa’), wherein:Attorney Docket No. QRL-028WOFormula (Illa’).
72. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (IV):Formula (IV).
73. The splice-switching oligonucleotide of any one of claims 37-49, wherein each of the first or second spacers is independently represented by Formula (V):Formula (V).
74. The splice-switching oligonucleotide of claim 31, wherein each of the first or second spacers is independently represented by Formula (lia’), wherein:Formula (lia’).
75. The splice-switching oligonucleotide of claim 32, wherein each of the first or second spacers is independently represented by Formula (V), wherein:Attorney Docket No. QRL-028WOFormula (V).
76. The splice-switching oligonucleotide of claim 33, wherein each of the first or second spacers is independently represented by Formula (IV), wherein:Formula (IV).
77. The splice-switching oligonucleotide of claim 34, wherein each of the first or second spacers is independently represented by Formula (Ilib), wherein:
78. The splice-switching oligonucleotide of any one of claims 12-77, wherein the spliceswitching oligonucleotide comprising the spacer has a GC content of at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, or at least 50%.
79. The splice-switching oligonucleotide of any one of claims 12-78, wherein the spliceswitching oligonucleotide is between 12 and 40 oligonucleotide units in length.
80. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-79, wherein at least one ( / .<., one or more) internucleoside linkage of the oligonucleotide is independently selected from the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3 -methoxy propyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidateAttorney Docket No. QRL-028WOlinkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, a phosphoryl guanidine (PN) linkage, a phosphoryl sulfonamide linkage, and a boranophosphate linkage.
81. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-80, wherein one or more intemucleoside linkage of the oligonucleotide is a modified intemucleoside linkage.
82. The splice-switching oligonucleotide or FMRI oligonucleotide of claim 81, wherein the modified intemucleoside linkage of the oligonucleotide is a phosphorothioate linkage.
83. The splice-switching oligonucleotide or FMRI oligonucleotide of claim 81 or 82, wherein all intemucleoside linkages of the oligonucleotide are phosphorothioate linkages.
84. The splice-switching oligonucleotide or FMRI oligonucleotide of claim 82, wherein the phosphorothioate linkage is in one of a Rp configuration or a A'p configuration.
85. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-84, wherein the oligonucleotide comprises at least one modified sugar moiety.
86. The splice-switching oligonucleotide or FMRI oligonucleotide of claim 85, wherein the modified sugar moiety is one of a 2’-0Me modified sugar moiety, bicyclic sugar moiety, 2’-< -(2-methoxyethyl) (2’-M0E), 2’ -deoxy-2’ -fluoro nucleoside, 2’-fluoro-P-D-arabinonucleoside, locked nucleic acid (LNA), 2’ -0-(N-m ethylacetamide) nucleoside, constrained ethyl 2’-4’-bridged nucleic acid (cEt), A'-cEt, hexitol nucleic acids (HNA), and tricyclic analog (e.g., tcDNA).
87. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-86, wherein the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
88. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 10% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.Attorney Docket No. QRL-028WO89. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 20% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
90. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 30% decrease of FMRI-217 transcript levels or the levels of the protein encoded by FMRI -217.
91. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 40% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
92. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 50% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
93. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 60% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
94. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 70% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
95. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least an 80% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
96. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 90% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
97. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 87-96, wherein decrease of the FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217 achieved using the splice-switching oligonucleotide or FMRI oligonucleotide is measured in comparison to a level of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217 achieved using a control oligonucleotide.Attorney Docket No. QRL-028WO98. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 40%, 50%, 60%, 70%, 80%, or 90% reduction of the level of FMRI -217 transcripts.
99. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 10%.
100. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 20%.
101. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%.
102. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%, and the oligonucleotide exhibits at least a 30% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
103. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 30%, and the oligonucleotide exhibits at least a 60% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
104. The splice-switching oligonucleotide or FMRI oligonucleotide of any one of the above claims, wherein the oligonucleotide does not reduce the level of FMRI -205 transcripts by more than about 10%, and the oligonucleotide exhibits at least a 70% decrease of FMRI -217 transcript levels or the levels of the protein encoded by FMRI -217.
105. A method of treating a FMRI -related disease or disorder and / or a neuropathy in a patient in need thereof, the method comprising administering to the patient a splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-104.
106. The method of claim 105, wherein the FMRI-related disease or disorder is selected from the group consisting of Fragile X Syndrome (FXS), Fragile X-associated PrimaryAttorney Docket No. QRL-028WOOvarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
107. A method of restoring axonal outgrowth and / or regeneration of a neuron, the method comprising exposing the neuron to a splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-104.
108. The method of claim 107, wherein the neuron is a neuron in the central nervous system.
109. The method of any one of claims 107-108, wherein the neuron is a neuron of a patient in need of treatment of a FMRI -related disease or disorder.
110. A method of restoring glia (e.g., astrocytes, microglia, or oligodendrocyte) cell health and / or function, the method comprising exposing the glia to a splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-104.
111. The method of any one of claims 107-109, wherein the exposing is performed in vivo or ex vivo.
112. The method of any one of claims 107-109, wherein the exposing comprises administering the splice-switching oligonucleotide or FMRI oligonucleotide to a patient in need thereof.
113. The method of any one of claims 107-112, wherein the splice-switching oligonucleotide or FMRI oligonucleotide is administered topically, parenterally, intravenously, subcutaneously, intrathecally, intrathalamically, intraci sternally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, intraduodenally, intraparenchymal, or intracerebroventricularly.
114. The method of claim 113, wherein the splice-switching oligonucleotide or FMRI oligonucleotide is administered orally, intravenously, or intrathecally.Attorney Docket No. QRL-028WO115. The method of any one of claims 107-113, wherein a therapeutically effective amount of the splice-switching oligonucleotide is administered intrathecally, intraparenchymal, intravenously, or subcutaneously.
116. The method of any one of claims 107-115, wherein the patient is a human.
117. A pharmaceutical composition comprising the splice-switching oligonucleotide or FMRI oligonucleotide of any one of claims 1-104, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
118. The pharmaceutical composition of claim 117, wherein the pharmaceutical composition is suitable for topical, intrathecal, intrathalamic, intracisternal, intracerebroventricular, intraparenchymal, parenteral, intravenous, subcutaneous, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.
119. A method of treating a FMRI -related disease or disorder or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 117 or 118.
120. The method of claim 119, wherein the FMRI-related disease or disorder is selected from the group consisting of Fragile X Syndrome (FXS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), Fragile X-associated tremor / ataxia syndrome (FXTAS), Parkinson’s disease (PD), Multiple sclerosis (MS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
121. The method of any one of claims 119-120, wherein the pharmaceutical composition is administered topically, parenterally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intraci sternally, intrathecally, intraparenchymally, intrathalamically, transdermally, intraduodenally, or intracerebroventricularly.
122. The method of any one of claims 119-121, wherein the pharmaceutical composition is administered intrathecally, intrathalamically, intravenously, subcutaneously, orintraci sternally.Attorney Docket No. QRL-028WO123. The method of any one of claims 119-122, wherein a therapeutically effective amount of the splice-switching oligonucleotide or FMRI oligonucleotide is administered intrathecally, intrathalamically, intravenously, subcutaneously, or intraci stemally.
124. The method of any one of claims 119-123, wherein the patient is human.
125. A method of treating a FMRI-related disease or disorder in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 117 or 118, in combination with a second therapeutic agent.
126. The method of claim 125, wherein the second therapeutic agent is selected from propranolol, primidone, gabapentin, topiramate, levetiracetam, amantadine, buspirone, gabapentin, varenicline, riluzole, carbidopa / levodopa, donepezil, galantamine, rivastigmine, Citocoline, memantine, allopregnanolone, sulfarophane, methylphenidate (Ritalin, Concerta, Methylyn, Metadate, Focalin, Aptensio, Daytrana, Quillivant), amphetamines and mixed amphetamine salts (Adderall), lisdexamphetamine (Vyvanse), dextroamphetamine (Dexedrine), atomoxetine (Strattera), modafinil (Provigil), fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), trazodone (Desyrel), bupropion (Wellbutrin), venlafaxine (Effexor), tricyclics (amitriptyline, imipramine, etc), Mirtazapine (Remeron), clonidine (Catapres, Kapvay), guanfacine (Tenex, Intuniv), haloperidol (Haldol), risperidone (Risperdal), aripiprazole (Abilify), quetiapine (Seroquel), ziprasidone (Geodon), olanzapine (Zyprexa), thioridazine (Mellaril), lurasidone (Latuda), iloperidone (Fanapt), brexpiprazole (Rexulti), topiramate (Topamax), Lithium, valproic acid (Depakote), carbamazepine (Tegretol), oxcarbazepine (Trileptal), lamotrigine (Lamictal), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), alprazolam (Xanax), buspirone (Buspar, Vanspar), Ambien, Fenobam, Mavoglurant, Basimglurant, lithium, lovastatin, trofinetide, minocycline, metformin, BPN14770, actinogen, CX516, ganaxolone, metadoxine (Alcobra), Arbaclofen, Acamprosate, gaboxadole, Donepezil, cannabidiol (CBD), Ergoloid mesylates / 5HTP, Sulindac, SPG601, sertraline, NNZ-2566, AZD7325, MG01C1, Oxytocin, CTH120, aripipazole, epigallocatechin Gallate (EGCG), STX107, Vitamin C, Vitamin E, NPL-2009, CX-516, and acamprosate.
